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Abstract 
Tumorigenesis is driven by changes in the expression profile of healthy cells which are 
caused mainly by the disruption of signaling pathways or by oncogenic transcription 
factors. Then, cancer cells become addicted to high levels of aberrant transcription and to 
the expression of certain oncogenes.  
Pediatric malignancies are characterized by a low mutational burden and are commonly 
caused by chromosomal translocations that originate fusion transcription factors (TFs). 
Hence, they are good candidates to study aberrant transcription. Fusion-positive 
rhabdomyosarcoma (FP-RMS) and Ewing sarcoma (ES) are two examples of this. Both 
tumors are driven by fusion TFs, PAX3-FOXO1 and EWS-FLI1 respectively, and are highly 
dependent on their transcriptional signature. 
One way of interfering with transcription driven by oncogenic TFs is by targeting their 
epigenetic cofactors. Epigenetics studies alterations in gene expression that do not arise 
from changes in the DNA sequence, but rather from post-translational modifications on 
histones and DNA methylation which signal to effector enzymes that modulate gene 
expression. Thus, targeting these epigenetic enzymatic motors is a good strategy to 
interfere with oncogenic transcription and for cancer therapy. For example, the inhibition 
of BET-bromodomains deeply affects the transcriptional signatures of many oncogenes and 
impacts several hematological malignancies and solid tumors. 
Here, we studied chromatin remodeling as a means to impair oncogenic transcription and 
cancer development. Chromatin remodelers use energy from ATP hydrolysis to move 
nucleosomes along the DNA and hence determine DNA accessibility to the transcription 
machinery. Despite their prominent role in transcription regulation, they have been so far 
neglected as therapeutic targets. In this study, we focused on the chromatin remodeler 
CHD4 and on its effect in FP-RMS and ES to highlight the role of chromatin remodeling in 
cancer.  
We started by studying the epigenetic landscape of FP-RMS. We showed that the driver 
oncogene, PAX3-FOXO1, establishes and binds to enhancers and super-enhancers (SEs) 
from where it regulates gene expression together with the epigenetic cofactors BRD4 and 
CHD4. We showed that CHD4 presence in SEs is crucial to keep these regulatory elements 
open and permissive to the binding of the fusion protein and BRD4. Consequently, silencing 
of CHD4 deeply impaired the oncogenic program of PAX3-FOXO1, caused tumor cell death 
in vitro and tumor regression in vivo. Furthermore, we described for the first time an 
association between CHD4 and BRD4, which suggests an interdependency between these 
two epigenetic factors in the regulation of SE-driven gene expression in FP-RMS. 
Abstract
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Ewing sarcoma, as previously stated, has similar characteristics to FP-RMS. Its driver, EWS-
FLI1, also establishes de novo enhancers from where it controls aberrant gene expression. 
In parallel to FP-RMS, ES is highly dependent on BRD4 and studies have suggested that 
CHD4 interacts with EWS-FLI1 to influence its repressive action. Here, we complemented 
this work by characterizing a new function of CHD4 in ES cell proliferation and tumor 
growth in vivo. 
Besides FP-RMS and ES, many tumors, like breast cancer, colorectal cancer, and acute 
myeloid leukemia, are dependent on CHD4. Interestingly, we and others observed that 
healthy cells are usually not affected by CHD4 silencing, which makes CHD4 a very 
interesting new cancer therapeutic target. In addition, we analyzed two genome-wide 
cancer dependency databases and observed that, amongst all SNF2-like ATPases, CHD4 
depletion affected the largest number of tumors, similarly to what has been described for 
BRD4.  
Motivated by these results, we decided to start developing the first-in-class CHD4 small 
molecule inhibitor. To do so, we focused on the reader domains of CHD4, named plant 
homeodomains (PHDs), and gathered a library of candidate small molecule inhibitors 
through in silico structure-based drug design. After biophysical validation of the candidate 
compounds by NMR experiments, we were able to identify a small molecule compound that 
could interact with the PHD2 domain of CHD4, although weakly. Thus, further optimization 
will be required to increase the binding affinity of this compound. 
In conclusion, we reveal here a new role of CHD4 as a regulator of SE-driven transcription. 
We show that this remodeler conditions chromatin accessibility to aberrant TFs and their 
cofactors, hence influencing oncogenic gene expression and tumor development. We also 
describe a co-dependency between CHD4 and BRD4, which might explain their vast 
relevance in oncogenic transcription regulation. In addition, we show a broad, and possibly 
specific, tumor dependency to CHD4 and reveal its promising features as a new tumor 
target. With this work, we hope to highlight the importance of chromatin remodelers in 
tumor development and to place them in the epigenetic drug development pipeline. 
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Cancer 
The word cancer comes from the Greek karkinos (crab). Hippocrates named it like that since 
the finger-like spreading projections seen in cancers resemble the shape of a crab1,2. Today, 
the Oxford Dictionary describes the disease as "an uncontrolled division of abnormal cells 
in a part of the body”3.   
Despite being an old disease, cancer is still the second cause of death and morbidity in 
Europe, after cardiovascular diseases4,5,6. The oldest description of cancer, the Edwin Smith 
Papyrus, comes from Egypt and dates to 3000 BC. There, 8 cases of breast cancer are 
described and the disease is identified as non-treatable1.  
In 2012, roughly 3.4 million new cases were diagnosed and 8.2 million people died of this 
disease4. In the USA, half of the men and one third of the women are estimated to develop 
cancer throughout their lifetime2. Europe has a particular challenging situation since, 
although it accounts for only one-ninth of the world population, it contains a quarter of the 
total number cancer cases7.  
 
1. Tumorigenesis 
Cancers can be divided into inherited or sporadic8.  The inherited ones  account for 5% of 
all tumors8 and are originated by germline mutations9. The well-known  BRC1/2 mutations 
and the hereditary breast or ovarian cancer illustrate an example inherited cancer8,10. In 
sporadic cancers, genetic alterations have different origins such as viral or environmental8.  
Nevertheless, both inherited and sporadic cancers go through a multistep process in which 
cells suffer sequential genetic alterations, in oncogenes and/or tumor suppressor genes, 
that confer growth advantages which then drive 
the consecutive clonal expansion of malignant 
cells. This process is called tumorigenesis and 
ultimately leads to cell transformation11.  
Oncogenes are genes that promote cell 
proliferation, like growth factor receptors, while 
tumor suppressor genes restrict cell growth, like 
pro-apoptotic proteins9. The hallmarks of cancer, 
depicted in Fig.1, describe the biologic 
capabilities acquired by the cancer cell that result 
from the imbalance between the activity of 
oncogenes and tumor suppressor genes12.   
Fig. 1 Established and emerging hallmarks of cancer12. 
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Not all mutations acquired are equally important. Gatekeeping mutations initiate the 
tumorigenesis process and allow a first clonal expansion. Other mutations that confer 
selective growth advantages are denominated driver mutations, while mutations that do 
not influence the neoplastic process are called passenger13. 
The clonality of cancer, meaning if tumors arise from genetic alterations in a single cell or 
in two or more cells, is still a subject of debate14. Nonetheless, cancer is an extremely 
heterogeneous disease, presenting intratumoral, intrametastic and intermetastatic 
diversity, which makes therapy very challenging13.  
 
2. The cancer genome 
The cancer genome is highly aberrant. A normal diploid cell has a total of 46 chromosomes, 
but neuroblastoma cells can have up to 80. Many point mutations, viral insertions, 
chromosomal or gene amplifications, deletions or rearrangements are found in the genome 
of cancer cells. Point mutations can activate oncogenes or inactivate tumor suppressor 
genes, and gene amplifications allow the tumor to overexpress oncogenes9. These genomic 
aberrations allow cancer cells to evade cell death and maintain a high level of proliferation. 
Cancer cells can survive under extreme stress conditions unlike healthy cells. Mutations in 
KRAS and BRAF allow cancer cells to grow in low glucose concentrations. Mutations in 
EGFR, RAS, PIK3CA, and PTEN keep growth factor related pathways active in the absence of 
growth factors. Deregulation of cell cycle and apoptosis, through mutations in MYC or BCL2, 
also confer growth advantages13.  
Understanding how mutations in the genome alter normal cellular processes is crucial to 
further guide cancer therapy. 
  
3. Cancer therapy 
The three pillars of cancer therapy are chemotherapy, radiotherapy, and surgery. 
Chemotherapy was introduced in the 1930s, and most of the drugs in use today were 
developed in the 1970s. This treatment modality consists in the combination of drugs, that 
act in different stages of the cell cycle, to more effectively kill the cancer cells. Unfortunately, 
the lack of specificity of these drugs causes severe side effects15.  
In the 1960s surgery and radiotherapy, were the basis of solid tumor treatment. Surgery 
has evolved from radical removal of tumor and adjacent tissue to less extensive and invasive 
techniques, like laparoscopy. Radiotherapy has also evolved, and now smaller and more 
localized radiation dosages are used. The latest advance is the usage of radiolabeled 
molecules, which fight cancer by delivering targeted radiation to specific receptor-bearing 
cells15.  
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The advances in chemotherapeutical 
regiments, surgery techniques and 
radiotherapy have considerably 
enhanced patient’s outcome (Fig.2)16. 
Nonetheless, we seem to have reached 
a plateau in the improvement of cancer 
survival. Hence, more specific and 
efficacious therapies are highly 
demanded. Targeted therapy, 
immunotherapy, and gene therapy 
hold great promise in cancer 
treatment.  
Pediatric cancer 
Childhood cancer is a rare event. In fact, pediatric cancer represents 1% of all cancer cases17. 
However, every year approximately 175.000 children are diagnosed with cancer 
worldwide18, and pediatric cancer is still the leading cause of death by disease in children 
over 1 year of age in developed countries6,19.  
 
1. Pediatric and adult cancer 
Pediatric and adult cancer differ in etiology, tumor type frequency, mutational burden, and 
prognosis. 
 
1.1 Etiology 
Pediatric tumors are thought to arise from 
embryonic developing tissues (Fig.3)19, while 
adult cancers originate mostly from epithelial 
cells17. The involvement of environmental 
factors in pediatric cancer development is still 
up to discussion. In adults, it is very well 
documented the relation between 
carcinogenesis and cigarette smoke, alcohol 
consumption, and sun exposure. On the other 
hand, in children, only a few chemicals (such 
as dioxin, pesticides, solvents and metals) have been associated with cancer but the effect 
of other  important carcinogens, like ionizing radiation,  is still debatable17.  
Fig. 2 Age-standardized 5-year net survival of all cancers, 
excluding non-melanoma skin cancer. Data collect in England 
and Wales16.  
Fig. 3 Pediatric solid tumors derived from the three 
germ layers. Adapted from22. 
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1.2 Tumor type frequency 
In children, the most common tumors are acute lymphoblastic leukemia (ALL), brain 
tumors (medulloblastoma and neuroblastoma), lymphomas, and soft-tissue sarcomas 
(rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, and Wilms tumor), while adults 
mainly suffer from malignancies of the gastrointestinal tract, lung, prostate, and breast 
(Fig.4)19. Amongst childhood cancer, there are also differences in tumor type incidence 
between young children and adolescents. Leukemia, followed by brain and other nervous 
system malignancies, is the most common cancer from the age of 1 to 14, while from the 
most common cancer is lymphoma, particularly Hodgkin lymphoma6.  
 
Fig. 4 Frequency of cancer subtypes diagnosed in children and adults19. 
 
1.3 Mutational burden 
Adult solid tumors display an average of 33 to 66 somatic mutations, but melanoma or lung 
cancer can harbor up to 200 non-synonymous mutations. In contrast, pediatric cancers have 
an average of only 9.6 mutations per tumor (Fig.5). One reason for this disparity is the fact 
that the number of mutations is directly related to the age of the patient. Moreover, potent 
mutagens, such as UV light and cigarette smoke, are involved in adult but not in childhood 
cancer13. 
Introduction
 ________________________________________________________________________________________________________ 
 
13 
 
Within the same tumor type, the mutations found in adults and children can differ. Pediatric 
glioblastomas are rich in a histone 3 lysine 27 (H3K27) mutation, but in adults this mutation 
is never observed. Within child demography there are also differences. In neuroblastoma, 
adolescent patients present mutations in ATRX, while infants do not19. 
Fig. 5 Number of somatic mutations in human cancer. The plot represents the median number of non-
synonymous mutations per tumor type (pediatric tumors are displayed blue). Horizontal bars indicate the 25 
and 75% quartiles. Adapted from13. NSC – non-small cell, SC – small cell. 
  
1.4 Prognosis 
Cure rates are significantly higher in children than in adults.  The 5-year relative survival 
rate in children diagnosed with cancer between 2007-2013 was of  83% versus only 69.2% 
in adults6,20.  
Since 1970, the death rates of childhood and adolescent cancers decreased 66%6. This 
change is mainly attributed to the enrollment of large numbers of patients in clinical trials, 
improvement of risk assessments, and targeted therapy. However, this decrease in death 
rate is very heterogeneous amongst tumor types, and is mainly due to a 75% reduction in 
non-Hodgkin lymphoma and a 60% reduction in ALL and acute myeloid leukemia (AML)21. 
In contrast, the 5-year survival rates of solid tumors have plateaued for the last 10-20 
years18. Importantly, children who survive cancer have a higher mortality risk due to late 
effects of the therapy such as increased likelihood of developing subsequent malignant 
neoplasms (50% more risk) and cardiac or pulmonary chronic diseases. In fact, of the 80% 
of children that survive the first malignancy 20% will die from recurrence17.  
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2. The origin of pediatric cancer 
Adult cancers occur gradually by accumulation of genetic lesions. The low mutational 
burden observed in childhood malignancies (Fig.5) suggests a different tumorigenesis 
process. One possibility is that childhood cancer is caused by acute genetic changes like 
chromothripsis and chromosomal translocations22. In fact, adult cancers with fusion driving 
mutations bear a lower mutational burden, comparable to the one found in pediatric 
cancers17.   
As previously stated, pediatric malignancies arise from developing tissues when 
multipotent progenitor cells undergo differentiation17,22.  The age of onset of the malignancy 
is possibly related to the differentiation timing of the cell of origin. Retinoblastoma is rarely 
diagnosed in children over 5 years of age, and the proliferation of retinal progenitor cells 
occurs in the first 2 trimesters of gestation. On the other hand, osteosarcoma is most 
commonly diagnosed in adolescents and young adults which coincides with the rapid 
growth of the skeletal system during puberty22.   
The establishment of mouse models that recapitulate the features of pediatric tumors is still 
challenging. Even when the driver mutation is known, it needs to occur in a certain timing 
and on the right cellular background in order to lead to cell transformation22.  
 
3. Chromosomal translocations, typical pediatric tumor drivers  
Chromosomal translocations juxtapose two previously separated genes. The first reciprocal 
chromosomal translocation, the Philadelphia chromosome, was discovered in 1973. This 
translocation occurs between chromosomes 9 and 22 and results in the expression of the 
BCR-ABL fusion protein which drives chronic myeloid leukemia (CML).  
Frequently, the result of a chromosomal rearrangement is a functional chimeric protein that 
acts as a transcription factor, driving aberrant gene expression (e.g. PAX3-FOXO1), or as a 
kinase, impairing signaling pathways (e.g. NPM-ALK)17. Fusion genes can also result in the 
inactivation of tumor suppressor genes (by truncation or separation of the gene from its 
promoter)13 or lead to overexpression of oncogenes (by juxtaposing the oncogene to highly 
active regulatory sequences, e.g. IGH-MYC or TMPRSS2-ERG)17. 
Many pediatric cancers, mainly hematologic and soft-tissue malignancies, bear 
chromosomal translocations that drive tumorigenesis (Table 1)9.  These fusion genes are 
uniquely expressed in defined tumor types, which makes them good biomarkers. The fusion 
EWS-FLI1 is characteristic of Ewing sarcoma, PAX3/7-FOXO1 of alveolar 
rhabdomyosarcoma and SSX18-SSX1/2 of synovial sarcoma17. Their tumor specificity and 
their role in tumorigenesis makes them attractive therapeutic targets. This became clear 
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with development of Gleevec, a BCR-ABL tyrosine kinase inhibitor, that accomplished an 
impressive 80% remission rate in CML17. 
 
Table 1 Common recurrent translocations in soft tissue tumors. Adapted from9. 
Tumor Genetic abnormality Fusion transcript 
Ewing sarcoma 
t(11;22)(q24;q12) 
t(21;22)(q22;q12) 
t(7;22)(p22;q12) 
t(17;22)(q12;q12) 
t(2;22)(q33;q12) 
FLI1-EWS 
ERG-EWS 
ETV1-EWS 
E1AF-EWS 
FEV-EWS 
Desmoplastic small round cell tumor 
t(11;22)(p13;q12) 
t(11;22)(q24;q12) 
WT1-EWS 
FLI1-EWS 
Synovial sarcoma 
t(X;18)(p11.23;q11) 
t(X;18)(p11.21;q11) 
SSX1-SYT 
SSX2-SYT 
Alveolar rhabdomyosarcoma 
t(2;13)(q35;q14) 
t(1;13)(p36;q14) 
PAX3-FKHR 
PAX7-FKHR 
 
Malignant melanoma of soft part  
(clear cell sarcoma) 
 
 
t(12;22)(q13;q12) 
 
ATF1-EWS 
Myxoid liposarcoma 
t(12;16)(q13;p11) 
t(12;22)(q13;q12) 
CHOP-TLS(FUS) 
CHOP-EWS 
 
Extra skeletal myxoid chondrosarcoma 
 
 
t(9;22)(q22;q12) 
 
CHN-EWS 
 
Dermatofibrosarcoma protuberans and 
Giant cell fibroblastoma 
 
 
t(17;22)(q22;q13) 
 
COL1A1-PDGFB 
 
Congenital fibrosarcoma and 
Mesoblastic nephroma 
 
 
t(12;15)(p13;q25) 
 
ETV6-NTRK3 
 
Pediatric sarcomas 
Sarcomas are rare and heterogeneous malignancies that arise from bone or soft tissues such 
as muscle or fat23. They account for 1% of all cancers in adults and about 13% in children23. 
The 5-year survival rate of pediatric sarcomas is roughly of 60% but falls to 20-30% in 
recurrent and metastatic cases23. Due to their rarity, this is a group of understudied 
diseases. 
 
1. Rhabdomyosarcoma 
Rhabdomyosarcoma (RMS) is a group of small, round, blue-cell tumors with features of 
skeletal myogenesis24,25. While rare in adults, in children it is the most common soft-tissue 
sarcoma, accounting for half of all soft-tissue sarcomas and 5% of all pediatric sarcomas24. 
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RMSs are mostly sporadic tumors, although a few have been associated with familial 
syndromes such as Li-Fraumeni syndrome (characterized by germline mutations of the 
tumor suppressor gene p53), Neurofibromatosis I and Costello syndrome26. 
 
1.1 Diagnosis 
RMS is usually an asymptomatic disease. Rarely, pain on the primary tumor site is felt due 
to the compression of adjacent tissues26. Diagnosis is based on imaging techniques, such as 
computerized tomography (CT), magnetic resonance imaging (MRI) or positron-emission 
tomography (PET) scans, and confirmed by biopsy26. The tissue collected in the biopsies is 
used for histological subtyping and immunohistochemistry. Desmin, vimentin, MyoD1, 
Myogenin, S100, EMA, LCA, FLI1, and Mic2 are some of the biomarkers tested27. Ideally, FISH 
(fluorescence in situ hybridization) is performed to identify the presence of the fusion 
protein. 
 
1.2 Histologic classification 
The World Health Organization (WHO) has classified RMS in four histological subtypes: 
embryonal, alveolar, pleomorphic, and sclerosing/spindle cell (Fig.6)28.  
Embryonal RMS (eRMS) resembles immature skeletal muscle and is the most prevalent 
subtype, accounting for 60% of all RMS cases. It mainly occurs in the head and neck, 
genitourinary tract, and retroperitoneum25. ERMS has a bimodal age distribution with the 
first peak of incidence occurring in children under 5 years and the second one in 
adolescents24.  
The alveolar subtype (aRMS), as the name suggests, histologically resembles lung alveoli. It 
accounts for 20% of all RMS cases and mainly takes place in the trunk and extremities24. 
Although it can affect all ages, it is more common in adolescents and young adults24 unlike 
the pleomorphic and the sclerosing/spindle variants which mainly affect adults26,28,29. 
Pleomorphic RMS is an aggressive neoplasm that typically arises in deep soft tissues of the 
extremities of patients older than 45 years26. These neoplasms have complex karyotypes 
and are highly aggressive29.  
Fig. 6 RMS subtypes based on histology. Adapted from29. 
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Finally, sclerosing/spindle cell RMS is generally found in the extremities and head and neck 
region in adults, while in children is mainly paratesticular. Similarly to the other subtypes, 
sclerosing/spindle cell tumors are more aggressive in adults than in children28,29.  
 
1.3 Molecular classification 
The two main RMS subtypes, eRMS and aRMS, have significantly different genomes. ERMS 
has a complex karyotype24, while aRMS presents very few mutations30 and, in 70% of the 
cases, is characterized by a specific translocation, resulting from a rearrangement of the PAX 
gene (Fig.7A)31. The presence of this fusion gene deeply affects tumor biology. In fact, aRMS 
tumors negative for the PAX fusion (circa 20% of all aRMS cases) are more similar to eRMS 
on the transcriptome level30,32–34 and in mutation burden (Fig.7A). In fact, fusion positive 
aRMS carry an average of 6.4 non-synonymous somatic mutations, while eRMS and fusion 
negative aRMS have approximately 17.830. The fusion status also defines the aggressiveness 
of the tumor. At the time of diagnosis, 46% of fusion positive aRMS, against only 17% for 
fusion negative, bear detectable metastasis35. Indeed, expression of the PAX fusion in the 
eRMS cell line RD increases cell growth and produces more invasive mouse xenografts36. 
Moreover, the prognosis of fusion negative aRMS is significantly better than the one of 
fusion positive and indistinguishable from eRMS (Fig.7B)31. 
Together, these findings suggest that the fusion status represents the tumor types better 
than histology in terms of genetics, molecular, and clinical features. Therefore, I will refer to 
fusion positive (FP-RMS) or fusion negative (FN-RMS) rhabdomyosarcoma from now on.  
 
  
A B 
Fig. 7 Clinical and molecular features of FP- and FN-RMS. (A) The genomic landscape of pediatric RMS. Adapted 
from37. (B) Kaplan-Meier curves showing the event-free survival for patients with fusion positive aRMS 
(ARMSp), fusion negative aRMS (ARMSn) and eRMS (ERMS). Adapted from31.  
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1.4 Mutational burden 
Recent large-scale sequencing studies of primary RMS tumors revealed a low overall 
mutation rate (0.31 protein-coding mutations/Mb)37.  
FN-RMS commonly presents mutations in the Ras pathway (Fig.7A), the receptor tyrosine 
kinase FGFR4, the catalytic component of the phosphoinositide-3 kinase complex 
(PIK3CA)30, neurofibromin (NF1), β-catenin (CTNNB1), and BCOR29. Frequent mutations in 
cell-cycle genes (FBXW7 and E3 ubiquitin ligase) and TP53, or focal losses of TP5330, as well 
as focal amplification of the p53 modulator MDM2, are also found37. Besides local mutations, 
loss-of-heterozygosity (LOH) is recurrently observed in FN-RMS. LOH mainly affects the 
11p15.5 region, which includes the IGF2, H19, and CDKN1C genes24,37.  
In FP-RMS, mutations occur at the extremely low rate of 0.1 protein-coding mutations/Mb37.  
The region 12q13-15, which contains the cell cycle-dependent kinase CDK4 and MDM2, is 
amplified in 28-56% of the cases and commonly associated with a worse prognosis25,30. 
Another important amplified region, in 14-19% of the cases, is 2p24 which contains the 
proto-oncogene MYCN25. MYCN is a phosphoprotein that functions as a transcription factor 
and is involved in the regulation of cell proliferation and differentiation38. In FP-RMS, MYCN 
overexpression or copy number gain is associated with poor outcome38. Finally, an 
amplification of 15q25-26 is also observed and leads to the overexpression of the insulin-
like growth factor type receptor I (IGF1R)39. Additionally, loss-of-imprinting (LOI) causes 
IGF2 overexpression in 50% of FP-RMS25. 
 
1.5 Therapy 
The standard of care for RMS is a multimodal treatment based on chemotherapy and 
surgery, with or without radiotherapy.  Chemotherapy comprises a three-drug regimen of 
vincristine, actinomycin D and cyclophosphamide (VAC). Radiotherapy is used in patients 
with unresectable disease or residual lymph node disease after surgery, and for patients of 
the alveolar subtype26. 
This treatment strategy was implemented in the 1970s and led to a 5-year survival close of 
61% in the 1990s, which has not improved since then35. In addition, this therapeutic scheme 
is not effective for high-risk patients or patients with recurrent disease, who maintain a 5-
year overall survival of 30% and 17% respectively37.  
Severe late side effects have been reported for this treatment modality. Alkylating agents, 
like cyclophosphamide, are associated with secondary malignancies and sterility, and 
radiotherapy can cause facial asymmetry and growth deficiency26. Hence, new targeted 
therapies with higher efficacy in high-risk patients and less side effects are urgently needed. 
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1.6 Prognosis 
Classically, RMS prognosis was defined based on the site of onset, histological variant, 
presence of metastasis, tumor size, and age of diagnosis26. In addition to these factors, today 
we are also aware of the role of fusion status in RMS prognosis (Fig.7B)40. 
Head and neck, genitourinary tract, and bile ducts were classified as sites of favorable 
outcome. The alveolar subtype has a worse prognosis than the embryonal since it presents 
frequently metastasis at the time of diagnosis and has a poorer response to therapy. In fact, 
eRMS has a 5-year overall survival of 73%, while the one of aRMS only reaches 48%, 
dropping to 10-30% in case of metastasis. The main metastasis sites are the lungs,  bone 
marrow, lymph nodes, and bones24. 
Adult RMS has significantly worse prognosis, with a 5–year overall of only 27% versus 61% 
in children. Also adolescents have a less favorable prognosis than children diagnosed 
between the age of 1 to 1026.  
 
2. Fusion positive rhabdomyosarcoma 
2.1 The fusion gene 
To date, 6 different PAX fusion genes have been identified in FP-RMS (Fig.8)25,32,37. PAX3-
FOXO1, the most common rearrangement, is present in roughly 60% of all aRMS cases 
followed by PAX7-FOXO1, which accounts for other 20%25. The remaining fusions are 
present in roughly 10% of all aRMS cases25.   
The fusions merge the N-terminal DNA-binding paired and homeodomains of PAX3/7 in-
frame with the transactivation domains of either the forkhead box O4 (AFX), the nuclear 
receptor coactivator (NCOA1/2), the chromatin remodeling gene (INO80D), or, more 
commonly, the forkhead box O1 protein (FKHR or FOXO1)37.  
Fig. 8 Fusion proteins associated with FP-RMS and their respective wildtype counterparts. Adapted from29. 
Introduction
 ________________________________________________________________________________________________________ 
 
20 
 
2.2 PAX3/7-FOXO1 
Despite the similarity between the fusion genes, PAX3-FOXO1 positive patients have a 
poorer prognosis than the ones carrying the PAX7-FOXO1 fusion40. In metastatic disease, 
the event-free survival at 4 years is 8% and 75% for PAX3- and PAX7-FOXO1, respectively39. 
In addition, PAX7-FOXO1 tumors localize more often to favorable sites and are typically 
present in younger patients41. Nevertheless, expression data have shown no difference in 
the repertoire of downstream targets of PAX3- or PAX7-FOXO134. 
The fusion gene is the main driver of FP-RMS tumorigenesis. Once expressed, the fusion 
protein acts as a transcription factor and drives aberrant gene expression leading to cell 
transformation. In fact, overexpression of the fusion is able to transform mouse (NIH3T3)42 
and chicken embryo fibroblasts43. The tumor cells then become addicted to continuous 
expression of the fusion protein24.  Antisense oligonucleotides targeting PAX3-FOXO1 
drastically decrease FP-RMS cell viability38.  
PAX3-FOXO1 transformation activity is dependent not only on the DNA binding activity of 
the Pax gene but also on the protein-protein interactions mediated by FOXO142. Ectopic 
expression of a fusion between the DNA-binding domains of PAX3 with the transcription 
repressor, KRABB, leads to downregulation of PAX3-FOXO1 targets and consequent 
reduction of cell growth in vitro and tumor formation in vivo44. 
In FP-RMS, PAX3/7-FOXO1 proteins are highly expressed and unresponsive to 
transcriptional repressors. The overexpression of PAX3-FOXO1 results from an increase in 
its transcription rate, while the one of PAX7-FOXO1 originates from the amplification of the 
gene45. Both fusions, unlike wildtype FOXO1, are resistant to AKT-dependent regulation of 
subcellular localization and are exclusively located in the nucleus38. Additionally, hDAXX is 
able to bind both wildtype PAX3 and the fusion, but PAX3-FOXO1 is resistant to its 
transcription repression46.  
 
2.3 PAX and FOXO gene families 
The PAX (paired box) family consists of 9 transcription factors (TFs) which control 
organogenesis. This family is defined by the conserved paired domain which is composed 
of 128 amino acids and recognizes the TCACGC/G DNA sequence. PAX2-8 possess a second 
DNA binding domain, the homeodomain, that binds to the consensus sequence TAAT-ATTA. 
Paired and homeodomain can bind cooperatively (consensus sequence AATTA-GTCACGC) 
or independently. Besides PAX2 and 6, the PAX family also contains an octapeptide motif 
between the paired and homeodomain (Fig.8). This 8 amino acid sequence functions as a 
transcriptional repressor, rendering PAX proteins as transcription activators or repressors 
depending on the context and cofactors41. 
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PAX3 and 7 are involved in the development of the nervous system and skeletal muscle39. 
Both commit cells to differentiation but at the same time inhibit terminal differentiation and 
sustain proliferation during migration. Once the cells reach their final destination, the PAX 
genes are downregulated and differentiation is completed45. Despite their similarity in 
structure, PAX3/7 have different roles in development. In somite compartments, Pax3 
expression is activated before Pax7, but Pax7 persists longer. In adult mice, Pax7, but not 
Pax3, is expressed in most myogenic satellite cells38. 
FOXO1 belongs to the family of the forkhead transcription factors and regulates metabolism, 
cell proliferation and apoptosis38. Regulation of apoptosis is mediated by the binding of 
FOXO1 to the insulin responsive elements (IREs) and the regulation of proapoptotic 
factors44.  
FOXO1 is not detectably expressed in FP-RMS, due to the loss of one copy caused by the 
translocation and the altered stability of the second one38,45. Overexpression of FOXO1 in 
FP-RMS, but not in FN-RMS, leads to cell cycle arrest and apoptosis by expression of the 
protease caspase-3, which is consistent with the role of FOXO1 as a tumor suppressor38.  
 
2.4 The fusion gene signature 
Initial attempts to identify PAX3-FOXO1 target genes relied on the ectopic expression of the 
fusion in different systems (e.g. the osteosarcoma cell line SaOS-247 and FN-RMS cell line 
RD33). These studies showed that the fusion gene mainly acts as a transcriptional activator 
and that it not only regulates PAX3 target genes, by binding to the same DNA sequence48, 
but also contains its own targets. Interestingly, the constitutive expression of PAX3/7 in the 
skeletal muscle lineage results in developmental defects but not in tumor formation25, 
which suggests that the target genes of wildtype PAX3/7 are not the ones driving 
tumorigenesis.  
Gene ontology analysis showed that PAX3-FOXO1 activated genes control cell adhesion, 
proliferation, programmed cell death and neurogenesis, while the ones downregulated are 
involved in muscle development (Table 2)33.  
PAX3-FOXO1 activates IGFR1 expression24, which, upon ligand binding, activates many 
downstream signaling pathways (MAPK, PI3K and mTOR) that contribute to cell survival49. 
Additionally, cell proliferation is promoted by the inactivation of the cyclin-dependent 
kinase inhibitor 2A (CDKN2A)39 and massive upregulation of several receptor tyrosine 
kinases (such as FGFR4 and ALK)37. Another important PAX3-FOXO1 target involved in cell 
proliferation is the transcription factor AP2β (TFAP2β). In fact, depletion of TFAP2β causes 
FP-RMS cell death by apoptosis25.  The fusion gene also activates the expression of the anti-
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apoptotic protein BCL-xL, which protects FP-RMS from cell death. Indeed, expression of 
BCL-xL rescues the cell death phenotype upon P3F depletion50.  
The invasive properties of FP-RMS have been associated with the upregulation MET, CXCR4 
and CNR125. MET is a tyrosine kinase receptor for the hepatocyte growth/scatter factor 
(HGF/SF). During skeletal muscle development, HGF/SF is downstream of PAX325 and 
promotes myoblast proliferation39. In FP-RMS, MET levels are correlated with a poorer 
prognosis and its depletion leads to apoptosis25. CXCR4 is a G-protein coupled chemokine 
surface receptor, normally expressed in satellite cells within skeletal muscle. In FP-RMS, 
CXCR4 induces chemotaxis, helping cell migration and invasion25. The cannabinoid receptor 
1 (CNR1) has been associated with the formation of lung metastasis25.  
MYCN and CDH3, both direct targets of the fusion, contribute to cell transformation. CDH3 
(P-Cadherin) expression maintains C2C12 myoblasts in a proliferative state and inhibits 
their differentiation25. MYCN is a transcription factor of the neural development and when 
co-expressed with PAX3-FOXO1 in the mouse NIH3T3 fibroblasts greatly improves the 
transformation activity of the fusion51. 
PAX3-FOXO1 keeps FP-RMS in an undifferentiated state while conferring it myogenic traits. 
The expression of the fusion gene in murine fibroblasts and mesenchymal stem cells 
activates the myogenic program but its expression in the murine myoblasts C2C12 inhibits 
terminal differentiation24. PAX3-FOXO1 induces MYOD and myogenin (MYOG) expression, 
committing cells to the myogenic program24. However, simultaneously, the fusion gene 
prevents MYOD1 activity24, thus inhibiting terminal differentiation, by keeping it 
phosphorylated and hence inactive52.   
 
Table 2 PAX3-FOXO1 target genes. 
 
 
 
 
 
 
 
  
Function Target genes Expression in FP-RMS 
Proliferation 
IGFR1 
FGFR4 
ALK 
MET 
TFAP2β 
BCL-xL 
CDKN2A 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
Downregulated 
Invasion 
MET 
CXCR4 
CNR1 
Upregulated 
Upregulated 
Upregulated 
Transformation 
MYCN 
CDH3 
Upregulated 
Upregulated 
Myogenic differentiation 
MYOD 
MYOG 
Upregulated 
Upregulated 
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2.5 Cell of origin 
Due to the myogenic features present in FP-RMS, it has been postulated that it may arise 
from muscle precursor cells. Nevertheless, rhabdomyosarcomas are found in organs that 
lack skeletal muscle, such as prostate, urinary bladder, and gallbladder, which suggests a 
highly plastic cell of origin. To date, mesenchymal stem cells (MSC) and satellite cells have 
been proposed as possible cells of origin of FP-RMS. MSCs have the ability to self-renew but 
are also committed to a differentiation program that originates either adipocytes, 
osteoblasts or skeletal myocytes (Fig.9). Interestingly, Pax3 commits MSCs to the muscle 
lineage. Satellite cells are the myogenic progenitors of postnatal muscle. These cells 
differentiate into myoblasts during postnatal growth or in response to damage45. PAX3-
FOXO1 expression in mice satellite cells does not lead to tumor development but to a smaller 
number of postnatal myoblasts. In MSCs, the expression of PAX3-FOXO1 induces the 
expression of MYOD and MYOG45. These results point to MSCs as the possible cell of origin 
of FP-RMS. However, MSCs form tumors if not only PAX3-FOXO1 is expressed but also if the 
p53 pathway is inactivated. This is 
contradictory to sequencing studies which 
have shown that, occasionally, the fusion 
protein is the only somatic genetic 
alteration encountered30. Hence, the origin 
of FP-RMS is still questionable. 
 
2.6 Targeted Therapy 
FP-RMS is dependent on continuous expression of its unique fusion protein and on its 
oncogenic gene expression program. Thus, interfering with PAX gene rearrangements, 
directly or indirectly, provides means to specifically target FP-RMS. 
One strategy to hamper PAX3-FOXO1 activity is to act on its target genes. For example, 
blocking IGFR1 impairs FP-RMS cell growth in vitro53. Unfortunately, clinical trials with the 
human immunoglobulin G monoclonal antibody against IGF1R, Cixutumumab37, showed no 
durable objective clinical response35. Pre-clinical studies have also shown the potential of 
FGFR4 inhibition, by the tyrosine kinase inhibitor ponatinib37. This drug suppresses STAT3, 
a downstream target of FGFR453, and inhibits RMS cell lines proliferation in vitro and tumor 
growth in mouse xenographs37.  
Direct targeting of PAX3-FOXO1 is more challenging due to its loose structure. Hence, 
strategies targeting the fusion stability have been developed. CDK4 inhibition abrogates the 
phosphorylation and the nuclear localization of PAX3-FOXO1. Treatment of FP-RMS cells 
with the CDK4/6 inhibitor palbociclib leads to G1 arrest and the expression of muscle-
Fig. 9 Differentiation routes of mesenchymal stem cells 
differentiation. Adapted from22. 
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specific markers37. PLK1 inhibitors increase ubiquitylation and degradation of PAX3-
FOXO1, and promote tumor regression in xenograft mouse models29. Furthermore, the 
HDAC inhibitor entinostat decreases PAX3-FOXO1 mRNA levels, and, consequently, reduces 
tumor growth54. 
 
3. Ewing Sarcoma 
Ewing Sarcoma (ES) is the second most common bone sarcoma in childhood and 
adolescence55, and was first described in 1866 as a small-round cell tumor56. In 1921, James 
Ewing separated this tumor entity from the osteogenic sarcoma and renamed it as “diffuse 
endothelioma of the bone”57. In the 1980s, a chromosome analysis detected the 
characteristic t(11;22)(q24;q12) translocation in ES cell lines, which later in 199258 was 
found to produce the chimeric protein and tumor driver EWS-FLI156. 
 
3.1 Disease prevalence 
The peak of ES incidence occurs between the ages of 15-2459 and is rarely diagnosed after 
the age of 3055. Nevertheless, to date, the oldest patient diagnosed with ES was 77 years 
old60. The average incidence of ES in adolescents and young adults is 2.6 per million, with a 
higher predominance in the male population (1,5:1), and rarely described in the black 
population55,56,61. The low susceptibility of the African population can be explained by their 
distribution of GGAA microsatellites. EWS-FLI1 has higher activity when GGAA 
microsatellites have a length of 20-30 repeats which is more commonly found in the 
Caucasian population compared to the African62,63. 
ES occurs mainly in bones (Fig.10) and is generally found in the diaphyseal portion of flat 
bones64. The most commonly affected bones are pelvis, ribs, spine, and femur55,65. However, 
in 30% of the cases, this tumor is found in soft tissue59. Extra skeletal regions include kidney, 
breast, gastrointestinal tract, prostate, endometrium, lung, adrenal gland, and meninges56,64. 
The prognosis for these locations is unfavorable in the 
first 2 years but afterwards the outcomes are 
significantly better compared to skeletal ES66. Primary 
metastasis in lungs, pleural space, bone, and bone 
marrow are detectable in 25% of patients at the time 
of diagnosis64.  
  
Fig. 10 Radiograph shows a ES mass in the 
metadiaphyseal region of the distal 
humerus. Adapted from65. 
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3.2 Diagnosis 
Pain at rest is the most common symptom present in ES patients64,67. It is usually 
locoregional, intermittent, and often erroneously attributed to trauma67,68. Other symptoms 
include swelling, venous dilation, palpable mass formation, paresthesia, and fever in the 
advanced stages56,64.  
The initial diagnosis is made through imaging techniques, such as CT and MRI, but definitive  
diagnosis is achieved by biopsy56,64. Provided enough biopsy material is available, 
conventional histology, immunohistochemistry, and molecular biology analysis are 
performed. Cytoplasmic glycogen and CD99 are usual ES makers, although not specific65,68. 
The identification of the characteristic EWS-FLI1 and EWS-ERG fusion proteins confirms the 
ES diagnosis69. In the clinics, the detection of the fusion protein is accomplished by reverse 
transcription polymerase chain reaction (RT-PCR) or FISH (Fig.11A)56. Nevertheless, a 
negative RT-PCR does not exclude ES since EWS-FLI1 and EWS-ERG are not the only fusion 
genes present in ES65.  
 
3.3 Histology 
ES represents a group of tumors with varying degrees of differentiation and can be divided 
into classical ES, primitive neuroectodermal tumor (PNET), and atypical ES65. Classical ES 
(Fig.11B), as described by James Ewing, is composed of "broad sheets of small polyhedral 
cells with pale cytoplasm, small hyperchromatic nuclei, well-defined cell borders, and 
complete absence of intercellular material"57. PNET are ES tumors with evident signs of 
neural differentiation such as Homer Wright rosettes or the presence of specific markers 
(neuron-specific enolase, S-100 protein and Leu-7)64,65,68. Atypical ES (large cell ES) refers 
to tumors with features that deviate from those of classical ES, such as nuclear enlargement 
and pleomorphism, irregularity of nuclear membrane, and prominent nucleoli.  
The new WHO report considers the distinction between ES and PNET obsolete70 since both 
express the oncogenic fusion protein and present no clinical differences. 
 
  
Fig. 11 (A) FISH detection of the EWS-FLI1 fusion protein. (B) Classical ES 
sarcoma histology. Adapted from56. 
A B 
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3.4 Mutational burden 
Besides the distinctive translocation, ES is characterized by a relatively simple karyotype 
(0.15 mutations⁄Mb71) with only a few numerical and structural aberrations (Fig.12)72.  
Structural changes of chromosomes 1 and 16 are present in roughly 20% of the tumors, 
which result in a gain of 1q and a loss of 16q, and the formation of the derivative 
chromosome der(1;16)64. Gain of chromosome 1q  is associated with the overexpression of 
CTD2 (cell division cycle protein 2), a protein involved in DNA damage repair73. Trisomy 8 
is present in nearly half72 of the cases and trisomy 12 in a third64. Chromosome 8 gain leads 
to an overexpression of the oncogene MYC, while chromosome 12 gain is associated with 
high expression of NANOG, CDK4, ERBB3, GLI1, and MDM273. Homologous deletion of the 
chromosomal region 9p21, containing ink4A (which encodes for the well-known cell cycle 
regulator CDKN2A), is present in 25-28% of ES cases64,72. LOH at 17p13, followed by 
mutation of the remaining p53 allele, occurs in less than 10% of the cases64.  
Mutations in TP53, STAG2 and CDKN2A are recurrent71,74,75. Mutations in TP53 occur in 6% 
of the cases and are usually accompanied by STAG2 mutations71,72,75. The presence of both 
TP53 and STAG2 mutations is correlated with unfavorable prognosis75. STAG2 mutations, 
which are associated with loss of STAG2 expression, are present in more than 15% of ES 
cases72. Interestingly, 88% of patients with STAG2 mutations present metastases at the time 
of diagnosis72, suggesting an association between STAG2 status and disease dissemination. 
CDKN2A is mutated in 12% of all ES cases and, interestingly, STAG2 mutations and CDKN2A 
deletions are mutually exclusive75. 
  
Fig. 12 Mutation landscape of ES. Adapted from75. 
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3.5 The fusion genes 
Ewing sarcoma is characterized by recurrent translocations that occur between members 
of the TET and ETS families of transcription factors. These chromosomal translocations 
originate different fusion genes that act as aberrant TFs and are associated with tumor 
development76. 
EWS-FLI is the most common fusion gene, being present in 85% of all ES cases76. This 
oncoprotein fuses the DNA-binding domain of FLI1 (friend leukemia virus integration site 
1; the ETS family member) in-frame with the N-terminal domain of EWSR1 (the TET family 
member), under the control of the EWSR1 promoter58. In ES, EWS is also found fused to 
other ETS family members (Fig.13) such as ERG (ETS-related gene)77, ETV1 (ETS-variant 
gene 1)78, ETV4 (ETS-variant gene 4, also called E1AF - adenovirus E1A enhancer-binding 
protein)79 and FEV (fifth Ewing sarcoma variant)80. EWS-ERG, the result of the 
t(21;22)(q22;q12) translocation, is the second most common rearrangement found in ES, 
accounting for 10% of the cases.  ERG shares 68% of overall amino acid sequence with FLI1 
and studies have shown no clinical difference between ES tumors bearing EWS-FLI1 or 
EWS-ERG fusion genes76. 
All EWS-ETS fusion proteins have similar structure and function. The amino-terminal 
transactivation domain of EWSR1 is fused to the ETS DNA-binding domain76,81. These 
fusions are all able to form tumors in mice when overexpressed in murine fibroblasts 
NIH3T382. Moreover, overexpression of a dominant negative mutant of EWS-ETV1 can 
inhibit NIH3T3 cell transformation by EWS-FLI183, which proves the redundancy of EWS-
ETS fusions. The transformation activity of the fusion protein is dependent on EWSR1 and 
both the DNA-binding domain of FLI184 and the COOH terminus of FLI185.  
Infrequently, non-EWS fusions have been identified in ES. In these cases, the fusion occurs 
between another TET family member named TLS (also called FUS) and the ETS members 
ERG86 or FEV87. These oncoproteins are thought to also recapitulate the oncogenic role of 
EWS-FLI76. Non-TET-ETS rearrangements have also been identified in small round cell 
sarcomas which histologically resemble ES and are categorized by WHO as Ewing-like 
sarcomas65.  
 
 
Fig. 13 Schematic representation of the EWS-FLI1 translocation. AD - Activation domain; RGG - arginine-glycine-
glycine-rich region; RRM - RNA recognition motif; ZNF - zinc finger domain; ETS-DBD - ETS DNA binding domain. 
Arrows indicate the regions where the translocation occurs. Adapted from81. 
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3.6 EWS-FLI1 
From the reciprocal translocation t(11;22)(q24;q12), only the EWS-FLI1 product is 
expressed58,64. The amino-terminal domain of EWS contains the EAD (EWS activation 
domain)76 which is composed of several repeats of serine-tyrosine-glycine-glutamine and is 
a stronger transcriptional activator than transactivation domain of FLI188.  The carboxy-
terminal of FLI1 contains the ETS DNA-binding domain and recognizes purine-rich 
sequences with the GGAA/T core motif76. 
EWS-FLI, rather than a single entity, is a group of highly related isoforms with different 
intronic breakpoints in the EWSR1 and FLI1 genes (Fig.14). The most common fusion is 
called type I and consists of EWSR1 exons 1-7 and FLI1 exons 6-1076. The relevance of the 
different fusions in the pathology of the disease is still unclear. 
Similarly to PAX fusions in FP-RMS, EWS-FLI1 is essential for ES. Depletion of EWS-FLI1 in 
ES cells inhibits cell proliferation in vitro, by apoptosis or cell cycle retention in G189, and 
tumor growth in vivo90,91. 
 
3.7 EWSR1 and FLI1 gene families 
The EWSR1 gene encodes the EWS protein, a member of the TET family which also includes 
TLS and TAF1576.  EWS plays a role in meiotic cell division, mitotic spindle formation, DNA 
repair, and ageing92. In its C-terminal, the EWS protein contains an RNA-binding domain 
which is important for RNA metabolism. EWS associates with members of the 
transcriptional machinery, including RNA polymerase II, TFIID and CBP/300, which 
suggests an active role in transcription regulation76. 
FLI1 encodes the FLI1 protein, a member of the ETS (E-26 transformation specific) family 
of transcription factors76. This family is characterized by a highly conserved winged helix-
loop-helix DNA-binding domain, known as the ETS domain76. All 27 members of the ETS 
family bind to the core GGAA/T motif93. ETS members function as signal-dependent 
transcriptional regulators of cellular differentiation and proliferation93. Besides ES, other 
translocations involving ETS family members have been involved in other cancers such as 
the TMPRSS2-ERG fusion in prostate cancer93. 
  
Fig. 14 Genomic structure of the EWSR1 and FLI1 genes. Exons are numbered and represented by rectangles 
and the connecting lines represent the breakpoints in the EWSR1 and FLI1 genes found in EWS-FLI1 
translocations. Adapted from76. 
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3.8 Fusion gene signature 
Two main approaches were used to identify EWS-FLI1 target genes. Either the fusion 
protein was ectopically expressed in a non-ES cell type (fibroblasts94, FN-RMS cells95, and 
MSCs96) or EWS-FLI1 was silenced in ES cell lines by RNAi97–100. These studies revealed that 
EWS-FLI1 can both activate and repress gene expression. A meta-analysis performed on the 
previously mentioned studies identified a core signature composed of 503 activated genes,  
and 293 repressed101. The activated core included NR0B198, NKX2.297, PTPN1102, ID2103, 
CAV199, and MYC94. Among the downregulated signature there was the insulin-like growth 
factor binding protein 3 (IGFBP3)100,101.  
Regarding molecular functions, genes upregulated by the fusion are implicated in oncogenic 
transformation (NR0B198, NKX2.297, GLI1104, c-Myc95, CAV199), cell proliferation (PTPN1102, 
ID2, CCND1 and CCNE105), drug-resistance (GSTM4106), immortalization (hTERT107), 
angiogenesis (VEGF94) and maintenance of pluripotency (EZH296). On the other hand, genes 
downregulated by EWS-FLI1 are involved in cell cycle progression (FOXO1108, p27 and 
p21105,109), evasion of apoptosis (IGFBP389), evasion of growth inhibition (TGFBRII110), 
apoptosis regulation (PHLDA1111) and cell transformation (LOX112). 
EWS-FLI-1 also induces the expression of neural cell markers including NYP1R, GRP, MSX1, 
EGR2, NKX2-2, NGFR, CITED2, CDH11, and MAPT95. 
 
3.9 Treatment 
Current treatment strategies include chemotherapy, surgery and radiotherapy56. 
Chemotherapeutic protocols consist of a combination of vincristine, actinomycin-D, 
cyclophosphamide, and doxorubicin (VACD) with or without ifosfamide and etoposide 
(VACD-IE)56.  Chemotherapy is applied preoperative to eradicate micro metastases and 
reduce the tumor volume. Local lesions are surgically removed, and radiotherapy follows 
with adjuvant chemotherapy56,64. If the tumor is inoperable, radiotherapy alone is 
employed68. Radiotherapy is applied at 40-45 Gy doses for microscopic and 50-60Gy for 
macroscopic disease68. Relapses occur in the first 3 years after therapy68 and there is still no 
standard treatment available for those56.  
Late effects of therapy comprise poor local orthopedic outcome, caused by surgery and 
radiotherapy, and systemic effects from radio and/or chemotherapy. Radio and 
chemotherapy can cause secondary malignancies, being leukemia the most common. The 
usage of anthracyclines, like doxorubicin, induces a dose-related cardiomyopathy. 
Alkylating agents (cyclophosphamide and ifosfamide) are associated with infertility and 
ifosfamide can also cause persistent renal tubular electrolyte loss and decrease in 
glomerular function64.  
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3.10 Targeted therapy 
Like in FP-RMS, the unique presence of the fusion protein and the tumor susceptibility to its 
continuous expression makes EWS-FLI1 an ideal target for therapy. Therefore, new 
therapies have been developed to influence the activity of the fusion by either targeting its 
binding partners, its target genes or by influencing it directly. 
PARP1 was shown to interact with both EWS-FLI1 and EWS-ERG, which linked these to DNA 
damage reponse113. Moreover, ES is defective in many DNA-damage repair genes, such as 
BRCA1, GEN1, and ATM114. Naturally then, ES cells are sensitive to PARP inhibitors, like 
olaparib, and this sensitivity is increased by the combination with DNA-damaging drugs, 
like irinotecan or temozolomide113,114. Unfortunately, in a phase II clinical trial, olaparib 
failed to produce a significant response115. EWS-FLI1 also interacts with the RNA helicase A, 
an integral component of protein complexes that regulate transcription and splicing116. This 
interaction can be blocked by the small molecule YK-4-279117, which induces apoptosis in 
ES cells and reduces the growth of mouse tumor orthotopic xenografts117.  
The IGF pathway is active in ES by upregulation of IGF1118 and downregulation of IGFBP3, 
which blocks the interaction between IGF1 and its receptor100.  Inhibition of this pathway 
through small molecule or monoclonal antibodies induces cell death and reduces ES tumor 
growth119,120. Clinical trials have shown that inhibitors of the IGF pathway can have a 
valuable effect in a selection of ES patients121. 
Interestingly, the chemotherapeutic actinomycin D can directly influence EWS-FLI1. This 
DNA-binding molecule specifically removes EWS-FLI1 from the chromatin and affects a 
wide range of the fusion target genes122. Sadly, due to its toxicity, it is not possible to achieve  
in humans the concentration necessary of actinomycin D for this effect122. Nevertheless, a 
similar effect on EWS-FLI1 target genes was observed with another chemotherapeutical 
drug, trabectedin123. 
 
3.11 Prognosis 
The current treatment strategies have improved the 5-year overall survival of ES from 10% 
to 60%, in localized disease124, and to 20-30% for metastatic disease68. Bone metastases 
confer poorer prognosis than the lung ones64. Age of diagnosis also plays a role in prognosis. 
Patients younger than 15 years have a 5-year overall survival of over 65% while it drops to 
50% for older patients55. Primary tumor location in the appendicular skeleton and tumor 
size ≤8 cm confer significant survival benefit, while race and neuroectodermal 
differentiation do not add prognostic value61,65. Despite the variety of breakpoints of EWS-
ETS fusions, there is no significant prognostic value of the fusion type on the risk of 
progression or relapse124.  
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3.12 Cell of origin 
James Ewing first predicted an endothelial origin for ES due to its similarity to angio-
endothelioma57.  Since then, many cell types have been considered as possible cradles of ES, 
being neural crest cells and mesenchymal stem cells the most promising candidates125. 
The neural crest cell hypothesis is supported by the presence of neuroectodermal markers 
and neuronal differentiation characteristics in some ES tumors65,126. Nevertheless, the 
occurrence of neuronal related morphology in ES varies from absent to prominent127. On 
the other hand, ES cells exposed to differentiation-inducing agents clearly undergo neuronal 
differentiation128 and neural crest stem cells are permissive to the expression of ectopic 
EWS-FLI1129, unlike fibroblasts which undergo p53-dependent growth arrest130. Gene 
expression profiling also positions ES tumors closer to neural crest stem cells than to bone 
marrow-derived human mesenchymal stem cells129. Yet, it is not known if the neuronal 
features of ES are derived from the cell of origin or a consequence of EWS-FLI1 expression. 
In fact, EWS-FLI1 expression in the FN-RMS cell line RD also leads to the upregulation of 
genes involved in the neural crest development95. 
Unlike neural crest stem cells, mesenchymal cells are normally present in the bone, the most 
common location of ES131. MSCs of the bone marrow can express neural markers 
spontaneously and can be induced to differentiate towards the neural lineage131. 
Interestingly, knock-down of EWS-FLI1 in ES cell lines switches their expression profile 
closer to the one of MSCs132. Moreover, concomitant silencing of EWS-FLI1 and incubation 
with differentiation media allows ES cell lines to differentiate into both adipogenic and 
osteogenic lineages, as do MSCs132. Additionally, ectopic expression of EWS-FLI1 in murine 
MSCs results in cell transformation and in the formation of tumors similar to ES133,134. In 
human MSCs, EWS-FLI1 induces the expression of neuroectodermal markers135 but fails to 
develop tumors in mice136. Furthermore, expression of EWS-ERG is not well tolerated by 
mouse progenitor cells137. Hence the mystery of ES origin remains unresolved. 
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Oncogene and transcriptional addiction 
Although cancer evolves by the progressive accumulation of mutations, disruption of one 
gene can completely abrogate the malignant phenotype. Switching on the c-myc oncogene 
in hematopoietic cells leads to the development of a leukemia highly dependent on it138. This 
observation led to the concept  of “oncogene addiction” by Weinstein139,140 which describes 
the need for continuous expression of one oncogene for the maintenance of the neoplastic 
state141. Myelocytic leukemias depend on BCR-ABL, melanomas depend on HRAS and the 
two pediatric sarcomas described above depend on PAX3/7-FOXO1 and EWS-FLI1. The 
discovery of these “Achilles’ heels” of cancer can guide targeted therapy. A good example of 
this is the use of imatinib to block the activity of BCR-ABL in CML141. Nevertheless, many of 
these “Achilles’ heels” are transcription factors (TFs) which are commonly described as 
undruggable targets due to their nuclear location and lack of enzymatic function142.  
One way of disturbing the action of oncogenic TFs is by targeting transcription itself. 
Transcription is required for all basic cell processes like survival, growth, and 
differentiation. However, transcription inhibitors affect more drastically cancer cells than 
non-transformed cells. Koumenis and GIaccia have shown that RNA polymerase II inhibitors 
induce growth arrest in non-transformed human fibroblast, while in fibroblasts with 
deregulated expression of c-MYC they lead to apoptosis143. These experiments supported 
the concept of transcriptional addiction (Fig.15) in cancer cells and made basal 
transcription machinery a valid target. Indeed, many of the chemotherapeutical drugs used 
in the clinics are in fact transcriptional inhibitors144. The sensitivity of cancer cells to 
transcription inhibitors can be explained by the fact that anti-apoptotic transcripts have a 
faster turnover than the pro-apoptotic ones145. Moreover, the expression of oncogenes is 
more easily disturbed by transcriptional inhibition than the one of housekeeping genes145, 
due to the epigenetic characteristics of their regulatory regions.  
Non-transformed cells 
Transcriptional inhibition 
Low depletion 
of transcripts 
Cell survival 
Cancer cells 
Transcriptional inhibition High depletion of 
oncogenic 
transcripts 
Cell death 
Fig. 15 Differential response of non-transformed cells and cancer cells to transcription inhibition. 
Adapted from145. 
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Epigenetics: the organization of life 
The term epigenetics was first applied by C. H. Waddington in 1942146. He defined it as  “the 
branch of biology which studies the causal interactions between genes and their products, 
which bring the phenotype into being”146.  
Epigenetics is the study of heritable changes in gene expression that occur independently 
of changes in the primary DNA sequence147. The epigenetic landscape also shapes the 
decision-making process during development (Fig.16A)148 and gives rational to cell 
differentiation. Even though our cells share the same genotype, we find a broad spectrum 
of phenotypes whose development is dependent on the epigenome.  
 
1. The epigenetic object: chromatin 
Chromatin is composed of DNA and histone proteins organized into units named 
nucleosomes. These nucleosomes allow the packaging of 2 meters of DNA into a 10-20μm 
nucleus149.  The nucleosome is formed by two copies of each histone protein (H2A, H2B, H3, 
and H4) assembled into an octamer around which 145–147 base pairs (bp) of DNA are 
wrapped150. The H1 histone wraps an additional 20 bp of DNA and forms a 166bp long 
structure called chromatosome149. The nucleosome unit is found every 200 ± 40 bp 
throughout all eukaryotic genomes, producing an electronic image of beads on a string 
(Fig.16B).  Each nucleosome is separated by an average of 20bp of DNA called the linker 
DNA149 and shape the DNA molecule into higher order helices (Fig. 16C).  
In conclusion, each chromosome is formed by a string of nucleosomes which are the 
principal packaging element of DNA and the primary determinant of DNA accessibility.  
Fig. 16 (A) Model of how the landscape (the epigenome) can define the path (phenotype) of the ball (cell). 
Adapted from148. (B) Beads on a string, an electron micrograph of chromatin.  (C) DNA packaging into 
chromosome. Adapted from149. 
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2. Epigenetic regulation of transcription  
Transcription, but also DNA-damage repair and replication, requires access to the DNA 
strands which is blocked by the compact structure of nucleosomes. Hence, there must be 
mechanisms that allow the transient and reversible opening of chromatin. 
Modifications to DNA and histones are dynamically added and removed by chromatin 
modifying enzymes in a highly regulated manner. These post-translational modifications 
(PTMs) are then “read” by different chromatin remodeling enzymes that make actively 
transcribed regions looser and accessible, and repressed regions more closely packed. To 
date, at least 4 different DNA modifications and 16 classes of histone modifications have 
been identified151.  
 
2.1 DNA methylation 
Methylation of the 5-carbon residues of cytosine was the first described covalent 
modification of DNA. DNA methylation represses transcription directly by inhibiting the 
binding of TFs or indirectly by recruiting proteins associated with repressive chromatin 
remodeling activities152. This covalent modification occurs primarily within centromeres, 
telomeres, the inactive X-chromosome, and repeated sequences152. Interestingly, 
methylation studies have found many actively transcribed genes to be methylated in their 
gene bodies, contradicting the dogma that DNA methylation is associated with silencing151.  
The DNA methylation machinery is composed of DNA methyltransferases (DNMTs) which 
establish and maintain DNA methylation patterns, methyl-CpG binding proteins (MBDs) 
which “read” the methylation marks152, and demethylases which erase them153. 
In mammals, DNA is mainly methylated at CpG dinucleotides154 which are concentrated in 
CpG-rich DNA stretches named “CpG islands”. These islands are then mainly located at the 
5’end of genes and occupy 60% of human gene promoters. 
In cancer, a global DNA hypomethylation is observed primarily due to the loss of 
methylation from repetitive regions152. However, 5-10% of normally unmethylated CpG 
islands become abnormally methylated, affecting the expression of genes involved in cell-
cycle regulation, tumor cell invasion, DNA repair, chromatin remodeling, and apoptosis152. 
In addition, DNMTs are commonly overexpressed (DNMT1 and DNMT3B) or mutated in 
cancers (DNMT3A)151,155,156.  
 
2.2 Histone modifications 
Post-translational modifications of histones were first described by Vincent Allfrey in 
1964157. Since then, many different PTMs have been described, including acetylation, 
methylation, phosphorylation, ubiquitinylation, sumoylation, ADP ribosylation, 
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deamination, propionylation, and butyrylation158. The most studied modifications are the 
ones occurring on the N-terminal histone ‘tail’ regions (Fig.17A), but PTMs in the globular 
domains of histones have also been described158.  
Histone PTMs influence chromatin compaction and accessibility by changing histone-
DNA/histone-histone interactions or by recruiting remodeling complexes and transcription 
factors(Fig.17B)158. Histone acetylation, for instance, unfolds chromatin since it neutralizes 
the positive charge of lysine, weakening the electrostatic interaction between histones and 
the negatively charged DNA159. Hence, acetylation of histones is associated with an “open” 
chromatin conformation, which is permissive to transcription160. Histone PTMs are also able 
to directly repress gene expression. Di or trimethylation of H4K20 enhances chromatin 
condensation, which impairs gene expression161.  
Histone PTMs are constantly being added by enzymes named “writers” and removed by 
“erasers”, which allows a tight control of gene expression and increases cell flexibility and 
adaptation to environmental changes. Acetylation marks, for example, are added by histone 
acetyl-transferases (HATs) and erased by histone deacetylases (HDACs). In between, 
histone modifications are read by specific enzymes with certain “reader” domains. For 
example, methylation is recognized by chromo, tudor, MBT and PHD domains, and 
acetylation is recognized by bromodomains159. 
Due to the significance of histone marks in chromatin architecture, Strahl and Allis proposed 
the existence of a “histone code” where distinct histone modifications can act sequentially 
or in combination to bring about distinct downstream events which are associated with 
certain chromatin states162. Grossly speaking, there are 2 types of chromatin environments 
in the genome, silent heterochromatin and active euchromatin (Fig.18)159. The histone code 
suggests that these states are associated with a distinct set of modifications. In mammals, 
the heterochromatic state is related with low levels of acetylation and high levels of 
Fig. 17 (A) Representation of histone modifications present in histone tails. Image retrieved from abcam website. 
(B) Epigenetic regulation of chromatin compaction and transcription. Black dots symbolize DNA methylation. 
Adapted from163. 
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methylated H3K9, H3K27, and H4K20159. Euchromatin, on the other hand, presents a more 
complex histone code since it is more flexible and changes according to need159. Active 
promoter regions are characterized by sharp peaks of H3K4me3 and histone acetylation, 
while repressed promoters are decorated with H3K27me3 and H3K9me3163. Promoters 
containing both active (H3K4me3) and repressive marks (H3K27me3),  termed “bivalent” 
or “poised”, are usually associated with developmental genes, being inactive in pluripotent 
cells and induced during differentiation163. Enhancers are elements that recruit TFs, RNA 
Polymerase II (Pol 2) and chromatin regulators to positively influence transcription at distal 
promoters163. These cis-regulatory 
regions are marked by H3K4me1 and 
H3K27ac163. Finally, actively 
transcribed genes are distinguished by 
the presence of H3K36me3 and 
H3K79me2 in their gene bodies163.   
In cancer, a global loss of H4K16ac, 
H3K4me3, and H3K20me3, and gains 
of H3K9me and H3K27me3 have been 
reported155. These alterations have 
been associated with mutations or 
overexpression of specific “writers” or 
“erasers”151,155. Hence, many 
epigenetic drugs have been developed 
and approved for therapy164.  
 
2.3 Chromatin remodeling 
Chromatin remodeling is involved in cell-fate commitment, response to environmental 
signals, genome replication, and DNA repair165. The remodeling process is conducted by 
helicase-like enzymes that hydrolyze ATP and transform chemical energy into mechanical 
motion166. These enzymes are able to assemble or evict nucleosomes during replication, 
exchange histone variants, and regulate transcription by changing chromatin accessibility 
(Fig.19A)167. 
All chromatin-remodeling enzymes belong to the SNF2 family and contain a SNF2 helicase-
like ATPase domain168, which is composed of two RecA-like fold domains (Dexx and 
HELICc)169 and is homologous to the ATPase domain of the Saccharomyces cerevisiae SNF2 
protein170. Importantly, SNF2 proteins are not bona fide helicases since they lack the ability 
Fig. 18 Epigenetic regulation of chromatin architecture. 
Adapted from164. 
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to separate nucleic acid strands. Instead, they are DNA translocases that apply torsional 
strain to DNA and provide the necessary force to remodel nucleosomes170.  
These ATP-dependent remodelers are grouped into 24 subfamilies166 in accordance with 
their structure similarities and the presence of other functional domains171.   The 4 main 
families (Fig.19B) are the SWI/SNF (characterized by the presence of bromodomains), the 
imitation SWI or ISWI (containing a SANT domain responsible for histone binding), the 
chromo and helicase-like domain or CHD (which presents amino-terminal chromodomains 
that interact with histone tails) and the INO80 (which defining feature is the “split” ATPase 
domain)172.  
Despite many ATP-dependent remodelers have been implicated in cancer, the role of 
chromatin remodeling in tumorigenesis is still not fully understood. BRG1, an ATPase 
subunit of the SWI/SNF complex, is mutated in cancer cell lines of several tumors types 
including breast, prostate, lung, pancreas, and colon173. Mice with heterozygous mutations 
of Brg1 are cancer-prone, which suggests a role of Brg1 as a tumor suppressor173. 
Nevertheless, BRG1 can also contribute to cancer development by constraining p53 
activity174. These findings suggest a context dependent activity for BRG1 in cancer 
development. More studies are necessary to further investigate the link between chromatin 
remodeling complexes and tumorigenesis, and to evaluate their therapeutic value. 
 
3. The NuRD complex 
The nucleosome remodeling and histone deacetylase complex (NuRD) was first described 
in 1998 as a multisubunit complex involved in transcription repression175. It is highly 
conserved among eukaryotes, ubiquitously expressed176, and, to date, the only chromatin 
remodeler complex bearing both nucleosome remodeling and histone deacetylase 
activity177. The chromatin remodeling function is carried out by CHD3 or CHD4 
(chromodomain-helicase DNA binding proteins) while the histone deacetylase function is 
performed by HDAC1 or HDAC2 (histone deacetylases)177. These HDACs share 85% in 
Fig. 19 (A) Chromatin remodeling mechanisms. Adapted from165. (B) Structural features of the 4 main 
subfamilies of the SNF2-like family of ATPases. Adapted from172. 
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sequence identity and are able to remove acetyl groups from lysine residues on histone tails 
and on other proteins, such as p53177,178.  
Other non-enzymatic subunits of NuRD include MBD2/3 (methyl-CpG-binding domain), 
RBBP4/7 (retinoblastoma-binding proteins), MTA1/2/3 (metastasis-associated) and 
GATAD2A/B (GATA Zinc Finger domain containing)177. These NuRD members are involved 
in the assembly and positioning of the complex on the chromatin. MBD2/3 are the smallest 
members of NuRD177 and have markedly different functions179. While MBD2 binds to 
methylated DNA180, MBD3 binds to hydroxymethylated DNA181. Furthermore, MBD3 
knockout, but not the one of MBD2, leads to embryonic lethality182. RBBP4/7 (also known 
as RbAp48 and RbAp46, respectively) share 92% of sequence homology and direct the 
complex to histone 3183.  The MTAs contribute to the assembly of the complex by mediating 
protein-protein interactions with the HDACs184,185. GATAD2A/B interact with the MBDs, 
increase the repressive function of MBD2, and direct the NuRD to unmodified histone 
tails176,177. Other enzymatic and non-enzymatic subunits have also been associated with this 
complex such as DOC1-1 (deleted in oral cancer-1) and LSD1 (lysine-specific histone 
demethylase)178. 
Structural studies suggest that the NuRD is composed by 2 HDACs and MTAs, 4 RBBPs and 
1 MBD, GATAD2 and CHD (Fig.20)176,186. The ATPase subunits, 
MTAs and MBDs are mutually exclusive and form complexes 
with different function175,178,187. Some subunits are exclusively 
present in the NuRD complex (CHDs, MBDs and MTAs), but 
others take part in other complexes, like HDAC1/2 and 
RBBP4/7 which are found in the co-repressor complexes SIN3, 
coREST, PRC2 and CAF-1178.  
 
3.1 The ATPases of NuRD 
CHD3 and CHD4 (Mi-2α and Mi-2β, respectively) were first discovered as autoantigens in 
an autoimmune disease related with cancer development named dermatomyositis188. 
Together with CHD5, which is also found in the context of NuRD, these proteins form the 
Mi-2 subclass of the SNF2-like ATPase family189.  In vitro studies demonstrated that CHD4 
and CHD3, unlike INO80, ISW1A or CHD1, remodel nucleosomes independently of the linker 
length and their initial position. Nevertheless, CHD3 and CHD4 remodeling activities result 
in different nucleosome positioning187. 
Fig. 20 The NuRD complex. 
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Both CHD3 and 4 are ubiquitously expressed and contain a C-terminal ATPase (Fig.21), 2 
plant zinc finger homeodomains (PHD1/2), 2 chromodomains and 2 C-terminal domains of 
unknown function (DUF)190.  The chromodomains directly bind to DNA while the PHD 
domains interact with histones191. These PHD domains are able to bind the N-tail of H3 with 
increased affinity when acetylation or methylation of Lys9 is present192–194. However, the 
PHD2 domain of CHD4 fails to bind to H3 in case of methylation of Lys4 or acetylation of 
Ala1194.  Importantly, the ATPase activity of CHD4 is dependent on the simultaneous binding 
of the PHD domains to histones and of the chromodomains to DNA195,196. Likewise, the 
ATPase domain activity promotes the association of the PHD and chromodomains to 
histones and DNA, respectively196.  
Despite their high homology, CHD3/4/5 have different functions. For example, during 
cortical development, the CHD subunits of NuRD exchange to regulate distinct aspects of 
differentiation. CHD4 promotes early proliferation of progenitor cells, CHD5 facilitates 
neuronal migration and CHD3 ensures proper layer specification197.  
 
3.2 NuRD in DNA-damage repair  
To initiate the DNA-damage repair (DDR), the chromatin must be accessible to checkpoint 
and repair factors. The NuRD is essential to the DDR since it allows an open chromatin 
conformation at damage sites. In fact, the depletion of CHD4 or MTAs leads to accumulation 
of spontaneous DNA damage, increased ionizing radiation sensitivity, and impaired 
homologous recombination repair198,199. The remodeling function of CHD4 seems to be 
crucial for the DDR, since CHD4 mutants with no helicase activity are not able to rescue the 
depletion phenotype199.Mechanistically, CHD4 is recruited to the sites of DNA damage by 
PARP200 where it participates in the recruitment of BRCA1(Fig.22A). The recruitment of 
CHD4 is also dependent on the ubiquitin ligase RNF8 and promotes the recruitment of RPA 
and RAD51199.  
 
3.3 NuRD in cell cycle progression, DNA replication and genome stability 
Besides DDR, the NuRD carries other non-transcription related functions such as regulation 
of cell cycle, DNA replication, and genome stability.  
PHD1 ATPase 
Histone binding DNA binding 
N-terminal C-terminal 
CD2 PHD2 DUF DUF CD1 
Fig. 21 Schematic representation of the structure of CHD3/4. 
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CHD4/NuRD regulates G1/S transition by controlling p53 acetylation status (Fig.22B)200. 
Indeed, CHD4 depletion leads to hyperacetylation of p53 which increases the expression of 
p21 and causes G1/S arrest200. 
In lymphocytes, NuRD localizes to pericentromeric heterochromatin (Fig.22C) during S 
phase together with proteins related to active replication forks such as the proliferating cell 
nuclear antigen (PCNA) and chromatin assembly protein (CAF1)201. 
The NuRD is also associated with pericentric heterochromatin where it promotes genome 
stability by inducing nucleosome compaction202. This association is driven by the 
heterochromatin containing HP1 proteins, H3K9me3203, and sumoylated KAP-1202. In fact, 
loss of CHD4 or MBD3 leads to defects in pericentric heterochromatin assembly and 
maintenance, which then induces a delayed S-phase progression204. 
 
Fig. 22 The NuRD complex functions in DNA replication (A), cell cycle progression (B) and DDR (C). Adapted 
from201. 
 
3.4 NuRD in gene regulation and cell fate commitment 
When first identified, NuRD was labelled as a repressor complex175 since MBD2 was found 
to localize to methylated promoters from where it induced gene silencing through 
collaboration with histone deacetylases205. However, more recently, many studies have 
shown the potential of NuRD as an activator. Sequencing studies position the MBD3 
component at active promoters and H3K27ac rich enhancers206. Moreover, during 
hematological development, NuRD mediates both activating and repressive functions. For 
example, in erythroid cell lines, NuRD coregulates FOG-1 dependent transcriptional 
activation207, while, during T-helper 2 cell differentiation, Chd4 forms a complex with Gata3 
and p300 that mediates both positive and negative gene regulation208. 
The NuRD complex plays many roles in cell differentiation. In embryonic stem cells (ESCs), 
NuRD-mediated deacetylation is associated with PRC2 recruitment and subsequent 
methylation of H3K27, which determines the transcription status of poised genes209. During 
muscle development, CHD4 is required for the correct differentiation of cardiac muscle. In 
fact, Chd4 depletion leads to aberrant expression of the skeletal muscle program and causes 
cardiomyopathy in mice210. Moreover, CHD4-mediated repression of skeletal and smooth 
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muscle myofibril isoforms is required for normal cardiac sarcomere formation211. In neural 
progenitor cells (NPCs), Chd4 interacts with Ezh2 and silences glial markers, preventing 
astroglial differentiation212.  Moreover, NuRD interacts with the TF LHX2 and controls the 
expression of Sox11 and Fezf2, two TFs essential for cortical neuron development213.  
Interestingly, some NuRD elements seem to have contradictory functions in development. 
Mbd3, in the absence of self-renewal signals, silences the expression of pluripotency genes 
in ESCs and allows the cell to respond to differentiation214. On the other hand, Chd4 was 
reported to be essential for the self-renewal of ESC215.  
 
3.5 NuRD and cancer 
Many NuRD components are overexpressed in cancer and involved in tumorigenesis. Less 
frequently, NuRD components are mutated during the tumorigenesis process. Nonetheless, 
19% of uterine serous carcinomas and 17% of endometrial cancers carry CHD4 loss-of-
function mutations216.  
MTA1 overexpression is associated with aggressiveness of breast, liver, colon, pancreas, and 
prostate cancers217. In breast cancer, MTA1 and MTA3 carry opposing functions. MTA1 
facilitates tumor progression through interaction and repression of the estrogen receptor 
transcriptional function, while MTA3 acts as a tumor suppressor by interfering with the 
expression of SNAI, a crucial TF that promotes epithelial-mesenchymal transition (EMT). 
Furthermore, MTA1 expression increases during breast cancer progression, while the one 
of MTA3 decreases201. In gastroesophageal junction adenocarcinoma, low levels of MTA3 
are also associated with a poorer prognosis218.  MTA1 is a downstream target of the 
oncoprotein c-MYC and is essential for c-MYC driven cell transformation219. These findings 
point to both an oncogenic and tumor suppressor function of NuRD members. In fact, on 
one hand, MBD2 contributes to the silencing of hypermethylated promoters of tumor 
suppressor genes, including the CDKN2A locus in colon cancer220, and, in breast cancer, the 
tumor suppressor SALL1 interacts with MBD3 to inhibit tumorigenesis and metastasis221. 
Thus, the role of NuRD in cancer seems to be subunit and context dependent and requires 
further investigation. 
 
4. Targeting epigenetic regulators  
Since epigenetic regulators control genome accessibility in a reversible manner, inhibitors 
targeting these regulators are promising anticancer strategies. In fact, many small 
molecules targeting DNA methyltransferases, histone methylases, demethylases and 
deacetylases have been developed and some are already in use in the clinics.  
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Two DNMTs inhibitors, azacitidin and decitabine, were approved by the FDA and are used 
in myelodysplastic syndrome (MDS) therapy. Nonetheless, there is still room for 
improvement considering that these drugs lack oral bioavailability, have a short half-life 
and lack specificity as they bind irreversibly to all catalytically active DNMTs222. HDAC 
inhibitors are also used in the clinics. Romidepsin and vorinostat have been approved for 
the treatment of cutaneous T-cell lymphoma. Nevertheless, the mechanism of action of 
HDAC inhibitors is still debatable. Their anti-tumor activity might be due to alterations in 
transcription or via regulation of the acetylation status of non-histone proteins, like p53223. 
Although, not in the clinics yet, targeting of the histone methyltransferases (HMTs) EZH2 
and DOT1L holds great promise in cancer therapy. EZH2 is the catalytic component of the 
Polycomb protein complex (PRC2) and is responsible for the H3K27me3 mark. In prostate, 
breast, kidney, and lung cancer, increased levels of EZH2 are associated with poor 
outcome224. DOT1L specifically methylates H3K79 and contributes to the transcriptional 
activation of HOXA10 and MEIS1, which are required for leukemia initiation225. Emerging 
preclinical data has shown the therapeutic potential of the pharmaceutical inhibition of the 
histone demethylase LSD1(lysine-specific histone demethylase 1A) in AML. There, LSD1 is 
required to sustain the expression of the target genes of the oncoprotein MLL-AF9. Besides 
AML, this epigenetic effector is highly expressed in prostate cancer, undifferentiated 
neuroblastoma, estrogen-negative breast cancer, bladder cancer and colorectal cancer224. 
LSD1 inhibitors are expected to go soon into phase I clinical trials. 
 
4.1 BET-bromodomain inhibition 
Bromodomains are a small family of proteins that recognize and bind to acetylated lysine 
residues on histone tails. There, they act as scaffold of large multi-component complexes 
that regulate chromatin accessibility and transcription224. 
The demonstration of the druggability of the reader bromodomain and extra-terminal 
(BET) subfamily (BRD2/3/4/T) has intensified the interest in these epigenetic regulators 
as therapeutic targets226. BET-bromodomain inhibitors cause dramatic antiproliferative 
and pro-apoptotic effects in a variety of cancer cell lines and tumor growth delays in mouse 
xenograft models. Especially susceptible to these inhibitors are hematological malignancies 
including AML, Burkitt’s lymphoma, multiple myeloma, and B-cell ALL155,226, where these 
inhibitors directly silence MYC expression. Interestingly, in neuroblastoma, these inhibitors 
affect MYCN expression and cause tumor cell death227,228. Consequently, two BET-
bromodomain inhibitors, GSK 525761 and OXT015, are now in phase I trials for carcinoma 
and hematological malignancies, respectively229.
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Aim 
Gene expression and its spaciotemporal regulation are essential for the correct 
development of cells. During tumorigenesis, aberrant transcription factors or dysregulated 
signaling pathways change gene expression programs and cause cell transformation. Tumor 
cells become addicted to the expression of certain oncogenes and to a high level of 
transcription, which also makes them vulnerable to transcription inhibition and creates 
therapeutic opportunities. This is particularly relevant for the two pediatric sarcomas 
studied here, fusion-positive rhabdomyosarcoma and Ewing sarcoma. 
FP-RMS and ES are driven by a fusion TF (PAX3-FOXO1 and EWS-FLI1, respectively) that 
binds to cis-regulatory regions in the genome, mainly enhancers, and, from there, controls 
gene expression. Targeted therapies developed for these sarcomas have been focused on 
the fusion protein interactors or on the inhibition of target proteins. These approaches carry 
many limitations, are prone to resistance development, and have been so far unsuccessful. 
A growing number of epigenetics studies has shown that the gene expression programs 
regulated by aberrant TFs are highly dependent on epigenetic regulators. Hence, targeting 
these regulators represents a valid strategy to interfere with the oncogenic signature. The 
development of JQ1, a small-molecule BRD4 inhibitor, provided evidence of the feasibility 
of such approach. Since its development, many in vitro and in vivo studies demonstrated 
that a broad number of cancers are sensitive to BET-bromodomain inhibition.  
We and others identified the chromatin remodeler CHD4 (chromodomain-helicase-DNA-
binding protein 4) as a new epigenetic coregulator of PAX3-FOXO1 and EWS-FLI1. 
Chromatin remodelers are ATPases capable of using energy drawn from ATP hydrolysis to 
move nucleosomes along the DNA. Consequently, they control chromatin accessibility to the 
transcription machinery and are essential to gene expression control. Despite the relevance 
of chromatin remodeling in transcription, it remains a poorly studied branch of epigenetics 
and is often overlooked by the drug discovery field. 
Here, we aim to explore chromatin remodeling and changes in DNA accessibility as valid 
strategies for cancer therapy. To do so, we aim to investigate the mechanisms employed by 
CHD4 in the control of the oncogenic signatures of both FP-RMS and ES. Through chromatin 
immunoprecipitation assays followed by genome-wide sequencing, we describe in detail 
the epigenetic mechanisms used by PAX3-FOXO1 to control gene expression in FP-RMS. In 
addition, by performing DNase hypersensitivity assays, we study the role of CHD4’s 
nucleosome remodeling activity in PAX3-FOXO1-driven transcription. We explore also the 
potential of CHD4 as therapeutic target in both FP-RMS and ES. At last, we aim to develop 
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the first CHD4 small molecule inhibitor, using structure-based drug design, to validate CHD4 
as druggable new therapeutic target in cancer.  
With this study, we hope to highlight the role of chromatin remodeling in oncogenic gene 
expression, to establish CHD4 as an unexpectedly broad tumor susceptibility and to boost 
chromatin remodeling as a new field of potential cancer therapeutic targets. 
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ABSTRACT 
In cancer, aberrant transcription factors and/or dysregulated signaling pathways lead to 
changes in gene expression that drive tumorigenesis. Hence, targeting transcription 
through inhibition of epigenetic regulators is a valuable cancer therapeutic strategy, as 
exemplified by the recent success of BET-bromodomain inhibition.  
Here, we explored the potential of chromatin remodelers as therapeutic targets, since they 
have been overlooked so far as drug targets. As models of transcriptional deregulation, we 
interrogated two pediatric sarcomas, fusion-positive rhabdomyosarcoma (FP-RMS) and 
Ewing sarcoma (ES), which are driven by oncogenic transcription factors, PAX3-FOXO1 and 
EWS-FLI1 respectively. In both tumors, we characterized the epigenetic role of the 
chromatin remodeler CHD4, which was previously identified as a necessary cofactor for 
PAX3-FOXO1and EWS-FLI1 activity. We demonstrate that CHD4 co-localizes with PAX3-
FOXO1 at super-enhancers together with BRD4 and the NuRD members HDAC2 and RBBP4. 
Surprisingly, CHD4 directly interacts with BRD4 at these sites and generates a chromatin 
architecture permissive for the binding of the fusion protein and of its cofactor BRD4. This 
allows expression of the oncogenic program of PAX3-FOXO1 and permits tumor cell 
survival. The other members of the NuRD complex influence transcription to minor extend 
and have a less relevant role in FP-RMS cell viability.  Our results suggest that CHD4 
depletion can disrupt super-enhancer driven gene regulation by interfering with chromatin 
architecture in a NuRD-independent manner. Other studies have shown that CHD4 interacts 
and coregulates EWS-FLI1 target genes and here, we show that depletion of this remodeler 
induces ES cell death in vitro and impedes tumor growth in vivo. Finally, analysis of genome-
wide cancer dependency databases identifies CHD4 as general novel cancer vulnerability.  
Together, our findings highlight chromatin remodeling as possible novel means to influence 
super-enhancer driven oncogenic gene expression and to impair tumor growth.   
 
 
Significance 
• CHD4 localizes to super-enhancers and regulates their influence on gene expression 
• BRD4 interacts and co-localizes with CHD4 at super-enhancers 
• CHD4 acts independently of NuRD to regulate PAX3-FOXO1 target genes 
• Silencing of CHD4 impairs Ewing sarcoma tumor growth in vivo 
• A vast number of cancer cells are susceptible to CHD4 inhibition 
 
Keywords: 
CHD4, chromatin remodeling, transcriptional regulation, super-enhancers, BRD4 
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INTRODUCTION 
Transcriptional programs control cell identity and survival. In cancer, oncogenic 
transcription factors (TFs) deregulate gene expression to cause cell transformation. As a 
result, cancer cells become addicted to not only the continuous expression of the oncogenic 
TF but also to high levels of transcription1,2. Indeed, targeting transcription represents a 
valid therapeutic strategy since cancer cells are more susceptible to transcription inhibition 
than healthy cells3 even though transcription regulators are broadly expressed and play 
essential roles in healthy cells. 
Epigenetics provides a new field of possible drug targets that can interfere with 
transcription. In fact, epigenetic regulators control the selective accessibility of TFs and of 
the transcriptional machinery to specific genomic elements, such as enhancers and 
promoters. These regulators are enzymes that can alter the chromatin chemically (via DNA 
methylation and post-translational modification of histones) or structurally (via chromatin 
remodeling)4. Since many epigenetic effectors are associated with tumorigenesis through 
mutation or overexpression, new classes of drugs have been developed5. DNA 
methyltransferase (DNMT) inhibitors are used as first-line treatment of myelodysplastic 
syndrome6 and histone deacetylase (HDAC) inhibitors are currently used in T-cell 
lymphoma therapy7,8. More recently, pharmacological inhibition of bromodomain-
containing protein 4 (BRD4), a BET-bromodomain protein that acts in concert with the 
positive elongation factor complex (P-TEFb) and is involved in the control of RNA Pol2 
pause release9,10, was shown to drastically impact oncogenic transcription, rendering many 
tumors susceptible to its inhibition11–14.   
Within epigenetic effectors, chromatin remodelers have been so far not considered as 
possible drug targets for cancer therapy. Chromatin remodelers regulate gene expression 
by controlling the packaging and unpackaging of DNA in the nucleosomes at regulatory 
sites15. Usually, chromatin remodelers work as protein complexes that contain SNF2-like 
ATPases. These enzymes use chemical energy drawn from ATP hydrolysis to cause 
mechanical movement of nucleosomes, and, hence, control DNA accessibility of the 
transcriptional machinery16,17. Therefore, also chromatin remodeling enzymes might 
constitute valuable targets to influence oncogenic transcription.  
Fusion-positive rhabdomyosarcoma (FP-RMS) and Ewing sarcoma (ES) are two pediatric 
tumors that carry a low mutational burden and are transcriptionally addicted to the 
oncogenic program of the fusion TFs PAX3-FOXO1 and EWS-FLI1, respectively18–23. This 
makes these sarcomas susceptible to epigenetic cofactors depletion. Indeed, BRD4 
inhibition was shown to affect the expression signature of both fusion proteins and, 
consequently, to impair proliferation of both tumors24–26.  
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Recently, we have identified the chromatin remodeler CHD4 (chromodomain-helicase-
DNA-binding protein 4) as a crucial coregulator of PAX3-FOXO1 target genes which is 
essential for FP-RMS cell viability27. However, the exact mechanisms by which CHD4 
influences gene expression in this tumor have not been clarified. Similarly, in Ewing 
sarcoma, CHD4 was shown to help the repressive function of EWS-FLI1, but no mechanistic 
details were provided28. 
In this study, we hypothesized that chromatin remodeling might constitute a novel valid 
strategy to interfere with oncogenic transcription and hence tumor development. To 
address this, we focused on the mechanisms by which CHD4 influences gene expression in 
FP-RMS and ES and describe a new role of CHD4 in the regulation of super-enhancer-driven 
gene expression. CHD4 co-localizes with PAX3-FOXO1 at super-enhancers, where it 
regulates DNA accessibility and, therefore, binding of the fusion protein and of its cofactor 
BRD4 to the chromatin. Moreover, we demonstrate the potential of CHD4 inhibition in 
Ewing sarcoma and highlight this chromatin remodeler as a promising new tumor target in 
a wide variety of cancer types.  
 
RESULTS 
CHD4 localizes at enhancers together with PAX3-FOXO1 and other members of the 
NuRD complex 
To localize the chromatin remodeler CHD4 in the FP-RMS genome, we performed chromatin 
immunoprecipitation assays followed by DNA sequencing (ChIP-seq) in the FP-RMS cell line 
RH4. Since all CHD4 antibodies currently available lack specificity, we introduced a 3xflag 
peptide in-frame at the N-terminal of the endogenous CHD4 protein via CRISPR/Cas9 
mediated repair. Immunoblotting confirmed the insertion of the flag peptide (Fig.S1A) 
while immunofluorescence showed that flagged CHD4 (N-CHD4) was nuclear (Fig.S1B). In 
addition, we confirmed that the flag insertion did not affect cell proliferation (Fig.S1C). This 
allowed us to perform ChIP-seq experiments with an anti-flag antibody to track CHD4 
location.  To localize PAX3-FOXO1 (P3F) in the genome we used a monoclonal breakpoint 
specific antibody29. Furthermore, we performed ChIP-seq for two members of  nucleosome 
remodeling and deacetylase complex (NuRD), HDAC2 and RBBP430, as CHD4 is commonly 
associated with this complex. Since BRD4 co-localizes and regulates P3F target genes, we 
used previously published ChIP-seq data for this epigenetic factor to investigate its relation 
to CHD424. Then, using ChIP-seq data from a comprehensive set of histone marks, we 
defined 16 chromatin states in FP-RMS31 (Fig.1A). The overlay of the ChIP signals of CHD4, 
RBBP4, HDAC2, BRD4, and P3F to these chromatin states demonstrated that CHD4, similarly 
to P3F and BRD4, localized mainly to enhancers and less so to promoters. RBBP4 and 
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HDAC2, were also present in enhancers but, unlike CHD4, showed an additional strong 
prevalence for promoters. Besides enhancers, our data revealed a strong presence of P3F in 
the transcription transition state. The overlap between the ChIP peaks of P3F, NuRD 
(represented by the co-localization of HDAC2 and RBBP4) and CHD4 (Fig.1B) showed that 
41% of P3F peaks (1531 out of 3694 of the peaks called for P3F) co-localized with CHD4 
and NuRD. An example of the co-localization of CHD4, RBBP4, HDAC2 with P3F and BRD4 
at an intronic enhancer of the P3F target gene ALK is displayed in Figure S2A. 
To further characterize the co-localization of CHD4 with P3F, we divided the genome in P3F-
only, CHD4-only and CHD4+P3F locations (Fig.1C/D). Interestingly, CHD4 co-localized with 
P3F in roughly half of all P3F binding sites (2011 out of 3694 P3F peaks). CHD4+P3F regions 
were rich in the enhancer marks H3K4me1, H3K27ac and H3K9ac, and poor in the 
repressive mark H3K27me3 and the promoter mark H3K4me3, confirming that these 
regions are indeed active enhancers. Moreover, CHD4+P3F binding sites were located distal 
to the transcription start sites (TSSs) and were mainly found in intergenic and intronic 
locations (Fig.S2B/C). As expected for activel regions, CHD4+P3F locations are more 
sensitive to DNase digestion than P3F- or CHD4-only regions (Fig.1C), suggesting a more 
open chromatin conformation. The same locations are also densely occupied by BRD4, 
MYCN and the master transcription factors (MTFs) of myogenesis MYOG and MYOD1 
(Fig.1D). Furthermore, motif analysis (Fig.1E) revealed that CHD4+P3F locations were 
enriched in motifs related to myogenic transcription factors (MYF5, MYOD, and MYOG). This 
is consistent with the myogenic features usually ascribed to this tumor19. Finally, GREAT 
ontology analysis (Fig.1F) on CHD4+P3F locations revealed that these regions are related 
to BMP signaling, neural tube closure and formation, and neuronal differentiation, which 
nicely reflects the role of PAX3 during normal neural development32. In addition, these 
findings suggest a function of CHD4 during development as well as in tumorigenesis. 
In conclusion, CHD4 was found to co-localize at enhancers with P3F, BRD4 and the NuRD 
members, HDAC2 and RBBP4, that displayed an open chromatin structure as well as at 
locations with more repressive characteristics in CHD4-only regions. These results indicate 
that the function of this remodeler is likely context dependent.  
 
CHD4 binds to super-enhancers and interacts with BRD4 
Super-enhancers (SEs) are enhancer clusters that are abundantly populated by TFs and 
cofactors like the mediator complex, the acetyltransferase p300, BRD4, and the cohesion 
complex33. During normal development, SEs regulate cell identity, while in cancer, they 
drive high levels of expression of genes related to cell proliferation and transformation33,34. 
Since P3F regulates the expression of oncogenes by binding to SEs together with other MTFs 
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of myogenesis and BRD424, we evaluated the presence of CHD4 at SEs.  Strikingly, CHD4 was 
found in 600 out of the total 810 SEs described in FP-RMS, and co-localized with P3F in 408 
out of the 452 SEs where the fusion was present (Fig.1G). HDAC2 and RBBP4 were present 
in a total of 805 SEs and co-localized with BRD4 in a total of 770 SEs (Fig.1G/H). This is 
exemplified by the MYOD1 SE in which P3F, RBBP4, HDAC2, BRD4, and CHD4 co-occupy the 
same genomic location (Fig. S2D).  
Recently, a direct physical interaction between CHD4 and the extra-terminal (ET) domain, 
a highly conserved domain, of BRD3 was reported35. Since BRD4 and CHD4 co-localized in 
FP-RMS at enhancers and SEs, we hypothesized that CHD4 might co-regulate P3F target 
genes by direct interaction with BRD4. To test this hypothesis, we performed co-
immunoprecipitation assays using N-terminal flag tagged endogenous BRD4, and N- and C-
terminal flag tagged endogenous CHD4. The knockins of the 3xflag sequence were obtained 
by CRISPR/Cas9 mediated repair and were validated as shown in Fig.S1 and S3. 
Immunoprecipitation of N-BRD4 (Fig.1I/J) clearly coprecipitated CHD4, as well as the NuRD 
members HDAC2 and MTA2. In the reverse setting, CHD4 immunoprecipitation was able to 
pull-down BRD4 (Fig.1K) as well as MTA2 and HDAC2, as expected. Together, these findings 
suggest that CHD4 might influence chromatin architecture to regulate enhancer-driven 
gene expression by collaborating with BRD4. 
 
CHD4 allows an open chromatin conformation at super-enhancers which is 
permissive to active transcription 
CHD4 is a nucleosome remodeler capable of moving nucleosomes along the DNA36. Thus, we 
hypothesized that CHD4 regulates transcription by changing the chromatin architecture at 
regulatory locations. To investigate this in detail, we performed DNase hypersensitivity 
(DNase HS) assays upon CHD4 or P3F depletion using RH4 cells with doxycycline-inducible 
shRNAs targeting either CHD4 or P3F, that were previously described 27. CHD4+P3F regions 
lost DNase HS signal after depletion of either CHD4 or P3F whereas CHD4-only locations 
were generally closed and therefore not affected by the silencing. As expected, P3F-only 
locations lost DNase HS signal after P3F silencing and were not as affected by CHD4 
depletion. Strikingly, when analyzing SE regions only, we observed that these were 
drastically affected by CHD4 but not by P3F deletion (Fig.2B), suggesting that occupancy by 
CHD4 is necessary for P3F binding at SEs.  
Hence, we next investigated whether changes in chromatin conformation would alter the 
genomic localization of P3F. To accomplish this, we performed ChIP-seq with a P3F 
breakpoint-specific antibody29 upon depletion of CHD4 or P3F. Indeed, while CHD4 
depletion caused only small changes in the P3F occupancy when looking at all CHD4+P3F 
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regions (Fig.2C), it showed clear reduction in P3F occupied sites when analyzing SEs 
separately (Fig.2D). As expected, P3F depletion reduced its occupancy in all regions. ChIP 
and DNase signals in the ALK and MYOD1 SEs, illustrating the displacement of P3F from SE 
loci upon CHD4 depletion, are shown in Figures 2E and F.  
To evaluate if changes in chromatin accessibility at SEs cause displacement of epigenetic 
cofactors, we selected regions where NuRD proteins and BRD4 bind together with CHD4 
and P3F and performed ChIP-qPCR assays after silencing of CHD4 or P3F. We observed that 
CHD4 and P3F depletion impaired the binding of both BRD4 and HDAC2 to the promoter of 
CDH3 and to the SE present in the intronic region of ALK but not to the one in ASS1.  
These findings suggest that the remodeling function of CHD4 is essential to keep the 
chromatin open at super-enhancers which allows the positioning of the oncogenic driver 
PAX3-FOXO1 and of its cofactor BRD4 and the expression of the fusion gene signature.  
 
NuRD-only localizes to promoters and participates in cellular homeostasis 
Recently, the role of CHD4 as a core member of NuRD has been challenged37. Since we also 
observed that CHD4, HDAC2, and RBBP4 did not co-occupy all genomic locations (Fig.1B), 
we aimed next to investigate the characteristics of CHD4-containing NuRD and NuRD-only 
regions (Fig.S4A). We observed that NuRD-only regions were predominantly found in 
promoters, as indicated by the strong signal of the promoter mark H3K4me3 (Fig.S4A and 
B). Indeed, NuRD-only peaks localized closer to TSSs than CHD4+NuRD locations (Fig.S4C). 
Interestingly, BRD4 co-localized with NuRD at both enhancer and promoter locations 
(Fig.S4A), suggesting that BRD4 might also be able to interact with members of the NuRD in 
the absence of CHD4. As an example, the TOP2A promoter occupied by NuRD and BRD4, but 
not by CHD4 is shown in Figure S4D. Gene ontology analysis revealed that the promoters 
occupied by NuRD-only regulate processes related to cell homeostasis such as RNA 
processing and ribosome biogenesis (Fig.S4E).  
These data suggest that NuRD locates differently depending on the presence of CHD4. In the 
presence of CHD4, NuRD localizes to enhancers and in the absence of it to promoters.  Since 
CHD4 and CHD3 are mutually exclusive subunits of the complex, the promoter regions 
enriched in HDAC2 and RBBP4 might represent CHD3-containing NuRD locations. In fact, 
studies have shown that CHD3 and CHD4 have distinct nuclear localization and also carry 
different remodeling activities38. At promoters, NuRD, possibly with CHD3, regulates 
housekeeping gene expression and at enhancers it might drive P3F oncogenic signature 
together with CHD4. 
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CHD4, but not NuRD, is essential for FP-RMS cell viability 
Previously, we have demonstrated that silencing  of CHD4 leads to FP-RMS cell death and 
tumor regression in vivo27. Here, we discovered that CHD4 co-localizes with P3F at SEs 
together with two members of the NuRD complex, HDAC2 and RBBP4. This raised questions 
regarding the role of NuRD in P3F-driven gene expression and FP-RMS viability. Therefore, 
we probed all known NuRD subunits for their role in FP-RMS cell proliferation. We 
established a NuRD-centered CRISPR/Cas9 screen in which we used FP-RMS cells stably 
expressing Cas9 (Fig.3A) and transduced them either with five RFP-labelled sgRNAs per 
NuRD member or with a BFP-labelled control guide (sgAAVS1). Two days after 
transduction, the blue and red population were mixed 1:1, and after 12 days, the 
propagation of the populations was assessed by FACS analysis. Guide RNAs targeting BRD4 
were used as positive control24. The results of this screen are depicted in Figure 3B as the 
ratio between red and blue population at day 12 normalized to day 2. We considered that 
the knockout had an effect in cell proliferation when at least 3 sgRNAs caused a ratio 
reduction superior to 25%.  According to these criteria, we observed that proliferation of 
FP-RMS was reduced not only by targeting CHD4 but also by HDAC1, RBBP4/7, and 
GATAD2A/B. Importantly, none of the MBD or MTA proteins, which are unique members of 
the NuRD39 complex, altered FP-RMS cell proliferation (Fig.3B). 
Since RBBP4 knockout showed comparable effects on proliferation to CHD4’s, we studied it 
further by establishing FP-RMS cell lines containing two doxycycline-inducible lentiviral 
shRNAs targeting RBBP4. Silencing was confirmed on protein and mRNA levels 72 hours 
after doxycycline induction (Fig.S5A/B). As expected, RBBP4 depletion decreased FP-RMS 
cell proliferation, as assessed by crystal violet and WST1 assays (Fig.S5C). Nonetheless, 
unlike CHD4 and P3F depletion, RBBP4 knock-down did not induce FP-RMS cell death 
(Fig.3C/D, S5D) or influenced the expression of 5 out of 6 selected P3F target genes (Fig.3E-
G). Hence, reduction of proliferation triggered by RBBP4 depletion occurs independently of 
the P3F signature. Taken together, these observations suggest that the loss of cell viability 
induced by CHD4 depletion does not dependent on the formation of the NuRD complex.  
 
CHD4 regulates the oncogenic program of FP-RMS  
To further investigate the transcriptional dependency on CHD4 in the context of the fusion 
gene signature, we performed RNA-seq experiments upon CHD4 or P3F depletion. The 
validation of the knockdowns obtained at 48hrs, both on protein and mRNA levels, is 
presented in Figure 4A and B. We observed that CHD4 does not regulate the expression of 
P3F itself, hence results obtained after CHD4 knockdown are not indirectly caused by 
reduction of the fusion protein.  
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Unsupervised clustering analysis (Pearson correlation) of the genes differentially regulated 
by CHD4 (fold change of at least 25% and FDR of 1%) identified a similar number of genes 
upregulated (3080) and downregulated (3220) upon CHD4 silencing with a high degree of 
reproducibility (Figure 4C). These results suggested both an activating as well as repressing 
function of CHD4. Of all CHD4 regulated genes, 2388 were coregulated by P3F (1238 
downregulated and 1150 upregulated).  
Gene set enrichment analysis (GSEA) performed on the CHD4+P3F transcriptome revealed 
an enrichment of the signatures of P3F-controlled enhancers and of FP-RMS (Fig.4D), which 
is consistent with the role described for CHD4 as cofactor of P3F in the regulation SE-driven 
expression. When we considered all genes differentially regulated by CHD4, we found an 
enrichment of MEF2 and embryonic stem cell signatures (Fig.4E). MEF2 comprises a family 
of transcription factors that collaborates with other myogenic transcription factors, such as 
MYOD, to drive skeletal muscle differentiation40. Therefore, these results supported a role 
of CHD4 in normal skeletal muscle differentiation41. In fact, during muscle differentiation, 
this chromatin remodeler, through binding to distal regulatory regions, directly regulates 
the expression of genes required for cardiac muscle development42.  
Unexpectedly, amongst the genes regulated by CHD4 we identified also the gene expression 
signatures of EWS-FLI1 and Ewing sarcoma (Fig.4E). This finding suggests some 
commonality amongst the oncogenic signatures of these sarcomas and could potentially 
help to identify physiologically relevant target genes.  
 
CHD4 depletion drastically decreases Ewing sarcoma cell viability and reduces tumor 
growth in vivo 
CHD4 has been shown to collaborate with EWS-FLI1 to repress some of its target genes28. 
Moreover, this remodeler is not only highly expressed in RMS but also in ES (Fig.5A) and 
regulates some ES genes in FP-RMS. Thus, we explored its possible role for ES cell viability. 
To this end, we established two ES cell lines, SKNMC and A673, to stably express two 
doxycycline-inducible shRNAs targeting CHD4. Validation of CHD4 depletion through 
doxycycline incubation is shown in Figure S6A and B. Indeed, and comparable to FP-RMS, 
CHD4 depletion deeply impaired ES cell proliferation, as shown by crystal violet and WST1 
assays, in both ES cell lines and with both shRNAs (Figure S6C-F), and induced tumor cell 
death (Figure S6G). 
To assess the effect of CHD4 depletion on tumor growth in vivo, NOD/SCID mice were 
engrafted subcutaneously with SKNMC cells containing either the scramble control shRNA 
construct or the shCHD4#1 (Fig.5B). Then, mice, with established tumors of an average size 
of 60mm3 per group, were treated intraperitoneally with a doxycycline solution (53.3 
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mg/kg) for two consecutive days, and, from then on, fed with doxycycline-supplemented 
food. Control mice were injected intraperitoneally with vehicle (PBS solution) and 
continued on a doxycycline-free diet. Immunohistochemistry assays validated the silencing 
of CHD4 in vivo (Fig.5C). CHD4 depletion clearly caused a delay in tumor growth (Fig.5D) 
and increased overall survival (Fig.5E). Interestingly, the doxycycline-treated tumors 
bearing the shCHD4#1 construct that grew back to 1000mm3 re-expressed CHD4 up to 
control levels (Fig.5F). Thus, CHD4 re-expression was the likely cause of the outgrowth of 
these tumors. These results validate CHD4 as a possible therapeutic target also in ES.  
 
Large-scale genome screens suggest CHD4 as a broad tumor dependency 
CHD4 has been implicated in the viability of different tumors. Here, we described its role in 
Ewing sarcoma cell survival and in the regulation of P3F-driven gene expression in FP-RMS. 
Furthermore, we observed that CHD4 collaborates with BRD4 for SE-driven gene 
expression regulation. Therefore, we questioned if CHD4 constitutes a general tumor 
susceptibility as demonstrated for BRD4. To answer this, we analyzed data generated by 
two genome-wide screens which aimed to identify cancer susceptibilities, the DRIVE43 and 
the Achilles projects ( https://portals.broadinstitute.org/achilles). In both projects, 
thousands of targets were screened using a shRNA- (DRIVE) or CRISPR-based (Achilles) 
library in nearly 400 cancer lines (Supplementary Table 1 and 2). Then, dependency scores 
were calculated and made publicly available. 
First, we analyzed the data available for all NuRD complex members in both datasets (Fig.6A 
and B). We observed that CHD4 impairs tumor cell viability in the majority of the cancer cell 
lines used in both projects (in the DRIVE database 323 out of 387 cancer cell lines had a 
score lower than -3 upon CHD4 silencing; in the Achilles database 386 out of 391 cancer cell 
lines tested had a score lower than -0.5 upon CHD4 knockout). Other NuRD members 
showed either no effect in all tumor cells or selected tumor dependencies, apart from RBBP4 
and GATAD2A depletion which had a broad effect on cancer cell viability in the Achilles 
platform only (Fig.6A).  
Next, we analyzed the effect of CHD4 with the one of all other SNF2-like chromatin 
remodelers and BRD417. In both databases, only INO80 and BRD4 depletion showed a 
similar general tumor dependency as the one observed for CHD4 (Fig.6C and D). 
This analysis suggests a vast tumor susceptibility to CHD4 depletion, beyond the two 
pediatric sarcomas here studied, and suggest it to be a promising new tumor target in a wide 
variety of cancer types 
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DISCUSSION 
Cancer is a very heterogenous disease with a high degree of variability within tumor types, 
which makes it difficult to identify common drug targets. Recently, attention has been 
brought to epigenetic targeting since BET-bromodomain inhibitors have been shown to 
drastically reduce tumor growth in many cancer types including hematological 
malignancies and a variety of solid tumors44.  
FP-RMS and ES are two pediatric tumors driven by a fusion transcription factor, PAX3-
FOXO1 and EWS-FLI1 respectively, generated by a chromosomal translocation. These 
aberrant TFs create and bind to enhancers and SEs, together with BRD4, from where they 
regulate gene expression related to cell proliferation, invasiveness, and cell survival24,29,45,46. 
Therefore, both tumors are transcriptionally addicted, and dependent on BRD4 to regulate 
their enhancer-driven expression signature which allows tumor growth24–26,47,48. Here, we 
demonstrate that FP-RMS and ES are both dependent on the chromatin remodeler CHD4 as 
well. We describe the detailed mechanisms by which CHD4 influences the viability of these 
pediatric sarcomas and define a new role for CHD4 in oncogenic transcription regulation. In 
FP-RMS, we demonstrate for the first time that CHD4 binds to enhancers and SEs together 
with BRD4 and the oncogenic driver P3F. The presence of CHD4 in SEs is essential to keep 
these regions open and permissive to the binding of P3F and BRD4, which is required for 
the expression of a subset of P3F-target genes (Fig.7). Similarly, in mouse embryonic stem 
cells, CHD4 was found to regulate the positioning of the TF Sall449. Additionally, we found 
that CHD4 directly interacts with BRD4 which suggests that these epigenetic factors might 
collaborate for the regulation of SE-driven transcription. Moreover, our transcriptomic data 
after CHD4 depletion revealed that this chromatin remodeler surprisingly controls the 
expression of known EWS-FLI1 target genes in FP-RMS, which suggests a common gene 
signature among these tumors. These results can help to identify the fusion protein’s target 
genes that are essential for tumor development. 
CHD4 is commonly described as a core member of the NuRD complex, although recent 
reports describe it as a peripheral unit37. Our results show that CHD4 co-localizes with 
NuRD members, such as HDAC2 and RBBP4, at P3F-containing SEs, however CHD4 free 
RBBP4+HDAC2-containing regions were also observed. Moreover, BRD4 not only interacts 
with CHD4 but also with the NuRD members HDAC2 and MTA2. Hence, we investigated the 
role of the NuRD complex in FP-RMS cell viability and found that, besides CHD4 depletion, 
knockout of RBBP4, HDAC1, and GATAD2A/B also affected FP-RMS cell proliferation. 
However, the knockout of the MBD, which are core and mutually exclusive subunits of 
NuRD50,51, and of the MTA proteins had no effect on FP-RMS viability, which supports the 
hypothesis that CHD4 acts independently of NuRD to maintain FP-RMS cell proliferation. 
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Furthermore, RBBP4 and HDAC1 are associated with other remodeling complexes like SIN3, 
coREST, PRC2 and CAF-139, hence, the effects observed upon their knockout might not 
reflect the actions of the NuRD complex. In addition, unlike CHD4 depletion, silencing of 
RBBP4 did not affect the expression of P3F target genes nor did it cause tumor cell death. 
Interestingly, in mouse embryonic stem cells, in the absence of nuclear Mbd3, Chd4 remains 
only associated with Gatad2b in the nucleus52. These findings suggest a supporting function 
of GATAD2B for CHD4 and could explain why we observe an effect upon GATAD2A/B 
depletion. 
Besides FP-RMS and ES, published data has shown that CHD4 depletion affects the growth 
of a number of additional tumors like glioblastoma53, liver cancer54, lung cancer55, and 
colorectal cancer56,57. Furthermore, and unlike other chromatin remodelers, CHD4 is rarely 
found mutated in cancer58, which could be an indicator of tumor dependency. Our analysis 
of two publicly available databases of tumor susceptibilities, Achilles and DRIVE, identified 
CHD4, amongst the SNF2-like ATPases and the NuRD members, as a new tumor 
susceptibility. The data indicate that CHD4 depletion, similar to the one of BRD4, impaired 
tumor cell viability in the majority of the cancer cell lines analyzed in both projects. 
Intriguingly, tumor sensitivity to CHD4 depletion seems to be selective since silencing of 
this chromatin remodeler has no influence on the cell proliferation of myoblasts and 
fibroblasts27. Supporting this observation, a RNAi screen identified CHD4 as an essential 
gene in breast cancer cells with no effect on the cell proliferation of non-transformed 
mammary epithelial cells (MCF10A)59. Another study has also shown that CHD4 is required 
for the maintenance of childhood acute myeloid leukemia but not for the proliferation and 
survival of normal primary hematopoietic cells60. These studies demonstrate the potential 
of CHD4 as a cancer-specific therapeutic target. In this study, we describe a positive effect 
of CHD4 in SE-driven gene expression that might partially explain the broad tumor 
dependency to CHD4. Nevertheless, the mechanisms associated with CHD4 dependency 
may vary among tumors. Colorectal cancer depends on CHD4 since it mediates the silencing 
of tumor suppressor genes by recruitment of DNMTs and EZH256. In acute myeloid 
leukemia, CHD4 depletion induces transcription alterations that impair colony formation61. 
CHD4 has also been associated with DNA-damage repair which might have implications in 
the genome stability of tumor cells. In fact, CHD4 depletion leads to the accumulation of 
spontaneous DNA damage, increased ionizing radiation sensitivity, and impaired 
homologous recombination repair62,63.  
In conclusion, by further investigating the role of CHD4 in FP-RMS, we describe for the first 
time the contribution of the remodeling activity of CHD4 for the control of SE-accessibility 
to oncogenic transcription factors and cofactors. Interestingly, CHD4 seems to control SE-
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driven gene expression and tumor cell viability in a NuRD-independent manner. In ES, we 
observe that CHD4 is also indispensable for tumor cell viability, and, since it collaborates 
with EWS-FLI1 for its repressive activity28, we hypothesize that this chromatin remodeler 
acts in a similar way in this tumor as in FP-RMS. Nevertheless, further studies are required 
to investigate the role of CHD4 in EWS-FLI1 activity. In addition, we identify a novel broad 
tumor dependency to CHD4 which can be partially explained by its influence in oncogenic 
SE-driven gene expression. Hence, this work puts CHD4 side-by-side with BRD4 as a 
prominent and promising new target for SE-disruption in cancer therapy.  
 
MATERIAL AND METHODS 
Cell lines 
The FP-RMS cell line RH4 was kindly provided by Peter Houghton at the Research Institute 
of the Nationwide Children’s Hospital, Columbus OH. The HEK293T cell line was used to 
produce lentiviral particles and was purchased from the American Type Cell Culture 
Collection, LGC Promochem, Molsheim Cedex, France. Both cell lines were routinely 
maintained in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich) supplemented 
with 10% fetal bovine serum (#F7524, Sigma Aldrich), 2 mM L-glutamine (Bioconcept AG) 
and 100 U/ml penicillin/streptomycin (Thermo Fisher Scientific AG). The Ewing sarcoma 
cell lines, A673 and SKNMC, were cultured in RPMI (Roswell Park Memorial Institute, 
Sigma-Aldrich) instead of DMEM. All cells were cultured in 5% CO2 at 37°C. The RH4 cell 
line was tested and authenticated by cell line typing analysis (STR profiling) in 2014/2015 
and positively matched66.  
 
CRISPR/Cas9 flag knockin 
The knockin of a 3xflag peptide in endogenous CHD4 or BRD4 in RH4 cells was performed 
using the CRISPR/Cas9 technology67. Guide RNAs targeting the N- or C-terminal of CHD4 or 
the N-terminal of BRD4 were cloned into the pSpCas9(BB)-2A-Puro PX459 vector (#62988, 
addgene) using the appropriate primers and the In-Fusion cloning HD kit (Clontech 
Laboratories Inc., Mountain View, CA, USA) according to the manufacturer’s instructions. 
Cloning was verified by sequencing. Then, the PX459 vector was transiently co-transfected 
with the specific donor DNA into RH4 cells using the JetPrime reagent (Polyplus 
Transfections, Illkirch, France). One day after transfection, cells were incubated with 1µM 
of non-homologous end-joining inhibitor SCR7. Clones were obtained by limited dilution 
and flag insertion was confirmed by immunofluorescence and western blot. Detailed 
information regarding the sequences of sgRNAs and donor DNAs can be found in 
Supplementary Tables 3 and 4. 
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Chromatin Immunoprecipitation-sequencing (ChIP-seq) 
ChIP assays were performed by using the ChIP-IT High Sensitivity kit (#53040, Active Motif) 
according to the manufacturer’s instructions. Briefly, cells were grown to confluence, fixed 
with 1% formaldehyde (Sigma-Aldrich) for 13 min, harvested and sonicated with the 
EpiShear™ ProbeSonicator (#53052, Active Motif) for 27 cycles (30% amp, 30sec ON, 30sec 
OFF). Sonicated lysates were then quantified and 30ug of chromatin were incubated 
overnight at 4°C with 5-10ug of antibody (antibodies listed in Supplementary Table 5). DNA 
was purified according to the manufacturer’s instructions. Details regarding sequencing can 
be found in supplementary material and methods. 
 
DNase Hypersensitivity assays 
DNase hypersensitivity assays were performed as previously described68.  Per condition, 10 
000 cells were washed and resuspended in RSB buffer (10mM Tris-HCl pH 7.4, 10mM NaCl, 
3mM MgCl2, 0.2% Triton X-100).  DNase I (#04-716-728-001, Roche; 10µL of a 0.33 U/µL 
DNase solution in RSB buffer) was added to a total of 40µL of cells and incubated for 5 
minutes at 37 ˚ C.  The digestion was halted with 50 µL of stop buffer (10 µM Tris-HCl pH 7.4, 
10 µM NaCl, 10µM EDTA, 0.15% SDS, supplemented with 125 µL proteinase K 
(#03115828001, Roche) per 10mL).  Proteinase K activation at 55 ˚C for 1 hour was 
followed by DNA purification (NucleoSpin Gel and PCR Clean-up, Macherey-Nagel GmbH & 
Co. KG). Library preparation was performed as with ChIP-seq samples, except that paired-
end was employed rather than single-end sequencing on the NextSeq 500 (Illumina). 
 
Co-immunoprecipitation assays 
Cells from three confluent 15cm dishes, per condition, were washed with PBS and 
harvested. Then, they were lysed with sucrose buffer (320mM sucrose, 3mM CaCl2, 2mM 
MgOAc, 0.1 mM EDTA, 10mM DTT, 0.5mM PMSF, 0.25% NP-40) and nuclei were pelleted by 
centrifugation (10min, 1100g, 4°C). Cytoplasmic fraction was collected and stored at -20°C. 
After wash with NP-40 free sucrose buffer, nuclei were lysed by incubation with lysis buffer 
(50mM HEPES pH 7.8, 3mM MgCl2, 300mM NaCl, 1mM DTT, 0.1mM PMSF) in presence of 
15u/ul of benzonase for 1hr at 4°C. Before antibody incubation, an input sample was 
collected and stored at -20°C. Protein G Dynabeads were coupled with 8µg of anti-flag 
antibody (clone M2, #F1804, Sigma Aldrich) per plate used and then incubated overnight 
together with the nuclear extracts. After wash, immunoprecitates were eluted in 50mM 
Tris-HCl pH 7.4, 150mM NaCl and 200µg/ml of flag peptide (#F4799, Sigma Aldrich) and 
analyzed by western blotting. 
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NuRD-centered CRISPR screen 
RH4 cells stably expressing Cas9 were obtained by transducing wildtype cells with the 
expression vector lentiCRISPRv2 puro (#98290, addgene) followed by puromycin selection 
(1µg/mL). Cas9 expression was confirmed by western blot and immunofluorescence (data 
not shown). 
Guide RNAs targeting the NuRD members or BRD4 were cloned into the RFP-labelled sgRNA 
expression construct (named here shuttle vector), and the control guide targeting the 
AAVS1 locus into the BFP-labelled shuttle vector. Both shuttle vectors were kindly provided 
by Dr. Yun Huang, University Children’s Hospital Zurich. Viruses were produced in 
HEK293T cells by co-transfection of pVSV-G, PAX2, and the shuttle vectors using CaPO4.  
Medium was replaced 24hrs after transfection and viruses were harvested after additional 
48hrs. Viral supernatant was cleared by centrifugation, filtered and concentrated (Amicon® 
Ultra 15 mL, Millipore).  
Cas9 expressing RH4 cells were infected with the viral supernatant, supplemented with 
8µg/ml polybrene (Sigma Aldrich) for 24hrs, containing either RFP-labelled or BFP-labelled 
lentiviral shuttle vectors. Two days after transduction the red and blue populations were 
mixed 1:1. The distribution of red and blue cells was assessed by FACS analysis, 2 and 12 
days after transduction. The results are shown as the ratio between red and blue population 
at day 12 normalized to day 2. Five guides per target were used. The sequences regarding 
the guide RNAs used can be found in Supplementary Table 6. 
 
Doxycycline-inducible knockdowns 
The pRSIT-U6Tet-shRNA-PGKTetRep-2A-GFP-2A-puro vectors with 2 shRNAs against 
RBBP4 were purchased from Cellecta Inc. with the following target sequences: shRBBP4#1 
5’ GCCTTTCTTTCAATCCTTATA 3’ and shRBBP4#2 5’ e: ATGAACCTTGGGTGATTTGTT 3’.  
Viruses were produced by co-transfection of the shRNA vectors and lentiviral packaging and 
envelope plasmids (pMDL, pREV and pVSV-G kindly provided by Oliver Pertz, Department 
of Biomedicine, University of Basel, Switzerland) into HEK293Tcells using CaPO4. Medium 
was replaced 24hrs after transfection and viruses were harvested after additional 48hrs. 
Viral supernatant was cleared by centrifugation, filtered and concentrated (Amicon® Ultra 
15 mL, Millipore).  RH4 cells were transduced for 24 hours in the presence of 8µg/ml 
polybrene (Sigma-Aldrich) and selected with puromycin (1µg/mL). RH4 scramble control 
RH4 cells carrying CHD4 or PAX3-FOXO1 targeting shRNAs were previously established27. 
ShRNA expression was induced using 100ng/ml doxycycline (Sigma-Aldrich). Data were 
normalized to corresponding uninduced cells and compared to scramble shRNA expressing 
cells. 
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Xenograft studies 
Five million SKNMC cells, containing stably integrated doxycycline-inducible shCHD4#1 or 
shScramble expression constructs, were engrafted subcutaneously in 30 mice (15 mice per 
construct). NOD/Scid female mice of 8 to 12 weeks old were used for this experiment 
(Charles River, Sulzfeld, Germany). Mice were divided in treatment (8 mice) and vehicle (7 
mice) groups, and, once the tumors reached an average of 60mm3/group, they were treated 
intraperitoneally with either sterile PBS or a doxycycline solution (53.3 mg/kg) for two 
consecutive days. Additionally, starting from the first day of treatment, mice were fed with 
doxycycline-supplemented food (625 mg doxycycline/kg) or control food. Tumor size was 
determined by daily measurements of two diameters (d1, d2) in right angles using a digital 
caliper. Total tumor volumes were calculated using the following formula (V= (4/3) π r3; r= 
(d1+d2)/4). Mice were euthanized when the tumors reached a volume of 1000 mm3. All 
animal experiments have been approved by the Swiss veterinary authorities and were 
performed according to the animal license ZH206/15.  
 
Statistics 
All statistical analysis (with the exception of GSEA analysis) were performed with the 
GraphPad prism software, version 7. Data are represented as mean ± SD, unless otherwise 
noted. 
 
RNA-seq 
For gene expression profiling, RNA of RH4 cells, containing either a doxycycline-inducible 
scramble shRNA or shRNAs targeting CHD4 and PAX3-FOXO1, was isolated 24 and 48hrs 
after the start of doxycycline treatment using RNeasy Mini Kit (Qiagen), including the DNase 
digestion step, according to the manufacturer`s instructions. For more details regarding 
sequencing and data analysis please refer to the supplementary material and methods. 
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FIGURES 
Figure 1 
Fig.1 – CHD4 co-localizes with PAX3-FOXO1 at super-enhancers and interacts with BRD4 
(A) Chromatin states identified in the FP-RMS cell line RH4 and abundance of ChIP-seq peaks/Gb of 
state of the indicated proteins. (B) Overlap of the ChIP-seq signal for PAX3-FOXO1 (P3F), CHD4 and 
NuRD (represented by the intersection between HDAC2 and RBBP4 peaks). (C) Heatmaps depicting 
the ChIP signal of the indicated proteins in RH4 cells at P3F-only (n=1598), CHD4+P3F (n=2090) and 
CHD4-only regions (n=8765). The rows show 7kb regions, centered on P3F or CHD4 peaks and 
ranked by the ChIP signal intensity of H3K27ac. Color shading corresponds to ChIP-seq read counts. 
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(D) Density plots displaying the average signal of the indicated proteins in the genome regions 
described in C.  (E) Motif enrichment analysis performed with P3F-only, CHD4+P3F and CHD4-only 
locations. Heatmap depicts the ratio between M (the percentage of a given motif in the studied 
regions) and B (the percentage of the same motif in the background genome). (F) Gene ontology 
analysis (assigned by GREAT) of the biological processes associated with the CHD4+P3F regions. (G) 
Representative plot of the occupancy of each of the indicated proteins in the 810 super-enhancers 
(SEs) identified in RH4 cells. (H) Density plot showing the average signal of the NuRD members 
RBBP4, HDAC2, and CHD4 at SEs. (I-K) CoIP assays performed by using an anti-flag antibody to 
immunoprecipitate the endogenous N-terminal flag tagged BRD4 and the N- or C-terminal flag tagged 
CHD4. RH4 wildtype cells (WT) were used as negative control. 
 
Figure 2 
Fig.2 – CHD4 changes chromatin accessibility and allows P3F and BRD4 binding to SEs  
(A/B) Density plots depicting the average DNase hypersensitivity (DNase HS) signal in RH4 cells 
upon CHD4 or P3F knockdown (48 hours of incubation with doxycycline). Each plot displays the 
DNase HS signal at CHD4+P3F (n=2090), P3F-only (n=1598), CHD4-only regions (n=8765), and at 
SEs (n=810). The signal shown is centered on P3F or CHD4 peaks. (C/D) Density plots depicting the 
average P3F ChIP-seq signal in RH4 cells upon CHD4 or P3F knockdown (48 hours of incubation with 
doxycycline). Each plot displays the P3F ChIP-seq signal at CHD4+P3F, P3F-only, CHD4-only regions, 
and at SEs. The signal shown is centered on P3F or CHD4 peaks. (E/F) Example of gene tracks of the 
DNase HS signal and of the P3F ChIP-seq signal at the ALK or MYOD1 SE loci in RH4 cells. (G) ChIP-
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qPCR experiments show the decrease in HDAC2 and BRD4 binding in selected P3F-binding regions 
upon CHD4 or P3F silencing (48 hours of incubation with doxycycline). Data is displayed as fold 
enrichment over negative control region (n=2). UNTR5 served as negative control.  
 
Figure 3 
Fig.3 – NuRD-centered CRISPR screen reveals FP-RMS cell proliferation susceptibilities 
(A) Illustrative scheme of the NuRD-centered CRISPR screen. (B) CRISPR screen results are displayed 
as the ratio, in percentage, between the NuRD knockout population and the control population at day 
12, normalized to day 2.  Each point represents the average of three biological replicates for each 
sgRNA used. Five sgRNAs were used per NuRD member. Guide RNAs targeting BRD4 and CHD4 were 
used as positive controls (C) Representative phase-contrast images of RH4 cells 5 days after 
doxycycline induction of shRNAs targeting RBBP4, CHD4, and P3F. A scramble shRNA was used as 
negative control. Also depicted are the uninduced RH4 cells carrying each construct. Scale bar - 
100µm. (D) Percentage of dead cells observed 5 days after doxycycline-induction of shRNAs targeting 
RBBP4, CHD4 and P3F in RH4 cells. Cells were stained with 7AAD and analyzed by FACS. A scrambled 
shRNA was used as negative control.  Values represented as mean ± SD of 3 independent experiments 
(*p< 0.1, **p < 0.01; ***p < 0.001, ratio paired t test) (E-G) Expression levels of the indicated P3F-
target genes quantified by qPCR in RH4 cells 48hrs upon RBBP4, P3F and CHD4 knockdown induction 
with doxycycline. Expression levels (relative to GAPDH) were normalized to uninduced cells. Data 
represented as mean ± SD (n=3). 
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Figure 4 
Fig.4 – CHD4 gene expression signature reveals common PAX3-FOXO1 and EWS-FLI1 target 
genes 
(A) Western blot validates the knockdown obtained after 48hrs of doxycycline-induction of shRNAs 
targeting CHD4 or P3F. GAPDH was used as a loading control. (B) Expression levels of CHD4 and P3F 
quantified by qPCR in RH4 cells after 48hrs of silencing induction. Expression levels (relative to 
GAPDH) were normalized to uninduced cells. Data represented as mean ± SD (n=3). (C) Heatmap of 
unsupervised hierarchical clustering analysis of CHD4 and P3F knockdown profiles in RH4 cells after 
24 or 48hrs of doxycycline-induced silencing. Displayed are the genes differentially expressed upon 
CHD4 silencing. A scrambled shRNA was used as control and 3 independent biological replicates 
were performed for each time point. (D/E) GSEA performed using either CHD4+P3F coregulated 
signature or CHD4 signature as preranked datasets. NES – normalized enrichment score, FDR – false 
discovery rate, FWER – family-wise error rate.  
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Figure 5 
  
Fig.5 – CHD4 silencing impairs Ewing sarcoma tumor growth in vivo 
(A) Violin plot displays CHD4 gene expression in the indicated datasets (R2 database). (B) 
Representative scheme of animal experiment. NOD/SCID mice were subcutaneously engrafted with 
SKNMC cells stably expressing a doxycycline-inducible shRNA targeting CHD4 or a scramble control. 
Mice bearing tumors of an average of 60mm3 per group were treated intraperitoneally (IP) with a 
doxycycline or vehicle solution (PBS) for two consecutive days. From then on, mice were fed with 
doxycycline-supplemented food or control food. When tumors reached 1000mm3, the animals were 
sacrificed. (C) Immunohistochemical staining of tumors with CHD4 antibody and HE (hematoxylin 
and eosin). Tumors were isolated 4 days after the beginning of the doxycycline treatment. Scale bar 
- 100µm. (D) Absolute tumor volumes measured by caliper at the indicated time points. Day 20 
represents the start of the doxycycline treatment. Vehicle groups were composed of 5 mice and 
treated groups of 6. (E) Kaplan-Meier plot displays the overall survival of the different groups. (F) 
CHD4 mRNA expression level, quantified by qPCR, at the indicated groups. Each point represents one 
tumor isolated from one mouse. In black are displayed tumors isolated at the end of the experiment 
and in grey or orange are tumors isolated 4 days after the beginning of the doxycycline treatment. 
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Figure 6 
 
Fig.6 – CHD4 as a broad tumor dependency. 
(A/C) Violin plots show the dependency scores of 391 cancer cell lines, calculated by CERES, for the 
indicated NuRD members and the chromatin remodelers of the SNF2-like family (Avana_public_18Q1 
dataset). CHD4 is indicated in orange and BRD4 in purple. (B/D) Violin plots show the sensitivity 
score of 398 cancer cell lines, as RSA, for the indicated NuRD members and the chromatin remodelers 
of SNF2-like family (DRIVE platform). CHD4 is indicated in orange and BRD4 in purple. 
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Figure 7 
 
 
Fig.7 – CHD4 regulates SE accessibility to oncogenic TFs and cofactors. 
In the presence of CHD4, P3F binds to SE, recruits many transcription cofactors, such as BRD4, and 
activates gene expression. By genetic depletion of CHD4, the P3F-bound SEs become less accessible 
and P3F and the cofactors BRD4 and HDAC2 are displaced from the chromatin which impairs SE-
driven gene expression.  
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SUPPLEMENTARY MATERIAL AND METHODS 
Supplementary Table 1 Tumor cell lines per tumor type tested in the Achilles database. 
Tumor type Number of cell lines 
AML 10 
Bladder 20 
Breast 26 
Cervical 1 
Colon 25 
Endometrial 14 
Esophageal 10 
Ewing's 4 
Gastric 11 
Glioblastoma 20 
Glioma 10 
Head and Neck 12 
Kidney 17 
Liver 13 
Lung 48 
Lymphoma 8 
Medulloblastoma 7 
Mesothelioma 1 
Myeloma 7 
Neuroblastoma 15 
Osteosarcoma 5 
Other 10 
Ovarian 31 
Pancreas 22 
Rhabdoid 3 
RMS 6 
Sarcoma 1 
Skin 29 
Synovial Sarcoma 2 
T-ALL 2 
Thyroid 1 
Total 391 
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Supplementary Table 2 Tumor cell lines per tumor type, according with the pathologist 
annotation, tested in the DRIVE database. 
Tumor Type Number of cell lines 
Biliary_Tract:Carcinoma 1 
Bone:Sarcoma_Chondro 1 
Cervix:Carcinoma 1 
CNS:Medulloblastoma 1 
Endometrium:Others 1 
Liver:Carcinoma_Adeno 1 
Liver:Hepatoblastoma 1 
Lung:Others 1 
PNET:Rhabdoid 1 
Salivary_Gland:Carcinoma 1 
Soft_Tissue:Sarcoma_Fibro 1 
Undefined:GIST 1 
Bone:Sarcoma_Osteo 2 
Prostate:Carcinoma 2 
Eye:Melanoma 3 
Bone:Sarcoma_Ewing 4 
Lymphoma:Multiple_Myeloma 4 
Lymphoma:NH_B_cell 4 
Leukemia:ALL 5 
Lung:Mesothelioma 5 
Soft_Tissue:Sarcoma_Synovial 5 
Thyroid:Carcinoma 5 
CNS:Glioma 6 
Lung:NSCLC_Large_Cell 6 
Lung:NSCLC_Others 6 
Oesophagus:Carcinoma 8 
Bladder:Carcinoma 9 
PNET:Neuroblastoma 9 
Soft_Tissue:Sarcoma_Rhabdoid 9 
Upper_Aerodigestive_Tract:Carcinoma 9 
Leukemia:AML 10 
Lung:NSCLC_Squamous 10 
Lung:SCLC 10 
Endometrium:Carcinoma 11 
CNS:Glioma_HighGrade 12 
Liver:HCC 13 
Kidney:Carcinoma 14 
Gastric:Carcinoma 15 
Ovary:Carcinoma 15 
Pancreas:Carcinoma 22 
Breast:Carcinoma 24 
Skin:Melanoma 29 
Lung:NSCLC_Adeno 30 
Colorectal:Carcinoma 40 
Total 368 
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Supplementary Table 3 Guide RNA sequences used in flag knockins. 
Primer Name Sequence 
sg_NCHD4 GAGCGGAAGGGGATGGCGTC 
sg_CCHD4 TCTGCATCTTCACTGCTGCT 
sg_NBRD4 ATGTCTGCGGAGAGCGGCCCTGG 
 
Supplementary Table 4 Donor DNA sequences used in flag knockins. 
Donor DNA Sequence 
N-terminal 
3xflag-CHD4 
GGGTGGGGGCAGGCTGTTGTTCAAAAGTGCATCCATATCCTCCTCCTCAC 
TGCCCGCCGAGCAGGGGGACGGGGAGCCCAGGCCCGACGCTTTATCGTCA 
TCATCTTTGTAGTCCTTGTCATCATCGTCCTTATAGTCCTTATCGTCGTC 
ATCCTTGTAATCCATCCCCTTCCGCTCCCGGCCAGGGAATTGGCCCAGCT 
 
C-terminal 
3xflag-CHD4 
TATCAGTGAATTCCCTTGAGATTGGGTGGATTCCTATCATCTGGAATTCT 
GACTCCTCGGGTCTCCTTCTCTAGGTAGCACAGCAACAGGATTACAAGGA 
TGACGACGATAAGGACTATAAGGACGATGATGACAAGGACTACAAAGATG 
ATGACGATAAATAGAGCAGTGAAGATGCAGACTGATACCACCTCCACCGC 
 
N-terminal 
3xflag-BRD4 
TTGGGCCTGGGCCTGTGTTGTAGACATTTGGGAAGTTTCTAGTCCATCCC 
CCATTACTGGCAGATTTCTCAATCTCGTCCCGGGGCCGCTCTCCGCAGAC 
TTGTCGTCATCGTCTTTGTAGTCCTTGTCGTCATCGTCTTTGTAGTCCTT 
GTCGTCATCGTCTTTGTAGTCCATGCTAGTGATCCCATCACATTCTTCAC 
 
 
Supplementary Table 5 Antibodies used in ChIP assays. 
Antibody target Catalog Number Company 
Flag F1804 Sigma Aldrich 
HDAC2 Ab7029 Abcam 
RBBP4 A-2703-050 Epigentek 
BRD4 A301-985A100 Bethyl Laboratories 
H3K9ac 61663 Active Motif 
H3K9me1 39887 Active Motif 
H3K9me3 39765 Active Motif 
RNA Pol 2 61667 Active Motif 
 
ChIP-seq data for H3K27ac, H3K27me3, H3K36me3, H3K4me1, H3K4me2, H3K4me3, 
BRD4, MYOD , MYOG, MYCN, CTCF, Rad21 in RH4 cells were obtained from15. 
 
Supplementary Table 6 Sequence of guide RNAs used in NuRD-centered CRISPR screen. 
Target Sequence 
CHD4 
CTCCTCACTGCCCGCCGAGCAGG 
TTAGGGATTTTAGGGTCCCGAGG 
AAGAGGGGCGCTCACTAGGAAGG 
ATGTATGTCGTAACCTATGTGGG 
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TATAAATACGAACGCATCGATGG 
CHD3 
ACGAGGGAGTACTCGGGCGCGGG 
GGAGTACTGCCGCGTATGCAAGG 
CTCGCCGGAGCCATAGTCCAGGG 
GAATTCATTCTCACGAATGATGG 
GCGCATCGATGGTGGTATCACGG 
HDAC1 
CGCAGACGCAGGGCACCCGGAGG 
TGAGTCATGCGGATTCGGTGAGG 
TTACGTCAATGATATCGTCTTGG 
TATTCACCATGGTGACGGCGTGG 
CATCAATCCCGTCTCGGAGCGGG 
HDAC2 
TGGGTCATGCGGATTCTATGAGG 
TACAACAGATCGTGTAATGACGG 
GATGTATCAACCTAGTGCTGTGG 
CTCATTATCTGGTGATAGACTGG 
TCCGTAATGTTGCTCGATGTTGG 
LSD1 
CGGACCCCGGCGGTTCCGCCAGG 
GTCGGACCAGCCGGCGCAAGCGG 
TGAGAAGTCATCCGGTCATGAGG 
CGAGTTGCCACATTTCGCAAAGG 
GAACTCGGCAGTAATATCTCTGG 
MBD2 
ATGCGCGCGCACCCGGGGGGAGG 
CGGCGACTCCGCCATAGAGCAGG 
CGCCACTCGGGGGACGGCCGCGG 
CCTTCTTCCATCCGGGGGGGAGG 
GCCTCAGTTGGCAAGGTACCTGG 
MBD3 
GAGTGCCCGGCGCTCCCGCAGGG 
CTTGCCCGTGCGGAAGTCGAAGG 
GCTTGAAGATGGACGCCGTCTGG 
CAGCAATGTCGAAGGCGTTCAGG 
CGTGGTGTTGAGCCATACGCCGG 
MTA1 
CGATTCTCCGGATCAGGTATGGG 
CTGCTATAAGGCCGGACCGGGGG 
CGACTCGGTCTCGTTGAGCAGGG 
TCGAGTAGGAAACCGGTACCAGG 
ATCAGAGGCCAACCTTTTCGAGG 
MTA2 
TTACCTGGTTAGACGGATTGAGG 
TGTCTGTCTTTTCCGGCGCAGGG 
GATCCCAGATCGCCTAGTAGAGG 
GCAAAGGAACGGCTACGACCTGG 
GGACTTCAATGATATTCGCCAGG 
MTA3 
GCAACCCATACCTAATAAGAAGG 
TGCGAGCATTATAAGTGTGTTGG 
CTCTGCCCGCAACACATATCAGG 
TCAATCTGTCGATCCGTAAGTGG 
AGTGTCTTAGTACCACTCGGAGG 
GATAD2A CCGAAGAAGCATGCCGAACACGG 
Manuscript 1
 ________________________________________________________________________________________________________ 
 
78 
 
GCGGCAGAGTCAAATACAAAAGG 
GCGGCCGCCTGTCGGCTTGCTGG 
AACTCGTTGTTGGCGGCGCTGGG 
AGACGGACTTCACGTGCCGCTGG 
GATAD2B 
GAATCTGTTGAAGCGGAGCTTGG 
ACGATTGGAAGAAGCCCGACTGG 
GGCAGCATCAGTCATGGCGCTGG 
CATGTAGATGAACTCGCTATTGG 
GGTGAAATCTGTGCGGCACTGGG 
RBBP4 
TTCTTCCACTGCGTCGTCGAAGG 
GTCTTTGTTGCGATGATACAAGG 
AGACTCATGGAGTAGATGCCAGG 
CAGTGTGAGCATCAACTGAGTGG 
CAGTCTGCGATCAGTACCACTGG 
RBBP7 
TACACCGTTTCTATATGACCTGG 
GCCCTTCATTGGCTAGTGCTGGG 
GGTGGCTTTGGTTCTGTAACAGG 
TGTCTGTGGGATATAAACGCAGG 
CTGCTGCACGAGTCATTGTTTGG 
BRD4 
AGATTTCTCAATCTCGTCCCAGG 
TAAGATCATTAAAACGCCTATGG 
TGATGTCACAGTAGTCGTGTAGG 
CCTGAGCATCACGGTACTCACGG 
AGTCGATTTCAATCTCGTCGGGG 
 
Supplementary Table 7 Primers used in ChIP-qPCR 
Primer Name Sequence 
ALK_FW GTCACTTTGGGTCACTTGCT 
ALK_RV GCCTTGTAGTTAGCTCTCCC 
ASS1_FW CAATGGTGGAGCGTGAAAT 
ASS1_RV ACCCTCCCATTCTCTTTGC 
CDH3_FW ATGCTCCCGAGATACCAGAT 
CDH3_RV AGAAGCGTTGTAATCCTCCAA 
UNTR5_FW TATAAAGGACCGTGGCTTCC 
UNTR5_RV TCATTCATTTGGTCATGGCT 
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Supplementary Table 8 TaqMan gene expression assays. 
Gene name Assay catalogue number 
ALK Hs00608284_m1 
ASS1 Hs01597981_gH 
CDH3 Hs01285856_cn 
CHD4 Hs00172349_m1 
CNR1 Hs01038522_s1 
GAPDH Hs02758991_g1 
PAX3-FOXO1 Hs03024825_ft 
PIPOX Hs04188864_m1 
RBBP4 Hs01568507_g1 
TFAP2B Hs00231468_m1 
 
Western Blot 
Cells were harvested and lysed in standard lysis buffer (50mM Tris-HCl pH 7.5, 150mM 
NaCl,1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1mM EGTA, 50mM NaF, 5mM 
Na4P2O7, 1mM Na3VO4, and 10mM ß-glycerolphosphate with protease inhibitor cocktail, 
cOmplete Mini®, Roche). Lysates were run through 20G needles and cleared by 
centrifugation. Protein concentration was measured with PierceTM BCA Protein Assay Kit 
(#23227, Thermo Scientific) according with the manufacturer’s instructions. Proteins were 
separated with NuPAGE 4-12% Bis-Tris pre-cast gels (ThermoFisher Scientific AG) and 
transferred into nitrocellulose membranes (GE Healthcare). Membranes were blocked with 
5% milk in TBST and primary antibodies (1:1000) were incubated over night at 4°C. After 
TBST wash, the membranes were incubated for 1hr with HRP-linked secondary antibodies 
at room temperature. Proteins were detected by chemiluminescence using AmershamTM 
ECLTM detection reagents (#RPN2209, GE Healthcare) or SuperSignalTM West Femto 
Maximum Sensitivity Substrate (#34095, ThermoFisher Scientific AG). The following 
commercial primary antibodies were used: anti-CHD4 (#A301-082A, Bethyl Laboratories), 
anti-Flag (clone M2, #F1804 , Sigma Aldrich), anti-BRD4 (#ab128874, Abcam), anti-FOXO1 
(H-128, #sc-11350, Santa Cruz Biotechnology), anti-HDAC2 (3F3, #5113S, Cell Signaling 
Technologies), anti-MTA2 (#M7569, Sigma Aldrich), anti-RBBP4 (A301-206A-M, Bethyl 
Laboratories) and anti-βTubulin (D3U1W, #86298S, Cell Signaling Technologies), and anti-
GAPDH (14C10, #2118L, Cell Signaling Technologies). 
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Immunofluorescence 
Cells were seeded on cover slides, fixed with 4% PFA for 15 min, followed by a 5 min 
incubation with 0.1M glycine in PBS, permeabilized for 15 min with 0.1% Triton X-100 in 
PBS and blocked with 4% horse serum in 0.1% Triton X-100/PBS. All steps were carried out 
at room temperature. Then, cells were incubated overnight with anti-flag antibody (clone 
M2, #F1804, Sigma Aldrich) at 1:250 dilution in 4% horse serum in 0.1% Triton X-100/PBS. 
Fluorescent secondary antibody (Alexa FluorTM 594 anti-mouse, #A11032, Thermo Fisher 
Scientific AG) at 1:200 dilution in PBS containing 4% horse serum was applied for 1hr at 
room temperature. Cover slides were fixed on objective glass with DAPI Vectashield® 
mounting medium (Vector laboratories Inc.) and analyzed by fluorescence microscopy. 
 
Cell count assay 
RH4 cells with or without flag knockin were platted (45 000 cells/well in 24-well plate) in 
duplicate and counted every day for 6 days. Three biological replicates were performed. 
 
ChIP-qPCR 
ChIP assays were performed using the same protocol as for ChIP-seq. Quantitative PCR was 
performed using PowerUpTM SYBR Green Master Mix (ThermoFisher Scientific AG) and 
primers were designed to target known binding sites of PAX3-FOXO1, HDAC2 and BRD4. As 
negative control, we used an untranscribed genomic region (UNTR5) and the commercially 
available Human Negative Control Primer Set 1 (#71001, Active Motif) was used for 
normalization. Primer sequences  used can be found in the Supplementary Table 7. 
 
Quantitative real time PCR 
Total RNA was extracted using the RNeasy mini Kit (#74106, Qiagen Instruments AG). cDNA 
synthesis was carried out using the High-Capacity Reverse Transcription Kit (#4368814, 
Applied Biosystems by ThermoFisher Scientific AG). Quantitative PCR was performed using 
TaqMan gene expression master mix and TaqMan gene expression assays (Applied 
Biosystems by ThermoFisher Scientific AG).  Data was analyzed with SDS 2.3 software and 
Ct values were normalized to GAPDH. Relative expression levels were calculated using the 
ΔΔCt method based on experiments performed in triplicates. Details regarding the gene 
expression assays used can be found in Supplementary Table 8. 
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Library preparation for ChIP-seq assays 
DNA libraries were created using Illumina TruSeq ChIP Library Prep Kit, after which DNA 
was size selected with SPRIselect reagent kit (to obtain a 250-300 bp average insert 
fragment size).  Libraries were multiplexed and sequenced using NextSeq500 High Output 
Kit v2 (75 cycles), #FC-404-2005 on an Illumina NextSeq500 machine.  25,000,000-
30,000,000 unique reads were generated per sample.   
 
ChIP-seq data processing 
ChIP enriched DNA reads were mapped to reference genome (version hg19) using BWA1. 
Duplicate reads were discarded.  For IGV sample track visualization, coverage density maps 
(tdf files) were generated by extending reads to the average size (measured by Agilent 
Bioanalyzer minus 121 bp for sequencing adapters) and counting the number of reads 
mapped to each 25bp window using igvtools 
(https://www.broadinstitute.org/igv/igvtools). ChIP-seq read density values were 
normalized per million mapped reads.  
 
ChIP-seq Peak calling  
High-confidence ChIP-seq peaks were called by MACS2 (https://github.com/taoliu/MACS) 
with the narrow algorithm2.  The peaks which overlapped with the possible anomalous 
artifact regions (such as high-mappability regions or satellite repeats) blacklisted by the 
ENCODE consortium (https://sites.google.com/site/anshulkundaje/projects/blacklists) 
were removed using BEDTools. Peaks from ChIP-seq were selected at a stringent p-value of 
at least 0.0000001.  Peaks within 2,500bp to the nearest TSS were set as promoter proximal, 
while all other were considered distal. The distribution of peaks (as intronic, intergenic, 
exonic, etc.) was annotated using HOMER.  
 
Chromatin state mapping 
Chromatin states were identified using a hidden Markov model to find complex patterns of 
chromatin modifications (http://compbio.mit.edu/ChromHMM/) which was developed for 
the ENCODE project3,4.  We defined chromatin states by integrated analysis of 9 histone 
modifications (H3K27ac, H3K27me3, H3K4me1, H3K4me2, H3K4me3, H3K36me3, 
H3K9ac, H3K9me1, and H3K9me3) and 2 architectural proteins (RAD21 and CTCF), 
allowing us to identify 16 states in RH4 cells.  
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Motif enrichment analysis  
Enrichment of known motifs was performed using HOMER script “findMotifsGenome.pl” 
(http://homer.salk.edu/homer/ngs/peakMotifs.html). 
 
Visualization of ChIP-seq and DNase-HS data 
Metagene plots and heatmaps of ChIP-seq and DNAse-HS data were performed using 
NGSplot5.  Scaling and plot adjustments were performed using replot.r function 
(https://github.com/shenlab-sinai/ngsplot/wiki/ProgramArguments101).   Colors for 
heatmaps were set in Adobe Photoshop, while sizing and placement were performed in 
Adobe Illustrator. 
 
RNA-seq library preparation and data analysis 
Library preparation and sequencing was performed by ATLAS Biolabs GmbH, Berlin, 
Germany. Poly-A selected cDNA libraries were prepared with the Illumina® TruSeq® 
Stranded mRNA Sample Preparation Kits and sequenced on an Illumina HiSeq2000.  RNA-
seq reads were aligned to the Ensembl release 91’s GRCh38 reference genome with the 
options “--rna-strandness RF --
fr”(ftp://ftp.ensembl.org/pub/release91/fasta/homo_sapiens/dna/Homo_sapiens.GRCh3
8.dna_sm.primary_assembly.fa.gz) using Hisat2 v2.1.06 and Samtools v1.77.  Mapping 
quality was assessed by qualimap v2.2.18.  
Transcripts from mapped reads were assembled using the Ensembl release 91’s reference 
transcriptome(ftp://ftp.ensembl.org/pub/release91/gtf/homo_sapiens/Homo_sapiens.G
RCh38.91.gtf.gz) and StringTie v1.3.49. Gene expression values were calculated at the gene 
level from the assembled transcripts using featureCounts v1.6.0 with the options of “reverse 
strand-specific” and “pairs with both ends mapped”10 based on the merged transcriptome 
of all samples generated by StringTie11. 
Differential gene expression was analyzed using the package DESeq2 v3.712 
(http://bioconductor.org/packages/devel/bioc/vignettes/DESeq2/inst/doc/DESeq2.html
) of R v3.4.3 with the false discovery rate set at 0.01 and p-value at 0.05. PCA analysis, 
clustering of gene expression by the Pearson correlation method, and clustered heatmaps 
using  the pheatmap package (https://www.rdocumentation.org/packages/pheatmap) 
were all carried out in R v3.4.3. 
 
Gene Set Enrichment Analysis 
Enrichment for curated gene sets (Molecular Signatures Database v6.2) was performed 
using GSEA software version 3.013,14.  The GSEA Preranked tool was employed with 1000 
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permutations, and only gene sets with a maximum list size of 500 were considered.  The 
differentially expressed gene lists were pre-ranked by the metric value calculated as 
log10(pvalue) and divided by the reverse sign of log2(fold-change). 
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SUPPLEMENTARY FIGURES 
Supplementary Figure 1 
Fig.S1 – CRISPR/Cas9 efficiently adds a 3xflag tag in-frame to the N-terminal of endogenous 
CHD4 in RH4 cells 
(A) Immunoblot, performed with anti-flag and anti-CHD4 antibodies, confirms the insertion of the 
3xflag tag in the N-terminal of CHD4 in RH4 cells (named N-CHD4).  GAPDH was used as a loading 
control. Wildtype RH4 cells (WT) served as negative control. (B) Immunofluorescence, performed 
with an anti-flag antibody, shows the expected nuclear localization of the flag tagged CHD4 in N-CHD4 
cells. DAPI was used to visualize the nucleus and wildtype RH4 cells (WT) as negative control. Scale 
bar - 100µm. (C) Cell counts throughout 6 days of wildtype RH4 cells (WT) and N-CHD4 cells. 
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Supplementary Figure 2 
Fig.S2 – CHD4 binds to distal intronic and intergenic enhancer regions 
(A) Example of gene tracks of the indicated proteins at the intronic enhancer present in the ALK gene. 
(B) Distribution of the peak counts according to the distance to the transcription start site (TSS), in 
percentage, of CHD4 or P3F within CHD4+P3F, CHD4-only and P3F-only regions (C) Distribution of 
the peak counts according to their genome location, in percentage, of CHD4 or P3F within CHD4+P3F, 
P3F-only, and CHD4-only regions. (D) Example of gene tracks of the indicated proteins at the MYOD1 
(myogenic differentiation 1) SE loci in RH4 cells. 
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Supplementary Figure 3 
 
 
Fig.S3 – CRISPR/Cas9 efficiently adds a 3xflag tag in-frame to the C-terminal of endogenous 
CHD4 protein and to the N-terminal of endogenous BRD4 protein in RH4 cells 
(A) Immunoblots, performed with anti-flag and anti-CHD4 antibodies, confirm the insertion of the 
3xflag tag in the C-terminal of CHD4 in RH4 cells (named C-CHD4).  GAPDH was used as a loading 
control and wildtype RH4 cells (WT) as negative control. (B) Cell counts throughout 6 days of 
wildtype RH4 (WT) and C-CHD4 cells. (C) Immunofluorescence, performed with an anti-flag 
antibody, shows the expected nuclear localization of flagged CHD4 in C-CHD4 cells and of flagged 
BRD4 in N-BRD4 cells. DAPI was used to visualize the nucleus and wildtype RH4 cells (WT) served 
as negative control. Scale bar - 100µm. (D) Immunoblots, performed with anti-flag and anti-BRD4 
antibodies, confirm the insertion of the 3xflag tag in the N-terminal of BRD4 in RH4 cells (named N-
BRD4).  (E) Cell counts throughout 6 days of wildtype RH4 cells (WT) and N-BRD4 cells. 
 
Supplementary Figure 4 
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Fig.S4 – CHD4-free NuRD localizes to promoters together with BRD4 
(A) Heatmaps depicting the signal of the indicated proteins at CHD4-only (n=6216), CHD4+NuRD 
(n=4720) and NuRD-only regions (n=12915) in the genome of RH4 cells. NuRD corresponds to the 
overlap between HDAC2 and RBBP4 ChIP signal. The rows show 7kb regions, centered on CHD4 or 
HDAC2 ChIP peaks and ranked by the signal intensity of H3K27ac. Color shading corresponds to 
ChIP-seq read counts. (B) Distribution, in percentage, of the peak counts of CHD4 or NuRD within 
CHD4-only, CHD4+NuRD and NuRD-only regions according to their genome location. (C) Distribution 
of the peak counts, in percentage, of CHD4 or NuRD within CHD4+NuRD, CHD4-only or NuRD-only 
regions according to the distance to the transcription start site (TSS). (D) Example of gene tracks of 
the indicated proteins at the CHD4-free NuRD-containing TOP2A (DNA topoisomerase II alpha) 
promoter in RH4 cells. (E) Gene ontology analysis (assigned by GREAT) of the biological processes 
associated with the promoters bound by NuRD-only.  
 
Supplementary Figure 5 
Fig.S5 – RBBP4 silencing influences FP-RMS cell proliferation 
(A) Immunoblotting confirms the knockdown (KD) of RBBP4 achieved with 2 doxycycline-inducible 
shRNAs (shRBBP4#1/2) in RH4 cells after 72hrs of treatment (Dox). RH4 cells expressing a 
scrambled shRNA (shScr) served as negative control and GAPDH was used as loading control. (B) 
Expression levels of RBBP4 quantified by qPCR in RH4 cells after 72hrs of doxycycline treatment. 
Expression levels (relative to GAPDH) were normalized to uninduced cells. Data represented as mean 
± SD (n=3). (C) RH4 cell proliferation was measured by crystal violet and WST1 assays at the 
indicated time points after silencing of RBBP4 by shRNA induction with doxycycline. Data is 
represented as mean ± SD (n=3) and was normalized to uninduced cells. A shScramble construct 
served as negative control. (D) Cell proliferation measured by BrdU incorporation in RH4 cells after 
72hrs of RBBP4 or CHD4 KD. Data is represented as percentage of absorbance at 450nm normalized 
to uninduced control. A scrambled shRNA was used as negative control. (* p< 0.1, **p < 0.01; ***p < 
0.001, ratio paired t test). 
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Supplementary Figure 6 
 
Fig.S6 – CHD4 silencing induces Ewing sarcoma cell death 
(A/B) Left panels Western blot validates the knockdown obtained in SKNMC and A673 cell lines after 
48hrs of doxycycline-induction of 2 shRNAs targeting CHD4. Tubulin was used as loading control. 
Right panels Expression levels of CHD4, quantified by qPCR, in SKNMC and A673 cells after 72hrs of 
silencing induction. Expression levels (relative to GAPDH) were normalized to uninduced cells. Data 
represented as mean ± SD (n of at least 3). (C/D) Cell proliferation of SKNMC and A673 cell lines 
measured by crystal violet and WST1 assays at the indicated time points after silencing of CHD4 by 
2 doxycycline-inducible shRNAs. Data is represented as mean ± SD (n=3) and was normalized to 
uninduced cells. A shScramble construct served as negative control. (E/F) Representative phase-
contrast images of SKNMC and A673 cells 72hrs after doxycycline-induction of 2 shRNAs targeting 
CHD4. Scale bar - 100µm. (G) Percentage of dead cells observed 72hrs after induction of CHD4 
silencing by doxycycline treatment. Cells were stained with 7AAD and analyzed by FACS. A scrambled 
shRNA served as negative control.  Values represented as mean ± SD of 3 independent experiments 
(*p< 0.1, **p < 0.01; ***p < 0.001, ratio paired t test).
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ABSTRACT 
CHD4 is a chromatin remodeler involved in transcription regulation, DNA-damage repair, 
and tumor development. In cancer, overexpression of CHD4 is associated with poor 
prognosis and its silencing causes cell death in a variety of tumors, such as breast cancer, 
acute myeloid leukemia, and fusion-positive rhabdomyosarcoma. Nevertheless, no 
inhibitors targeting this protein have been developed yet. 
CHD4 is composed of a C-terminal ATPase, 2 plant homeodomains (PHD1/2), 2 
chromodomains and 2 C-terminal domains of unknown function (DUF).  Since high 
resolution structural information is available for the PHD domains and the ATPase activity 
is dependent on the binding of these domains to histones, we aimed to target this chromatin 
remodeler by developing small molecule inhibitors against its second PHD domain. We 
hypothesized that by preventing the binding of CHD4 to histones we might be able to 
interfere with the remodeling activity of CHD4 and hence affect tumor development.  
By structure-based drug design we originated a comprehensive library of potential PHD2 
binding small molecule inhibitors. These candidates were tested for binding to recombinant 
PHD2 by NMR, both by ligand and protein observation assays. From the 105 compounds 
tested, we identified one weak binder. To our knowledge, this is the first attempt on 
targeting a H3K9-binding PHD domain. Although the PHD ligand reported here should 
undergo optimization cycles to improve its binding affinity, this study shows that the PHD 
reader domain, otherwise deemed undruggable, can still be considered as a feasible target 
for structure-based drug design efforts. 
 
 
 
 
Significance 
• First report of a structure-based drug design study targeting a H3K9-binding PHD 
domain and targeting the chromatin remodeler CHD4 
• Identification of weak small molecule binding the second PHD domain of CHD4 
 
 
 
Keywords 
Plant homeodomain, NMR, SEED, Pharmit, CHD4 
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INTRODUCTION 
Nucleosomes are the fundamental packaging units of our genome and they allow the fitting 
of nearly  2 meters of DNA into a 10-20μm nucleus1.  These packaging units are formed by 
two copies of four histone proteins, H2A, H2B, H3, and H4, that assemble into an octamer, 
around which 145–147 base pairs of DNA are wrapped2.  
Histones are  subjected to many post-translational modifications (PTMs), such as 
methylation and acetylation, that influence DNA compaction and hence the accessibility of 
the genome to the transcription machinery3. These PTMs, commonly named histone marks, 
work as docking sites of effector proteins that possess catalytic activity and can influence 
chromatin structure. The docking of these effectors is mediated by “reader” domains that 
recognize and bind to specific histone marks. For example, acetylation is recognized by 
bromodomains, while methylation is recognized by chromo, tudor, MBT (malignant brain 
tumor), and PHD domains4. These epigenetic “readers” are promising therapeutic targets as 
shown by the success story of JQ1, the small molecule inhibitor of the acetyl-lysine binding 
BET-bromodomain of BRD45,6. Since its development, many studies have shown in vitro and 
in vivo benefits of JQ1 treatment in many hematological malignancies as well as in a variety 
of solid tumors such as glioblastoma, medulloblastoma, hepatocellular carcinoma, colon 
cancer, pancreatic cancer, prostate cancer, lung cancer, and breast cancer7. 
Plant homeodomains (PHD) are small (circa 65 residues) zinc-finger “reader” domains 
found in many chromatin-remodeling proteins. Mutations in these domains are linked to 
several human diseases, including cancer, mental retardation, and immunodeficiencies. 
PHD fingers can be subdivided into groups according to the histone mark that they 
recognize, such as H3K4me3, H3K9me3, H3/H4 acetylated at various lysines, or unmodified 
tail of histone 38. 
CHD4 (chromodomain-helicase-DNA binding protein 4) is an ATPase from the SNF2-like 
family with nucleosome remodeling activity9,10. This chromatin remodeler collaborates with 
oncogenic transcription factors, like PAX3-FOXO1 and EWS-FLI1, and coregulates aberrant 
gene expression11,12. Moreover, CHD4 silencing causes tumor cell death in fusion-positive 
rhabdomyosarcoma, breast cancer, and acute myeloid leukemia11,13,14, making it an 
attractive target for therapy. This remodeler is composed of a C-terminal ATPase, 2 plant 
homeodomains (PHD1/2), 2 chromodomains and 2 C-terminal domains of unknown 
function (DUF)9.  Its chromodomains bind directly to DNA, while its PHD domains interact 
with histones15. These PHD domains recognize the N-tail of histone 3, with increased affinity 
when Lys9 is methylated or acetylated16–18 and in the absence of methylation of Lys4 or 
acetylation of Ala118. Importantly, the ATPase activity of CHD4 is dependent on the 
simultaneous binding of the PHD domains to histones and of the chromodomains to 
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DNA19,20. Hence, we hypothesized that, by preventing the binding of the PHD domains to 
histone 3, we could interfere with the remodeling activity of CHD4.  
In this study, we aimed to develop the first in-class small molecule inhibitor of CHD4 by 
targeting its second PHD domain. Structure-based drug design allowed us to compose a 
library of potential PHD2-CHD4 small molecule inhibitors which were validated by NMR 
protein and ligand observation experiments.  
 
RESULTS 
The structure of PHD2-H3 interaction informs in silico screens 
The second PHD finger of CHD4 is a “reader” of the H3 N-terminal tail. This zinc finger has 
a very loose conformation, comprised of a small β-sheet and an α-helix, which are held 
together by the coordination with two zinc ions (Fig.S1A). PHD2 recognizes unmodified H3, 
H3K9me1/2/3 and H3K9ac18. The H3 tail occupies an elongated binding site on PHD2, 
forming a third antiparallel β-strand which pairs with the first β-strand of PHD2, and is held 
in place through a conserved set of salt bridges and hydrogen bonds (Fig.S1B). The binding 
is stabilized by backbone interactions between Arg2, Lys4, and Thr6 of H3 with the residues 
Cys513, Leu511, Gly500 or Gly508. Further, the interaction is restrained by the co-
ordination of the amino group of Ala1 by Gly536 and Glu537, the formation of a salt bridge 
between Arg2 and Asp515, and hydrogen bonding interactions involving Lys4, Thr6 and 
Arg8. Methylation or acetylation of Lys9 increases the affinity of the binding, since it allows 
Arg8 to form a salt bridge with Glu500. Moreover, the aromatic ring of a phenylalanine lies 
orthogonal to the protein surface and may favorably interact with H3K9ac or form 
hydrophobic and cation-π contacts with methylated Lys9. 
Experimental evidence21,22 indicates that the primary sequence and post-translational 
modification status of the first residues of the H3 N-terminal histone tail is crucial to the 
binding to the PHD finger, whereas computational results suggest that the latter residues 
(mainly, H3R8 and H3K9) modulate the fine tuning of binding23. Since we aimed to abolish 
the PHD finger/histone tail binding, we decided to focus our computational efforts on the 
PHD finger surface establishing interactions with residues H3A1–H3K4 (Fig.1A). In 
particular, we undertook two different in silico screening approaches: two screening 
campaigns were performed using SEED (Fig.1B/C)24,25 and one was performed with Pharmit 
(Fig.1D)26. From these three in silico screens, a library of 105 candidate small molecules 
binding the PHD2 domain of CHD4 was generated and purchased. More details regarding 
these screens are available in the material and methods section. 
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The purified PHD2-CHD4 domain is functional  
To test the candidate compounds, we purified the PHD2 domain of CHD4 (amino acid 
sequence depicted on Fig.2A) using a GST tag (Fig.2B), which was cleaved off by the TEV 
enzyme (tobacco etch virus) before NMR binding studies were performed (purification 
scheme depicted on Fig.2C). Separation of the recombinant PHD2-domain from the TEV 
enzyme and the cleaved tag was obtained by size exclusion chromatography (SEC) and 
confirmed by gel electrophoresis (Fig.2D) and mass spectrometry (Fig.2E). Our mass 
spectrometry analysis (Fig.2E) also shows that the purified protein had the expected 
molecular weight (6,53 KDa) and was highly pure. The 1D 1H-NMR spectrum of the PHD2-
CHD4 domain (Fig.2F) shows well dispersed protein peaks which indicates that the protein 
was folded. 
As previously stated, the PHD2 domain of CHD4 recognizes the N-terminus of histone H3 
and this interaction is facilitated by methylation of Lys927. Hence, to assess if the protein 
purified from bacteria was correctly folded and functional, we performed NMR binding 
assays, through protein observation, between the recombinant PHD2-CHD4 protein and the 
12-mer peptides, H3K9 and H3K9me3. For this purpose, we acquired 1D 1H-NMR spectra of 
PHD2-CHD4 in the presence of 16-fold excess of either H3K9 (Fig.3A) or H3K9me3 peptides 
(Fig.3B). We can observe that the presence of either of the peptides results in drastic 
chemical shift perturbations in the PHD2-CHD4 spectrum, which implies binding between 
the peptides and the recombinant protein. These results suggest that the purified PHD2 
domain of CHD4 is correctly folded and functional.  
 
1H-NMR small molecule screen 
After having established the purification of functional PHD2-CHD4, we performed a first 
small protein-compound binding screen with the 10 candidate compounds obtained from 
the first in silico screening using SEED. The screen was carried out using 30µM of 
recombinant protein in the presence of 16-fold excess of each compound (480µM) in 
protein buffer (50mM Tris-HCl, 150mM NaCl, 100µM ZnCl2, 1mM DTT, pH 8) supplemented 
with 10% D2O and 0.2mM DSS (used as chemical shift reference).  Before the screen was 
performed, 1D 1H-NMR spectra were collected for each compound to determine the 
solubility of the compounds in protein buffer. 
To assess binding, we used the same protein observation method described above to 
evaluate the function of the purified PHD2 domain. The 1D 1H-NMR spectra acquired with 
the first library of 10 compounds revealed no binders (example depicted on Fig. 3C).  
Previous studies27 have shown that the binding between PHD2 and the H3 tail is weak (18 
µM binding affinity towards unmodified H3 and 0.9 µM for H3K9me3). Therefore, we 
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decided to perform 2D 1H,15N-NMR protein-compound binding experiments, as the 
improved signal dispersion in 2D NMR spectra is better suited to study weaker interactions. 
 
15N-labelled PHD2 is functional and shows higher affinity to methylated H3K9 
To perform 2D-NMR screens we labelled the PHD2 domain with 15N. The same purification 
procedure and quality control was performed for 15N-labelled PHD2-CHD4 recombinant 
protein as for unlabeled protein. To evaluate the functionality of the labelled protein, we 
recorded 2D 1H,15N-HSQC spectra of the protein and performed a titration series of both 
H3K9 (Fig.4A) and H3K9me3 peptides (Fig.4B) at variable peptide concentrations. Both 
peptides caused chemical shift perturbations in a diverse set of peaks, although the 
magnitude of these perturbations were significantly larger for the methylated version of 
H3K9. Indeed, a higher binding affinity (KD = 0.3mM) was determined for H3K9me3, 
whereas a KD of 0.7mM was measured for unmodified H3K9. These results are in agreement 
with previous published data27 that showed that methylation of H3K9 increases the binding 
affinity between the H3 tail and the PHD2 domain. Furthermore, these data validate the use 
of the 15N-labelled PHD2-CHD4 for compound binding assays. 
 
15N-NMR small molecule screen 
A total of 105 compounds were tested for binding to PHD2-CHD4. Binding assays were 
performed in protein buffer (50mM Tris-HCl, 150mM NaCl, 100µM ZnCl2, 1mM DTT, pH 8, 
supplemented with 10%D2O and 0.2mM DSS) with 30µM of recombinant protein and 16-
fold excess of each compound (480µM). Binding was determined by chemical shift 
perturbations assessment by overlaying the spectrum of unbound PHD2 with the spectrum 
of PHD2 acquired in the presence of each compound.  
As a result, no strong binders were detected, which was expected due to the loose 
conformation of the PHD2 domain and the weak affinity of this domain to its natural 
interacting partner. Weak binding was detected for compound DSP_C42_003 (Fig.5A). 
Chemical shift perturbations in 3 residues are illustrated in Figure 5B. The binding between 
this compound and the PHD2 domain of CHD4 was confirmed by ligand observation assays. 
One-dimensional WaterLOGSY experiments showed a positive phase for the peaks of the 
DSP_C42_003 compound, which indicates binding (Fig.5C). T1ρ relaxation ligand 
observation experiments showed an attenuation of the intensity of the compound peaks at 
larger relaxation delay, which is in agreement with a fast relaxation behavior, indicating 
binding to the protein (Fig.5D). 
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DSP_C42_003 possible binding interactions with PHD2-CHD4 
The 4,5,6,7-tetrahydro-1H-indazole and the 1,2,4-triazole of DSP_C42_003 establish polar 
interactions with the carbonyl oxygen of His89 and the sidechain of Asp87. Of note, there 
are other potential H-bond acceptors in the vicinity, including the sidechain of Ser111 and 
the backbone carbonyl oxygen of Met90. Interestingly, the indazole N2 atom lies merely 0.7 
Å from where the ε primary amine of H3K4 is located in the reported NMR structure 
(2l75.pdb).  
The ethylbenzene moiety, which was not included in the docked fragment, protrudes out 
towards the solvent and is likely not contributing to the interaction energy. Being fully 
solvated, this nonpolar group can have detrimental effects on the compound’s affinity by 
affecting its solubility or favoring spurious interactions with other proteins or molecules.  
 
DISCUSSION 
Numerous studies have demonstrated an oncogenic role for CHD4. In FP-RMS, CHD4 
collaborates with the fusion protein, PAX3-FOXO1, to maintain its aberrant gene expression 
program11. In glioblastoma, this chromatin remodeler regulates expression, together with 
the transcription factor ZFHX4, and allows the tumor-initiation cell state28. In colon cancer, 
CHD4 keeps the expression of tumor suppressor genes silenced29. Furthermore, many 
studies have also shown that CHD4 depletion, through genetic engineering, causes tumor 
cell death in a variety of cancers, such as breast cancer and acute myeloid leukemia11,13,14. 
Together, these data strongly encourage the development of CHD4 inhibitors and show the 
vast number of possible therapeutic applications. 
The enzymatic domain of CHD4, the ATPase, would be the most logical domain to use to 
disrupt CHD4’s activity. Nevertheless, due to its complexity and size, no structure 
information is currently available. Moreover, all proteins from the SNF2-like family30–32, 
which carry a diversity of essential physiological roles, have very similar ATPase domains, 
which may render development of specific inhibitors unfeasible. 
NMR based structural data is available for both PHD and chromodomains of CHD4, the 
histone- and DNA-binding domains of the protein33–35. Protein-DNA binding and protein-
protein interactions are difficult to model, which makes the development of inhibitors for 
both PHD and chromodomains challenging. Nevertheless, histone “reader” domains have 
been successfully targeted5. In fact, small molecule inhibitors of PHD domains binding to 
H3K4me3 have been already developed36. Moreover, the activity of CHD4 in transcription 
regulation was shown to be dependent on the binding between the PHD domains and 
histones37. Hence, we decided to interfere with CHD4’s activity by targeting its second PHD 
domain, since PHD2 has a higher affinity than PHD1 for the H3 tail37. 
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The PHD finger is a small domain characterized by a cysteine- and histidine-containing 
signature coordinating two Zinc ions. This domain fold is quite loose and is composed by  
with a short two-stranded antiparallel β-sheet, an occasional short C-terminal α-helix, and 
three loops of variable length and residue composition38. This minimal fold is maintained 
by the Zinc ions and conserved hydrophobic residues that form a small hydrophobic core39.  
PHD fingers bind to histone 3 N-terminal tails with a handful of features constantly 
observed in the available crystallographic and NMR structures, namely, (a) the backbone 
atoms of the first residues of the histone 3 tail establish H-bonds with the backbone of the 
antiparallel β-sheet of the PHD finger, effectively forming its third strand, (b) the positively 
charged N-terminus of the histone tail is coordinated by the oxygen atoms of the backbone 
carbonyl of a semi-conserved P-X-G-X-W motif (X is any residue) in the most C-terminal 
loop, and (c) binding does not lead to significant structural rearrangements of the 
conformation of the PHD finger40,41.  
The histone-binding surface of the PHD finger is shallow and polar. Therefore, while still 
deemed feasible targets for structure-based drug design efforts42, PHD fingers are possibly 
considered the hardest epigenetic “reader” domain to drug43-45. Noteworthy, attempts of 
targeting PHD domains focused on the H3K4me3-binding subfamily of the PHD finger 
domains, whose members display an aromatic cage46 which appears to be more druggable 
than the relatively flat, solvent exposed and polar H3K4me0-binding surface. 
Given the experimental evidence and computational analyses21–23, in our efforts to identify 
small molecules inhibiting the PHD2 finger/histone tail interaction, we focused on the 
interactions established between this domain and the first four residues of the histone tail.  
Our in silico efforts gathered a library of 105 candidate PHD2-CHD4 ligands. Validation of 
these candidates was performed by 2D 1H,15N-NMR binding assays, based on protein 
observation. One compound, DSP_C42_003, showed weak binding capability towards the 
PHD2 domain, which was confirmed by ligand observation assays. 
In spite of not being positively charged, one of the nitrogen atoms in the 4,5,6,7-tetrahydro-
1H-indazole group of DSP_C42_003 seems to somehow mimic the side chain amine of H3K4, 
establishing polar contacts with the negatively charged patch of the PHD2 finger surface. 
The interactions are reinforced by similar contacts provided by another nitrogen atom of 
the 1,2,4-triazole. Presumably, such polar contacts in a solvent exposed area are likely to be 
transient and labile in nature. It will be therefore imperative for the PHD finger ligand to 
undergo optimization cycles in order to improve its binding affinity. To this end, 
experimental indications based on the protein chemical shift perturbations upon titration 
of the ligand and focused chemical synthesis derivatives of this hit will be crucial. For 
example, upon experimental validation of the calculated structure shown in Figure 6, the 
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first round of optimization of DSP_C42_003 could remove the ethylbenzene and branch the 
indazole 6-member ring introducing H-bond donors and acceptors to mimic the backbone 
of H3K4.  
In summary, we have identified the first small molecule binder of the PHD2 domain of CHD4 
and proved the feasibility of targeting of H3K9-binding “reader” domains, although further 
studies are required to enhance the affinity of the compound identified. 
 
MATERIAL AND METHODS 
Cloning, Expression, and Purification of PHD2-CHD4 
The PHD2-CHD4 (496-551) construct was generated by PCR, using cDNA from the RH4 cell 
line as template and the appropriate set of primers (see supplementary material and 
methods). The amplified PCR product was cloned into the bacterial expression vector 
pETM-30, encoding a N-terminal GST-tag followed by a TEV cleavage site. Correct insertion 
of the PHD2-CHD4 sequence was verified by DNA sequencing. E. coli BL21 (DE3) cells were 
transformed with the expression vector and grown overnight at 37°C in LB media in the 
presence of kanamycin and 150µM of ZnCl2. Then, when the culture reached an OD600 of 
0.6, expression was induced with 1mM of isopropyl-thiogalactopyranoside (IPTG) for at 
least 4 hours. Cell pellets were frozen at -80°C and thawed in lysis buffer (50mM Tris-HCl, 
150mM NaCl, 10% glycerol, 0.2% NP-40, 100µM ZnCl2, 5mM DTT, pH 8, and EDTA-free 
protease inhibitor cocktail tablets – cOmplete Roche) on the next day. Bacteria were lysed, 
in the presence of DNase, by a French press. After centrifugation, the recombinant protein 
present in the lysate supernatant was purified by binding of the GST-tagged protein to a 
glutathione sepharose resin (Glutathione Sepharose 4 Fast Flow, GE Healthcare). After 
several washes, GST-tagged protein was eluted off the resin by 10mM of L-glutathione 
(Sigma Aldrich) in 50mM Tris-HCl, 150mM NaCl, 100µM ZnCl2, 5mM DTT, pH 8. 
Subsequently, the eluted recombinant protein was submitted to a one-step overnight 
dialysis, where the GST-tag was cleaved off by TEV enzyme. PHD2-CHD4 was further 
purified by size exclusion chromatography (SEC) and concentrated through 10 KDa MWCO 
centrifugal concentrators (Millipore) in 50mM Tris-HCl, 150mM NaCl, 100µM ZnCl2, 1mM 
DTT, pH 8. 
 
15N-labelled PHD2-CHD4 
15N-labelled PHD2-CHD4 was obtained by growing the transformed bacteria in minimal 
medium supplemented with 15NH4Cl (see supplementary material and methods). The 
subsequent purification was carried out following the same protocol as for the unlabeled 
protein. 
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In silico screenings  
All computational screenings were performed using as target a conformation of the solution 
structure of PHD2-CHD4 in complex with H3K9me3 (2l75.pdb) and parametrizing the 
compounds’ structures using CHARMM36/CGenFF force field47,48.  
 
In silico screenings using SEED  
Rigid-ligand docking campaigns were performed using the software SEED24,25, which 
calculates the poses’ binding free energy using a force-field-based energy function with 
approximation of desolvation effects in the continuum dielectric representation. Of note, 
two of the NMR models (the first and the tenth) were used during this in silico screen to take 
into account the flexibility of the N-terminal tail.  
 
First in silico screening using SEED 
The first screen performed using SEED was run using fragments. Starting from 1,984,949 
small molecules available at the time in the ZINC library, 106,534 fragments containing at 
least a ring and a H-bond donor or acceptor were generated using DAIM49, and 96,980 of 
which were parametrized using MATCH50. The overall procedure can be found in51.  
These fragments were docked into the PHD2-CHD4 domain. SEED allows the user to provide 
a list of coordinates that serve to select polar and apolar receptor vectors. For this docking, 
three coordinates of the histone tail residues H3T3 and H3K4 lying in the center of the 
histone tail-binding region were used. The docked fragments were then scored according 
to a consensus calculated as the median of the rankings of the following terms: receptor 
desolvation, van der Waals, and ligand efficiency. 
The 200-best scoring fragments were visually inspected and, in case the parent compound 
had no moieties sterically interfering with the calculated binding mode, the compound was 
selected. This resulted in the selection and purchase of 40 and 10 compounds, respectively.  
 
Second in silico screening using SEED 
514 compounds, available at the time at the Biomolecular Screening Facility of the EPFL in 
Lausanne with no more than two rotatable bonds, were selected as starting point for the in 
silico library of the second computational screening using SEED. 3,464 tautomers were 
generated using the calculator plugin of Marvin and docked using SEED.  
Docking and scoring approaches similar to those described previously were employed 
which ultimately resulted in the purchase of 72 compounds for experimental validation. 
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In silico screening using Pharmit 
In parallel, we undertook a pharmacophore search using Pharmit26. Based on the key 
mediators of the PHD finger/histone peptide interactions we chose four pharmacophores, 
two polar (the H-bond donor and acceptor based on H3R2 carbonyl oxygen and the H3K4 
backbone amide hydrogen) and two non-polar (the side chain methyl groups of H3A1 and 
H3T3). Screens were run using seven libraries (namely CHEMBL21, ChemDiv, Chemspace, 
MolPort, NCI Open Chemical Repository, PubChem, and ZINC), resulting in more than 
145,000,000 compounds. The exclusive shape constraints was set to 0.5, to implicitly take 
into account the molecules’ flexibility, and an energy minimization step was performed to 
optimize shape complementarity and H-bonds. The filtering based on the molecules’ 
properties (non-hydrogen atom counts lower than 26 and logP lower than 3) resulted in 
9,340 compounds.  
Then, 24,730 tautomers were generated taking advantage of the calculator plugin of Marvin, 
keeping only the 9,497 that were represented in at least 40% of the conformations at pH 
7.4. The 4,624 molecules containing at least one positive charge were then parametrized 
and the PHD finger/small molecule complex was energy-minimized. The pbeq plugin of 
CHARMM52 was used for finite-difference Poisson calculations on the minimized 
structures53.  
To analyze the plethora of calculated binding poses, the following filters were applied: (1) 
the computed strain energy for the small molecule had to be lower than 5 kcal/mol, (2) a 
nitrogen atom had to be present within 8.5 Å of the point where the N-terminus of the H3 
peptide is supposed to be, and (3) compounds had not to contain nitro groups. 3,404 
compounds were left after enforcing these filters. Several consensus scores were then 
calculated based on different permutations of a subset of the following criteria: (a) 
CHARMM total energy, (b) intermolecular electrostatic term normalized on the heavy atom 
count, (c) intermolecular van der Waals term normalized on the heavy atom count, (d) 
CHARMM total energy normalized on the heavy atom number count, and (e) difference 
between the electrostatic interaction energy between ligand and protein in water and the 
free energy of solvation of the ligand in the conformation upon investigation. Upon visual 
inspection of the best-scoring conformations, 23 compounds were selected. 
 
NMR spectroscopy 
All NMR spectra were acquired at 296K on 600 or 800MHz Bruker spectrometers (Bruker, 
Switzerland) equipped with a 5mm TXI triple resonance CryoprobeTM and a SampleJetTM for 
sample automation, which was fed with 3mm NMR tubes containing a sample volume of 
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180l. The NMR spectra were transformed and analyzed with TopSpin (Bruker, 
Switzerland). 
 
Solubility assays 
The solubility of all tested compounds was assessed by 1D 1H-NMR spectra, which were also 
used to confirm the structure of the purchased compounds. All compounds were first 
dissolved in d6-DMSO to a 50mM concentration. Then, they were diluted in protein buffer 
(50mM Tris-HCl, 150mM NaCl, 100µM ZnCl2, 1mM DTT, pH 8) to a final concentration of 
0.6mM in the presence of 10% 2H2O and 0.2mM DSS (4,4-dimethyl-4-silapentane-1-sulfonic 
acid), used as an internal concentration and chemical shift reference. The actual compound 
concentration was determined from the integral ratio of the compound peaks and the 0.00 
ppm DSS signal. 
 
Ligand-protein binding experiments  
Ligand-protein binding experiments were carried out either with unlabeled or uniformly 
15N-labelled PHD2-CHD4 in protein buffer (as described above) supplemented with 10% 
2H2O and 0.2mM DSS. For all experiments a protein concentration of 30µM was used. All 
compounds were individually tested in a 16-fold excess relative to the protein 
concentration (480µM). Spectra of the protein in the presence of an equivalent amount of 
d6-DMSO were also acquired as a control. The 12-mer peptides H3K9 and H3K9me3, the 
natural PHD2-CHD4 interactors, were purchased from LifeTein LLC, Hillsborough, NJ, USA. 
They were used as positive controls and to assess the functionality of the produced 
recombinant PHD2-CHD4 protein. 
For NMR screening, series of ligand observation 1D 1H T1ρ relaxation experiments54 with 
spin-lock times of 10ms and 200ms, and PO-WaterLOGSY experiments55 were performed. 
In addition to the experiments in the presence of the protein, as described above, the same 
measurements were performed in the absence of protein as negative controls. A compound 
was identified as a hit in the case that one or more of its lines in the spectra recorded in the 
presence of protein showed a signal decrease of at least 33% in the T1ρ relaxation spectrum 
with 200ms spin-lock duration, when compared with the one recorded with 10ms (I200 : I10 
< 0.67). Additionally, these changes in signal intensity cannot not occur in the 
corresponding spectra recorded in absence of protein (negative control). Moreover, hits 
were identified by observation of positive signals in WaterLOGSY spectra (relative to Tris 
and DMSO signals, which were arbitrarily phased with negative sign). 
In addition to the ligand observation experiments described above, all compounds were 
screened as singles by protein observation NMR experiments. These experiments were used 
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to assess chemical shift perturbations by compound binding, using either unlabeled protein 
to measure 1D 1H-NMR spectra or 15N-labelled PHD2-CHD4 to record 2D 15N-HSQC 
(heteronuclear single quantum coherence) spectra.  
Binding affinities with the natural interactor peptides, H3K9 and H3K9me3, were 
determined by monitoring the chemical shift changes of the backbone amide as a function 
of peptide concentration. Multiple binding curves were obtained by titrating each peptide 
into separate samples of 15N-labelled PHD2-CHD4 and acquiring 2D 15N-HSQC spectra for 4 
different ligand:protein ratios from the range 1:1 to 16:1. Chemical shift changes in both 1H 
and 15N dimensions were logged and fitted by non-linear regression analysis to a single site 
binding model, using a least square fitting search to find the values of KD and the chemical 
shift of the fully saturated protein56. 
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FIGURES 
Figure 1 
 
 
Fig.1 – Molecular model of the second PHD domain of CHD4 binding to H3K9me3 allows in 
silico screening of potential small molecule binders 
(A-C) Molecular model of PHD2 domain of CHD4 (PDB code: 2L75), with the PHD finger shown as a 
grey cartoon and a grey surface (the grey spheres indicate the Zinc atoms) and the H3K9me3 peptide 
indicated by sticks (C, N and O atoms are colored in yellow, blue, and red, respectively). The areas 
targeted by the in silico screenings performed using SEED are colored in purple. Two possible CHD4-
PHD2 small molecule binders, DSP_C42_004 (B) and DSP_C42_008 (C), are shown as teal spheres. (D) 
The pharmacophores chosen for the in silico screen performed using Pharmit are shown with 
spheres (violet, red, and white for “methyl groups”, “H-bond acceptors” and “H-bond donors”, 
respectively). The PHD finger is shown as grey surface (grey spheres represent the Zinc atoms) while 
the H3K9me3 peptide is shown as sticks (C, N and O atoms colored in violet, blue and red, 
respectively).  
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Figure 2 
 
Fig.2 – Purification of the PHD2 domain of CHD4 
(A) Amino acid sequence of CHD4 (496-551) cloned into the expression construct. Arrows indicate 
the beginning and end of the PHD2 domain. (B) Scheme of the recombinant GST-tagged PHD2-CHD4 
protein. (C) Purification scheme of the PHD2 domain of CHD4. (D) Gel electrophoresis demonstrates 
the purity of the obtained recombinant PHD2-CHD4. In A, we can observe the bands corresponding 
to the GST-tagged PHD2, the TEV enzyme, the cleaved tag, and the recombinant PHD2-CHD4. B shows 
the purity of the recombinant protein obtained after SEC. (E) Mass spectrometry confirms the purity 
of the recombinant PHD2-CHD4. (F) One-dimensional 1H-NMR spectrum of purified PHD2-CHD4 
(30µM) recorded in 50mM Tris-HCl, 150mM NaCl, 100µM ZnCl2, 1mM DTT, pH 8, supplemented with 
10% 2H2O and 0.2mM DSS. 
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Figure 3 
 
 
Fig.3 – Purified PHD2-CHD4 can bind 12-mer H3K9 and H3K9me3 peptides 
(A) One-dimensional 1H-NMR spectrum of purified PHD2-CHD4 (30µM) in the presence (red) or 
absence (blue) of the 12-mer H3K9 peptide (480µM). (B) One-dimensional 1H-NMR spectrum of 
purified PHD2-CHD4 (30µM) in the presence (red) or absence (blue) of the 12-mer H3K9me3 peptide 
(480µM). (C) Example of first compound screen. One-dimensional 1H-NMR spectrum of purified 
PHD2-CHD4 (30µM) in the presence (red) or absence (blue) of 480µM of DSP_C42_003.  
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Figure 4 
 
Fig.4 – Purified 15N-labelled PHD2-CHD4 binds to H3K9 with increased affinity when Lys9 is 
methylated 
(A and B) Overlay of the 2D 1H,15N-HSQC spectra of unbound PHD2 (blue) and PHD2 in the presence 
of increasing concentrations (30µM – red, 60µM – green, 120µM – purple) of the 12-mer H3K9 (A) 
and H3K9me3 (B) peptides. 
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Figure 5 
 
Fig.5 – DSP_C42_003 binds weakly to the PHD2 domain of CHD4 
(A) Chemical structure of DSP_C42_003. (B) Overlay of the 2D 1H,15N-HSQC spectra of 30µM of 
unbound PHD2 (blue) and of 30µM of PHD2 in the presence of 480µM of DSP_C42_003 (red). (C) One-
dimensional WaterLOGSY spectra of 30µM of PHD2 (in blue) and of 30µM of PHD2 in the presence of 
480µM of DSP_C42_003. The arrows in the spectra indicate the positive peaks of the compound. (D) 
T1ρ shows binding between the PHD2 domain of CHD4 and compound DSP_C42_003. The one-
dimensional 1H-NMR spectrum of 480µM DSP_C42_003 in the presence of 30µM of PHD2 is shown in 
blue. In green (200ms) and red (10ms) are shown the one-dimensional 1H-NMR spectra of 480µM 
DSP_C42_003 in the presence of 30µM of PHD2. 
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Figure 6 
 
Fig.6 – Molecular modeling of DSP_C42_003 reveals residues potentially important for its 
binding to PHD2 
(A) Docked binding pose of DSP_C42_003 in the second PHD finger of CHD4. The protein domain is 
shown as in Figure 1A, while the small molecule is shown as sticks (C atoms are colored in violet, N 
in blue, and H in grey). (B) Zoom of the docked binding pose, with relevant residues of the PHD finger 
shown as sticks 
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SUPPLEMENTARY MATERIAL AND METHODS 
Cloning primers 
ETM_PHD2_FW – TTTCAGGGCGCCATGGACCACCATATGGAATTCTG 
ETM_PHD2_RV - GACGGAGCTCGAATTCTATTTGCCCTTCAGAGCTG 
 
Minimal media composition 
Supplementary Table 1 Minimal media components 
Minimal Media Concentration 
trace elements 1x 
NH4Cl 1g/L 
Glucose 0.4% 
MgSO4 0.2µM 
CaCl2 0.3µM 
Biotin 1mg/L 
Thiamin 1mg/L 
ZnCl2 0.15mM 
5X M9 1x 
  
Supplementary Table 2 100x trace elements composition 
100x trace elements Concentration (mM) 
EDTA 17.1 
FeCl3*6H2O 3.07 
ZnCl2 0.62 
CuCl2*2H2O 0.08 
CoCl2*6H2O 0.04 
H3BO3 0.16 
MnCl2*4H2O 0.007 
  
Supplementary Table 3 M9 media composition 
5x M9 Concentration (M) 
Na2HPO4 0.250 
KH2PO4 0.110 
NaCl 0.04 
 
  
Manuscript 2
 ________________________________________________________________________________________________________ 
 
115 
 
SUPPLEMENTARY FIGURES 
Supplementary Figure 1 
 
Fig.S1 – Molecular model of the second PHD domain of CHD4 and its interaction with the first 
nine amino acids of the H3 N-tail 
(A) Molecular model of PHD2 domain of CHD4 (PDB code: 2L75), with the PHD finger shown as a 
grey cartoon and a grey surface. In green we can observe the small α-helix and in blue the β-sheet. 
Also visible are the two zinc ions which are coordinated with this domain in a cross-brace 
arrangement. (B) Molecular model of the interaction between the PHD2 domain and the first nine 
amino acids of the H3 N-tail, shown as sticks (C atoms are in yellow, N in blue and O in red). Indicated 
are the main amino acids responsible for the binding between PHD2 and H3. 
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Introduction
Rhabdomyosarcoma (RMS) is a heterogeneous family of tumors 
sharing features with the skeletal muscle lineage. It is the most 
common soft tissue sarcoma in childhood and can be classified into 
2 main histological subtypes, alveolar RMS (aRMS) and embryonal 
RMS (eRMS). These are not only histologically distinguishable but 
also associated with distinct clinical and molecular profiles. aRMS 
is the more aggressive form of RMS, with a higher rate of metasta-
sis and a poorer prognosis. Current treatment modalities, including 
chemotherapy, surgery, and radiation, have steadily improved sur-
vival of RMS patients, but, especially for aRMS patients with meta-
static disease, survival rates remain dismal (1, 2). So far there are no 
targeted therapies available that could improve overall cure rates 
and reduce long-term sequelae. About 80% of aRMSs are charac-
terized by a specific chromosomal translocation generating PAX3-
FOXO1 or PAX7-FOXO1 fusion transcription factors (fusion-posi-
tive RMS [FP-RMS]) (3). It is now well accepted that fusion status 
drives unfavorable outcome in patients with RMS, especially for 
the PAX3-FOXO1 fusion (4–7). Therefore fusion status has become 
a very important prognostic marker in the clinics. The fusion 
proteins are characterized by aberrant expression levels, greater 
posttranslational stability, exclusive nuclear localization, and a 
more potent transcriptional function compared with WT PAX3/
PAX7 (8–11). Furthermore, numerous studies have highlighted the 
oncogenic ability of the PAX3-FOXO1 fusion protein and its funda-
mental contribution toward FP-RMS tumorigenesis (12–17). Since 
FP-RMS cells are addicted to the oncogenic capacity of PAX3-
FOXO1 expression, it remains a very attractive therapeutic target 
(18–21). However, direct targeting of transcription factors persists 
in being challenging. Therefore, many studies have been conduct-
ed to identify PAX3-FOXO1 downstream targets or cooperating 
mutations that are potentially required for oncogenic transforma-
tion (reviewed in ref. 22). Many putative therapeutically relevant 
signaling pathways have been described with varying degrees of 
tumor cells’ dependence on them and therefore also varying tumor 
response upon inhibition. Also, their complexity, crosstalk, and 
acquired drug resistance often limit clinical application of drugs 
targeting key components of these pathways (23–25). Furthermore, 
pediatric cancers in general are known to carry very few mutations 
compared with adult tumors, and recent comprehensive genomic 
analysis has identified a particularly low overall mutational burden 
in FP-RMS, decreasing the number of potential actionable targets 
and underscoring the importance of the fusion proteins as domi-
nant driver (26, 27).
Epigenetic regulation is an emerging field in cancer biolo-
gy and provides novel therapeutic possibilities (28). Several his-
tone demethylases and histone methyltransferases are highly 
expressed in FP-RMS and have been shown to maintain the undif-
ferentiated phenotype of tumor cells or promote their survival. 
In these known cases, epigenetic modulators act as either direct 
A vast number of cancer genes are transcription factors that drive tumorigenesis as oncogenic fusion proteins. Although 
the direct targeting of transcription factors remains challenging, therapies aimed at oncogenic fusion proteins are attractive 
as potential treatments for cancer. There is particular interest in targeting the oncogenic PAX3-FOXO1 fusion transcription 
factor, which induces alveolar rhabdomyosarcoma (aRMS), an aggressive cancer of skeletal muscle cells for which patient 
outcomes remain dismal. In this work, we have defined the interactome of PAX3-FOXO1 and screened 60 candidate 
interactors using siRNA-mediated depletion to identify candidates that affect fusion protein activity in aRMS cells. We 
report that chromodomain helicase DNA binding protein 4 (CHD4), an ATP-dependent chromatin remodeler, acts as crucial 
coregulator of PAX3-FOXO1 activity. CHD4 interacts with PAX3-FOXO1 via short DNA fragments. Together, they bind to 
regulatory regions of PAX3-FOXO1 target genes. Gene expression analysis suggested that CHD4 coregulatory activity is 
essential for a subset of PAX3-FOXO1 target genes. Depletion of CHD4 reduced cell viability of fusion-positive but not of 
fusion-negative RMS in vitro, which resembled loss of PAX3-FOXO1. It also caused specific regression of fusion-positive 
xenograft tumors in vivo. Therefore, this work identifies CHD4 as an epigenetic coregulator of PAX3-FOXO1 activity, 
providing rational evidence for CHD4 as a potential therapeutic target in aRMS.
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ity and serve as rational therapeutic targets, we designed a 2-step 
screening approach (Figure 1A). First, we performed mass spec-
trometry (MS) analysis of proteins that interact with PAX3-FOXO1. 
FP-RMS cells RH4 and RMS13 were transiently transfected with 
triple FLAG-tagged PAX3-FOXO1 or, as control, FLAG only expres-
sion vectors. Using both N- and C-terminally FLAG-tagged PAX3-
FOXO1 prevented loss of interactors due to interference with the 
localization of the tag. Additionally, we combined high-level CMV 
promoter–driven PAX3-FOXO1 expression for maximum protein 
recovery with low-level long terminal repeat promoter–driven 
PAX3-FOXO1 expression, minimizing nonspecific interactions 
(Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI85057DS1). We analyzed 4 inde-
pendent FLAG-affinity purifications of PAX3-FOXO1 together 
with controls (Figure 1B) by MS, which confirmed the presence of 
PAX3-FOXO1 with a minimum coverage of 54% in each replicate 
experiment including PAX3-FOXO1 breakpoint-specific peptides 
(Supplemental Figure 1B). Considering only proteins found with a 
or indirect target genes downstream of PAX3-FOXO1 (29–32). 
In contrast, epigenetic mechanisms that would orchestrate the 
network of aberrant transcriptional activity at the level of PAX3-
FOXO1 itself are largely unknown.
Here, we used a 2-step screening approach to identify novel 
PAX3-FOXO1 coregulators that might be essential for its aberrant 
transcriptional activity. We identified chromodomain helicase 
DNA binding protein 4 (CHD4) as crucial coregulator of PAX3-
FOXO1 activity that co-occupies a subset of PAX3-FOXO1 binding 
regions. Our results suggest that CHD4 represents a novel onco-
genic epigenetic chromatin remodeler required to orchestrate a 
subsignature of PAX3-FOXO1 target genes and thereby maintain 
tumor cell survival.
Results
A 2-step screening approach identifies several NuRD complex compo-
nents as PAX3-FOXO1 coregulators. To identify PAX3-FOXO1–inter-
acting proteins in FP-RMS that may contribute to its aberrant activ-
Figure 1. Two-step proteomic and siRNA screen identifies putative PAX3-FOXO1 interaction partners. (A) Schematic representation of the 2-step screen-
ing approach. (B) Representative silver-stained gel of FLAG immunoprecipitates from RMS13 cells transfected with FLAG-tagged PAX3-FOXO1. The aster-
isk marks the band corresponding to FLAG-PAX3-FOXO1. RMS13 cells expressing only FLAG-tag served as negative control. (C) SiRNA screening results 
for 60 candidate interactors. Each candidate was silenced using 3 different siRNAs per target. Fold change of expression of PAX3-FOXO1 target genes was 
measured by quantitative real-time PCR relative to RH4 cells treated with scrambled control. Values for the 9 candidate interactors resulting from the 
siRNA screen are indicated. (D) Schematic representation of the NuRD complex. General subunit composition and components with enzymatic activity are 
displayed. NuRD subunits identified by MS are marked in red.
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classes of genes affected by PAX3-FOXO1, including those activat-
ed from enhancer sites (NMYC), from intronic sites or promoters 
(PIPOX and CDH3 ), or via unknown mechanisms (TFAP2B), as 
well as 1 repressed gene (MYL1) (19, 34–37). For each siRNA, fold 
change of target gene expression relative to scrambled control was 
determined by quantitative real-time PCR. We considered a fold 
change below 0.75 for activated and above 1.25 for repressed target 
genes as threshold to narrow down the list of candidates (Figure 
1C). Considering, in addition, candidates affecting at least 2 target 
genes by at least 2 independent siRNAs, we identified 9 interactors 
that might potentially modulate PAX3-FOXO1 activity (Figure 1C 
and Supplemental Figure 2). Each of the 9 candidate interactors 
affected expression of only a subset of the target genes measured, 
reflecting potentially diverse mechanisms by which the fusion pro-
tein regulates target gene expression. 
minimum of 2 unique peptides in at least 2 replicate experiments 
and none of the controls, we identified 230 putative PAX3-FOXO1 
candidate interactors (Supplemental Table 1). 
To narrow down the list to candidate interactors that potential-
ly would affect PAX3-FOXO1 transcriptional activity, we applied 
a subsequent siRNA screen (Figure 1A) targeting 60 preselected 
candidate interactors (Supplemental Table 2). Preselection was 
based on number of unique peptides identified by MS combined 
with possible function as described in the literature. Additionally, 
we used gene expression data from different FP-RMSs to include 
only candidates with detectable expression levels (24). RH4 cells, 
whose gene expression signature represents most closely tumor 
biopsies (19, 33), were individually transfected with 3 unique siRNA 
sequences per target and transcript levels of 5 PAX3-FOXO1 target 
genes measured after 48 hours. These genes represent different 
Figure 2. Silencing of CHD4 affects specifically FP-RMS cell expansion. (A) Left panels: Western blots after knockdown of CHD4 or LSD1 in RH4 cell 
extracts 72 hours after induction with doxycycline (Dox.). Uninduced cells served as negative control, and actin or tubulin was used as loading control. 
Right panels: RH4 cell expansion was measured by WST assay at indicated time points after silencing of LSD1 or CHD4 by shRNA induction with doxycy-
cline. Data represent the mean ± SD of 3 independent experiments and were normalized to uninduced cells. PAX3-FOXO1 knockdown served as positive 
control. (B) Western blots and cell expansion after LSD1 or CHD4 knockdown in RD cells treated and analyzed as in A. (C) Western blots and cell prolifera-
tion after CHD4 knockdown in human myoblast or MRC5 cells treated and analyzed as in A.
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In conclusion, our 2-step screening approach identified sev-
eral chromatin remodeling proteins and complexes as potentially 
interacting directly or indirectly with PAX3-FOXO1, and points 
particularly to a specific role of the NuRD complex in regulating 
PAX3-FOXO1 target genes.
CHD4 is crucial for FP-RMS cell expansion in vitro. To fur-
ther study the biological role of the NuRD complex, we select-
ed CHD4 and LSD1 as members of the complex, which have 
not been studied in RMS and possess a potentially druggable 
enzymatic activity, and assessed whether their silencing would 
affect FP-RMS cell expansion. We established an inducible len-
tiviral expression system of stable cell lines expressing LSD1- or 
CHD4-specific shRNAs upon doxycycline treatment. Silenc-
ing was validated on mRNA and protein expression levels 72 
hours after induction of shRNA expression with 2 independent 
Remarkably, 5 of the 9 candidates represent components of 
chromatin remodeling complexes. CHD4, lysine-specific demeth-
ylase 1 (LSD1), and retinoblastoma binding protein 4 (RBBP4) 
are components of the nucleosome remodeling and deacetylase 
(NuRD) complex (38, 39), whereas REST corepressor 1 (RCOR1) 
and LSD1 can also be subunits of the CoREST complex (40, 41). 
In addition, the atypical tyrosine protein kinase BAZ1B is a bromo-
domain-containing protein found in different chromatin remod-
eling complexes (42). Importantly, our MS experiments identified 
several subunits of the NuRD complex, namely RBBP7 and his-
tone deacetylases 1 and 2 (HDAC1 and HDAC2), which can func-
tion in diverse chromatin-regulating complexes, as well as GATA 
zinc finger–containing protein 2A (GATAD2A) and metastasis-as-
sociated protein 2 (MTA2), which are more specific components of 
the NuRD complex (Figure 1D and Supplemental Table 1).
Figure 3. CHD4 knockdown decreases viability of FP-RMS cells. (A) Caspase-3/7 activity was measured in RH4 cells 72 hours after induction of CHD4 
silencing. Fold change of caspase-3/7 activity was normalized to uninduced cells. Shscr-treated cells served as negative and PAX3-FOXO1 knockdown 
cells as positive controls. Values represent the mean ± SD of 3 independent biological experiments. (B) Percentage of dead cells 96 hours after induction 
of CHD4 silencing. Cells were stained with NucView Caspase-3 Substrate and 7AAD and analyzed by flow cytometry. Values represent the mean ± SD of 4 
independent experiments (**P < 0.01; ***P < 0.001; uncorrected Fisher’s LSD). (C) Western blot of PARP and cleaved caspase-7 from extracts of RH4 cells 
72 hours after induction of CHD4 or PAX3-FOXO1 silencing and uninduced or shscr-treated control cells. (D) Representative phase-contrast images of RH4 
cells 72 hours after induction of silencing with doxycycline (Dox.) transduced with indicated constructs; original magnification, ×100. (E) Clonogenic assays 
of RH4 cells 12 days after induction of CHD4 silencing. Quantitation of number of colonies with black lines representing the mean values. Representative 
images of crystal violet–stained colonies are shown in the right panel.
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CHD4 but not LSD1 function is essential for expansion specif-
ically of translocation-driven FP-RMS cells, whereas it does 
not affect the growth of normal cells. Based on this result, we 
focused our studies on CHD4.
CHD4 promotes FP-RMS cell survival. Next, we asked wheth-
er reduction in cell numbers upon CHD4 depletion was due to 
loss of viability. To this end, we measured caspase-3/7 activity 
after induction of CHD4 silencing in 2 FP-RMS cell lines (RH4 
and RMS) over a period of 3 days (Figure 3A and Supplemental 
Figure 4A). Both CHD4-specific shRNAs increased caspase-3/7 
activity between 3- and 6-fold in RH4 cells and to a lesser extent 
in the FP-RMS cell line RMS relative to control. Increased 
caspase-3/7 activity after CHD4 knockdown was additionally 
confirmed in both cell lines by detection of active caspase-3/7 in 
individual cells by flow cytometry (Supplemental Figure 5). Fur-
thermore, we quantified the percentage of dead cells 96 hours 
after induction of CHD4 silencing by combined detection of 
sequences per target in 2 different FP-RMS cell lines (RH4 and 
RMS) (Figure 2A and Supplemental Figure 3, A and B). As posi-
tive control we used a shRNA sequence based on a recently pub-
lished PAX3-FOXO1 breakpoint-specific siRNA (siPF2) (ref. 18 
and Supplemental Figure 3, A and B). Cell expansion was mea-
sured over 4 days and normalized to control cells to exclude dox-
ycycline-mediated effects (43). We found that LSD1 depletion 
had only minor effects on RH4 expansion. In contrast, CHD4 
knockdown decreased cell numbers of both cell lines to less than 
30% of control, comparable to depletion of the fusion protein 
itself (Figure 2A and Supplemental Figure 3C). To assess spec-
ificity for FP-RMS, we performed the same experiments in the 
fusion-negative RMS (FN-RMS) cell line RD and did not observe 
any influence of CHD4 depletion on cell numbers (Figure 2B). 
Importantly, neither nontransformed human fibroblasts nor 
normal primary myoblast cells were affected by CHD4 deple-
tion (Figure 2C). Taken together these results demonstrate that 
Figure 4. CHD4 and PAX3-FOXO1 mainly interact via short DNA fragments. (A) Representative Western blots of endogenous PAX3-FOXO1 immunopre-
cipitates and lysates from 3 different FP-RMS cell lines. PAX3-FOXO1 was immunoprecipitated by the anti-FOXO1 antibody, and uncoated beads served as 
negative control (ctrl). (B) Representative Western blot of reciprocal CHD4 immunoprecipitate from RH4 cells. Endogenous CHD4 was immunoprecipitated 
by an anti-CHD4 antibody, and uncoated beads served as negative control (ctrl). (C) Western blot detection of indicated proteins in anti-FLAG immu-
noprecipitates and lysates from 293T cells transfected with FLAG-tagged P3F and Myc-tagged CHD4. Cell lysate was treated with indicated amounts of 
Benzonase during immunoprecipitation to digest the DNA, and DNA digestion was evaluated by agarose gel electrophoresis. (D) Western blot detection of 
indicated endogenous proteins in anti-FOXO1 immunoprecipitates from RH4 cells. Uncoated beads served as negative control (ctrl). Lysates were digested 
or not with 250 U/ml Benzonase, and DNA digestion was evaluated by agarose gel electrophoresis. (E) Western blot detection of indicated endogenous 
proteins in anti-FLAG immunoprecipitates from RH4 cells with stable knock-in of 3X FLAG at C-terminus of CHD4. Uncoated beads served as negative 
control (Ctrl). Lysates were digested or not with 250 U/ml Benzonase, and DNA digestion was evaluated by agarose gel electrophoresis.
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active caspase-3/7–positive and 7-aminoactinomycin D–posi-
tive (7-AAD–positive) cells (Figure 3B, Supplemental Figure 4B, 
and Supplemental Figure 6). This revealed that CHD4 depletion 
increased the percentage of dead cells from 22% to 48% in RH4 
(21% to 51% in the cell line RMS), a level similar to that seen 
with depletion of PAX3-FOXO1 (increase from 20% to 43% in 
RH4, 21% to 47% in the cell line RMS), whereas caspase-3/7 was 
active in the majority of dying cells. In addition, protein anal-
ysis of CHD4-depleted cells demonstrated increased levels of 
cleaved caspase-7 and cleaved PARP in FP-RMS cells (Figure 
3C and Supplemental Figure 4C), which were not detected in 
normal human fibroblasts or myoblasts (data not shown). These 
markers of apoptotic cell death also correlated with an increased 
number of floating cells, observed only in FP-RMS cells but not 
in normal human fibroblasts or myoblasts (Figure 3D, Supple-
mental Figure 4D, and Supplemental Figure 7). Finally, CHD4 
depletion impaired the ability of both FP-RMS cell lines to form 
colonies in clonogenic cell survival assays (Figure 3E and Sup-
plemental Figure 4E). In summary, the data demonstrate that 
the antiproliferative effect of CHD4 depletion in FP-RMS cells 
is due to increased cell death, suggesting that CHD4 expression 
is necessary to promote tumor cell survival.
CHD4 interacts with PAX3-FOXO1 via short DNA fragments. 
To get mechanistic insights into the interaction of PAX3-FOXO1 
with NuRD complex members, we first immunoprecipitated 
endogenous PAX3-FOXO1 from 3 different FP-RMS cell lines 
(RH4, RMS13, and RMS) with an anti-FOXO1 antibody and 
found specific coprecipitation of HDAC1, HDAC2, LSD1, and 
CHD4, but not with the negative control (Figure 4A). Impor-
tantly, these interactions persisted also after silencing of WT 
FOXO1 with a FOXO1-specific siRNA (Supplemental Figure 8), 
indicating that they do not depend on WT FOXO1, which can 
also be immunoprecipitated by the anti-FOXO1 antibody. In 
support, immunoprecipitation of CHD4 was able to pull down 
PAX3-FOXO1 (Figure 4B) in the reciprocal approach. To fur-
ther investigate whether interaction of CHD4 and PAX3-FOXO1 
occurs by direct protein-protein contact, we expressed tagged 
proteins together in HEK293T cells and immunoprecipitated 
FLAG-PAX3-FOXO1. Interestingly, under normal conditions 
we observed efficient pull-down of CHD4, whereas digestion of 
DNA with increasing amounts of Benzonase gradually decreased 
coprecipitated CHD4 (Figure 4C). Similar observations were 
made with the endogenous proteins CHD4 and HDAC2 in 
FP-RMS cells (Figure 4D), whereas the previously characterized 
Figure 5. CHD4 coregulates PAX3-FOXO1–activated target genes. (A) Heat map of unsupervised hierarchical clustering of PAX3-FOXO1 (siP3F) and CHD4 
(shCHD4#1) knockdown profiles using the gene set directly regulated by PAX3-FOXO1 (638 genes differently expressed between siP3F-treated and sis-
cr-treated [24 and 48 hours after transfection] or untreated RH4 cells; fold change >1.5; P < 0.05). Each column represents a different time point for shR-
NA-treated cells in singlicate and for siRNA-treated cells in duplicate (24, 48, 72 hours from left to right for each condition). Numbers of coexpressed genes 
between these transcriptional profiles are displayed. (B) Schematic representation of genes directly regulated by PAX3-FOXO1 and CHD4 (fold change 
>1.5; P < 0.05 between siP3F-treated and siscr-treated [24 and 48 hours after transfection] or untreated RH4 cells and between shCHD4-expressing and 
shscr-expressing RH4 cells [24 and 48 hours after doxycycline induction] or uninduced control cells). The coregulated subset as read out from the heatmap 
clustering in A is displayed. (C) GSEA using CHD4-regulated genes in RH4 cells as the rank-ordered data set and targets directly upregulated by PAX3-
FOXO1 as the gene set (259 genes differently expressed between siP3F-treated and siscr-treated or untreated RH4 cells 24 and 48 hours after transfection; 
fold change >1.7; P < 0.05). Normalized enrichment score (NES) and P value are shown.
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interaction between the NuRD components CHD4 and HDAC2 
was unaffected by Benzonase treatment (Figure 4E). The data 
suggest that the interaction between PAX3-FOXO1 and CHD4 is 
mainly dependent on short DNA fragments to which the 2 factors 
bind in close proximity.
CHD4 depletion affects PAX3-FOXO1–activated target genes. 
Given the importance of CHD4 for FP-RMS cell survival and the 
observation that none of the initial candidates, including CHD4, 
affected all 5 PAX3-FOXO1 target genes in our primary siRNA 
screen, we sought to explore the global effects of CHD4 depletion 
on the PAX3-FOXO1 transcriptome. Therefore, we performed gene 
expression profiling on RNA isolated from RH4 cells 24, 48, and 72 
hours after CHD4 depletion. We analyzed gene expression chang-
es in regard to a recently published PAX3-FOXO1 gene expression 
signature (19), since we hypothesized that predominantly direct 
PAX3-FOXO1 target genes might be affected, focusing on genes 
showing at least 1.5-fold up- or downregulation at the early time 
points (24 and 48 hours) after PAX3-FOXO1 silencing. Hierarchi-
cal clustering of this target gene signature revealed that the CHD4 
gene expression signature clusters together with the PAX3-FOXO1 
signature and not with the control-treated cells (Figure 5A). Com-
parison of both signatures affirms that CHD4 depletion affects 
only a subset of the PAX3-FOXO1 target gene signature and mainly 
overlaps in genes that are normally upregulated by PAX3-FOXO1. 
Indeed, the overlapping coregulated subset is composed of 257 
genes of a total of 638 genes affected by PAX3-FOXO1 depletion 
(Figure 5B). This further supports a model in which PAX3-FOXO1 
drives expression of target gene subsets in concert with different 
(epigenetic) mechanisms and indicates that CHD4 is important 
for a subset of PAX3-FOXO1–mediated transcriptionally activated 
target genes. Gene set enrichment analysis (GSEA) confirmed this 
conclusion by unraveling a significant correlation of CHD4 expres-
sion signature only with genes directly activated by PAX3-FOXO1, 
not with genes inhibited by PAX3-FOXO1 nor with genes showing 
changes only at later time points (Figure 5C and Supplemental Fig-
ure 9). The leading-edge subset of this coactivated gene set con-
sists of 47 genes (Supplemental Table 3). Besides the PAX3-FOXO1 
target genes already examined in our primary siRNA screen, we 
found that CHD4 inhibition had a strong impact on expression of 
anaplastic lymphoma kinase (ALK) and cannabinoid receptor 1 
(CB1), both PAX3-FOXO1 target genes that have been implicated 
in the tumor biology of FP-RMS (44, 45). In particular, expression 
of CB1 has been correlated with increased invasiveness of FP-RMS 
tumors (45). Therefore, our data suggest that CHD4 expression is 
required to coregulate a subset of PAX3-FOXO1 target genes that 
are necessary and sufficient to promote FP-RMS survival.
Figure 6. CHD4 colocalizes to PAX3-FOXO1 binding sites. (A) Expression levels of indicated PAX3-FOXO1 target genes were quantified by quantitative real-
time PCR after CHD4 knockdown in 2 FP-RMS cell lines. Bar charts are geometric means from 4 independent experiments with 95% CI (P < 0.05; Dunnett’s 
multiple comparison test). Fold change of mRNA expression was normalized to uninduced cells with PAX3-FOXO1 knockdown serving as positive control. 
(B) ChIP was performed in RH4 cells using PAX3/7 and CHD4 antibodies on known PAX3-FOXO1 DNA binding sites in target genes, and only beads without 
antibody served as negative control (Beads G). Bar charts indicate the mean ± SEM of at least 3 independent biological replicates. Abundance of precip-
itated DNA fragments was measured by quantitative PCR, and results are presented as the percentage of input. The GAPDH promoter region served as 
negative control. (C) Effect on PAX3-FOXO1 binding upon CHD4 silencing (48 hours of incubation with doxycycline) was determined by ChIP as described in 
B and is shown as fold enrichment over PAX3-FOXO1 ChIP signal in the presence of CHD4 (no doxycycline control).
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PAX3-FOXO1 in the GAPDH promoter region. This indicates that 
fusion protein binding is modulated by the presence of CHD4. 
Further, CHD4 and PAX3-FOXO1 co-occupy the same sites in 
PAX3-FOXO1 target genes, suggesting coregulation of target gene 
expression by both CHD4 and the fusion protein, at least for a sub-
set of target genes.
CHD4 inhibition causes tumor regression in mouse xenografts. 
Based on the observation that CHD4 inhibition reduces FP-RMS 
cell proliferation and survival in vitro, we aimed to assess wheth-
er CHD4 inhibition affects FP-RMS tumor growth in vivo using 
xenograft mouse models. Immunocompromised NOD/SCID 
mice were engrafted s.c. with RH4 cells, containing stably inte-
grated tet-inducible shCHD4#1 or shscr expression vectors. Mice 
with established tumors of varying size (170–400 mm3) were treat-
ed i.p. with either vehicle or doxycycline solution at a dose of 53.3 
mg/kg on 2 consecutive days. Additionally, starting from the first 
day of treatment, mice were fed with doxycycline-supplemented 
or control food. Strikingly, we observed regression of tumor size 
upon CHD4 depletion, even in tumors with a large starting volume 
of 380 mm3 (Figure 7A). Both immunohistochemical analyses of 
tumors and determination of mRNA levels showed strong reduc-
tion of CHD4 expression in all depleted tumors (Figure 7, B and 
C). The CHD4-depleted tumors also displayed high expression of 
the apoptotic marker cleaved caspase-3, similar to our previous in 
vitro findings (Figure 7C).
CHD4 and PAX3-FOXO1 colocalize at PAX3-FOXO1 target 
genes. To examine whether the fusion protein indeed binds to 
target genes together with CHD4, we first validated selected 
PAX3-FOXO1 target genes with a known role in FP-RMS pathol-
ogy, in 2 different FP-RMS cell lines (RH4 and RMS) 72 hours 
after induction of CHD4 depletion (Figure 6A) (22, 36, 44–46). 
We observed similar modulation of target gene levels by deplet-
ing CHD4 or PAX3-FOXO1. Next, we used ChIP on previously 
published PAX3-FOXO1 binding sites at selected target genes 
(34). It is of note that the sites of PAX3-FOXO1 binding are most-
ly enhancer regions (e.g., NMYC, FGFR4, PIPOX) and only rarely 
promoter regions (e.g., CDH3) promoter region). We analyzed the 
occupancy of CHD4 around PAX3-FOXO1 binding sites together 
with the GAPDH promoter region as negative control. We were 
able to measure ChIP PCR values that were low, but significantly 
above background. First, we confirmed PAX3-FOXO1 binding to 
all selected target genes, but not to the GAPDH promoter (Figure 
6B). For precipitation of PAX3-FOXO1 we used a PAX3/7 antibody 
that has been recently used in ChIP analysis, since expression of 
WT PAX3 is 1,000-fold lower and, as such, negligible in RH4 cells 
(19, 36). Next, we observed that CHD4 also is specifically bound to 
the same fragments of all target genes. Interestingly, prior deple-
tion of CHD4 using the stable shRNA cells caused a clear reduc-
tion of PAX3-FOXO1 binding on all target genes (Figure 6C), 
whereas addition of doxycycline had no effect on the binding of 
Figure 7. CHD4 inhibition causes 
tumor regression in mouse xeno-
grafts. In vivo treatment of NOD/
SCID mice engrafted with RH4 
cells containing stably integrated 
doxycycline-inducible shCHD4#1 or 
shscr expression vectors. Mice bear-
ing palpable tumors were treated 
i.p. for 2 days with either vehicle 
control or doxycycline at a dose of 
53.3 mg/kg. Additionally, they were 
fed with doxycycline-supplemented 
or control food. (A) Absolute tumor 
volumes of FP-RMS xenografts as 
measured by caliper. Vehicle-treat-
ed control groups consisted of 
6 mice, and doxycycline-treated 
groups consisted of 5 (shscr) and 
7 (shCHD4#1) mice. (B) CHD4 
mRNA expression level in indicated 
tumors of doxycycline- or vehicle 
control–treated mice analyzed by 
quantitative real-time PCR. Tumors 
were isolated at the end of treat-
ment (black; tumor set shown in A) 
or after 4 days of treatment (red; 
separate tumor set). Fold changes 
of mRNA expression are normal-
ized to the mean of CHD4 expres-
sion in shscr vehicle control–treated 
tumors. (C) Immunohistochemical 
staining of tumors with indicated 
antibodies. Tumors were isolated 4 
days after the start of treatment.
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Additionally, experimental evidence supports a role for CHD4 
specifically in FP-RMS cell survival, which is a core function of 
the fusion protein. Interestingly, when comparing gene signa-
tures after CHD4 depletion with the transcriptional profile regu-
lated directly by PAX3-FOXO1 (33, 46, 52), we identified around 
40% of target genes as being coregulated, suggesting that genes 
responsible for cell survival might be part of this new limited sub-
set signature. The exact contribution of the individual genes to 
cell survival remains to be determined, as it is not to be expected 
that they all act as drivers. However, it is important to emphasize 
that few of the well-characterized PAX3-FOXO1 target genes 
were identified in our gene set enrichment analysis (Supplemen-
tal Table 3). These included ALK, CDH3, and TFAP2B, of which 
only TFAP2B has been implicated in cell survival previously (19). 
Attempts to correlate expression of these genes individually with 
patient survival data using published expression profiling data 
sets have failed so far (data not shown). Nevertheless, our data 
suggest that other epigenetic regulators such as members of the 
SWI/SNF complex that were also identified in the MS analysis 
might be involved in modulating expression of the remaining sub-
set of PAX3-FOXO1 target genes.
Mechanistically, it is, at this stage, not possible to deter-
mine the exact composition of the complex at the different loca-
tions. Although we first confirmed individual interactions for 
CHD4, LSD1, HDAC1, and HDAC2 under standard conditions, it 
remained unclear whether they all bind to the fusion protein via 
direct protein-protein interaction. Hence, we carried out immuno-
precipitation experiments under conditions where potential resid-
ual DNA is digested. Indeed, this dramatically reduced the amount 
of coprecipitated PAX3-FOXO1, allowing us to conclude that they 
bind nearby to small DNA fragments, and unlikely via direct pro-
tein-protein interactions. Whether this also applies to the other 
chromatin complexes identified remains to be demonstrated.
Given the strong impact of CHD4 on PAX3-FOXO1 target gene 
activation, it might even be plausible that CHD4 acts in a NuRD 
complex–independent manner. This hypothesis is supported by the 
observation that depletion of several other NuRD subunits by si RNA 
(HDAC1, HDAC2, RBBP7, GATAD2A, MTA2) had only minor effects 
on target gene expression (data not shown). Interestingly, it has been 
suggested previously that CHD4 can function outside of the repres-
sive NuRD complex to activate transcription (53–56). Such onco-
genic properties of CHD4 in FP-RMS are in agreement with find-
ings in other tumors such as glioblastoma and colorectal cancer (57, 
58). On the other hand, CHD4 is frequently mutated in endome-
trial cancers and colorectal or gastric cancers with microsatellite 
instability (59, 60), suggesting that its oncogenic or tumor-suppres-
sive functions depend on the cellular context.
Finally, we demonstrate that CHD4 depletion induces 
regression of FP-RMS tumors in xenograft mouse models, but, 
importantly, had no effect on FN-RMS tumors. Altogether, this 
validates CHD4 inhibition as a potential targeted strategy to 
inhibit an essential coregulator of PAX3-FOXO1 activity. Never-
theless, at present we cannot exclude the possibility that addi-
tional mechanisms besides modulation of PAX3-FOXO1 target 
genes contribute to the growth-suppressive phenotype, given 
that CHD4 has been also implicated in DNA damage response 
and G1/S cell cycle progression (61–64).
Interestingly, tumors that recurred after 21 days of treatment 
(Figure 7A) showed recovery of CHD4 mRNA expression levels to 
nearly 100% and comparable to those in untreated controls (Fig-
ure 7B). Hence, it is likely that cells with insufficient CHD4 deple-
tion did finally outgrow.
To investigate whether CHD4 depletion also affects FN-RMS 
tumors, we measured RD cell tumor growth in vivo under doxy-
cycline addition. Interestingly, we observed only a slight growth 
retardation by doxycycline per se, but no tumor regression upon 
CHD4 depletion (Supplemental Figure 10). This was not due to 
generally lower CHD4 expression levels in FN-RMS, as both sub-
types have a similar expression pattern assessed on a human RMS 
tumor tissue microarray (Supplemental Figure 11). Taken togeth-
er, these data clearly demonstrate that the epigenetic regulator 
CHD4 plays an important role in FP-RMS tumor progression and 
survival, and identify CHD4 as novel potential treatment target 
for this pediatric sarcoma.
Discussion
Although PAX3-FOXO1 expression on its own might not be suf-
ficient for RMS development, it is the dominant oncogenic driv-
er and sole relevant genetic abnormality in a large fraction of 
tumors (27). Since direct pharmacological inhibition of transcrip-
tion factors is still elusive, blocking the activity of PAX3-FOXO1 
accessory proteins may therefore represent a viable alternative 
therapeutic strategy.
In the current study, we provide the first comprehensive anal-
ysis of the interactome of PAX3-FOXO1 directly purified from 
FP-RMS cells. A biochemical proteomic approach was used in a 
first step and then followed by a functional siRNA screen evalu-
ating expression levels of selected PAX3-FOXO1 target genes as 
readout (47). Interestingly, the final list of 9 putative accessory 
proteins revealed 6 protein subunits of chromatin remodeling 
complexes, suggesting that the fusion protein influences diverse 
epigenetic mechanisms. This is remarkably similar to the function 
of other fusion proteins in pediatric sarcomas, such as the Ewing 
sarcoma fusion EWS-FLI1, which is known to use divergent chro-
matin remodeling mechanisms to orchestrate target gene expres-
sion (48), and the SSX-SS18 fusion, which disrupts the BAF com-
plex in synovial sarcoma (49).
Most of the chromatin remodelers identified are subunits of 
the NuRD complex, namely CHD4, LSD1, and RBBP4. Further, 
we identified additional components of this complex in our initial 
proteomic screen, namely RBBP7, MTA2, GATAD2A, GATAD2B, 
HDAC1, and HDAC2, suggesting that PAX3-FOXO1 might 
indeed interact with the NuRD complex. It has been demon-
strated that this remodeling complex is also required for EWS-
FLI1–mediated transcriptional repression (50), and inhibition of 
LSD1 using small-molecule inhibitors impaired Ewing sarcoma 
cell viability (51). Hence, we next thought to identify components 
of the complex that might be necessary for PAX3-FOXO1 func-
tion. Whereas we observed only minor effects on proliferation of 
FP-RMS cells upon genetic depletion of LSD1, CHD4 depletion 
decreased FP-RMS cell proliferation and induced cell death to an 
extent similar to that seen with inhibition of PAX3-FOXO1 itself, 
without influencing proliferation of normal human fibroblasts 
and myoblasts, thereby opening a potential therapeutic window. 
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Coomassie (InstantBlue, Expedeon) or by silver staining (Bio-Rad). 
Coomassie-stained gels were cut into slices and prepared for MS as 
described in Supplemental Methods.
SiRNA screen. A siRNA library (Supplemental Table 2) targeting 
60 candidate interactors identified in the primary MS analysis (Ambi-
on Silencer Select Custom siRNA Library, Thermo Fisher Scientific, 
LuBioScience) was used with 3 unique siRNAs per target. Silencer 
Select Negative Control siRNA (4390846) served as nontargeting neg-
ative control and PAX3-FOXO1 breakpoint-specific siRNA (18) as pos-
itive control (both Ambion, Thermo Fisher Scientific, LuBioScience). 
For silencing of gene expression, 40,000 RH4 cells were reverse 
transfected with 4.6 nM siRNA in 24-well format using Interferin 
transfection reagent according to the manufacturer’s protocol (Poly-
plus Transfection SA). RNA was harvested 48 hours after transfection 
and used for quantitative real-time PCR.
Western blotting. For Western blots, total protein extracts were 
obtained from cells lysed with RIPA buffer containing 50 mM Tris-
Cl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 1 mM 
EGTA, 0.1% SDS, 50 mM NaF, 10 mM sodium β-glycerolphosphate, 
5 mM sodium pyrophosphate, and 1 mM sodium orthovanadate and 
supplemented with Complete Mini Protease Inhibitor cocktail (Roche 
Diagnostics). Protein concentration was measured with Pierce BCA 
protein Assay Kit (Thermo Fisher Scientific, LuBioScience). Proteins 
were separated using 4%–12% Bis-Tris SDS-PAGE gels (Thermo Fish-
er Scientific, LuBioScience) and transferred to nitrocellulose mem-
branes (Protran, Schleicher & Schuell). After blocking with 5% milk 
powder in TBS/0.1% Tween, membranes were incubated with prima-
ry antibodies overnight at 4°C. After washing in TBS/0.1% Tween, 
membranes were incubated with HRP-linked IgG antibodies. Proteins 
were detected by chemiluminescence using ECL detection reagent or 
SuperSignal West Femto Maximum Sensitivity Substrate (both Ther-
mo Fisher Scientific) after washing in TBS/0.1% Tween.
Coimmunoprecipitation. Cells were lysed in 1 ml lysis buffer per 
10-cm dish and incubated for 1 hour at 4°C with antibody directed 
against the protein of interest coupled to Dynabeads Protein G (Novex 
by Thermo Fisher Scientific, LuBioScience) or empty beads as negative 
control. Antibodies used were directed against FOXO1 (C-20) (sc-9808, 
Santa Cruz Biotechnology), FLAG-tag (Sigma-Aldrich), or CHD4 (A301-
082A, polyclonal, rabbit, Bethyl Laboratories). Benzonase (Novagen) 
was added to the lysate during this incubation when indicated. After 
washing 4 times with lysis buffer, proteins were eluted with 200 μg/ml 
3X FLAG peptide or with 1X NuPAGE LDS sample buffer (Thermo Fish-
er Scientific, LuBioScience) at 70°C and analyzed by Western blotting.
Detection of DNA fragmentation by agarose gel electrophoresis. 
Twelve microliters of immunoprecipitation supernatants were run on 
1% agarose gels, and resolved DNA was stained with GelRed.
Cell viability assay. For cell viability assays, aRMS, MRC5, and human 
myoblast cells were cultured in 96-well format. At various time points 
after induction of shRNA expression, cell viability was measured by 
WST-1 assay (Roche Diagnostics) and normalized to uninduced control 
cells. At least 3 biological replicates were performed for each experiment.
Clonogenic assay. For clonogenic assays, 24 hours after induction 
of shRNA expression, 2,000 (RH4) or 5,500 (RMS) cells were seed-
ed on 6-well plates. Doxycycline-containing complete medium was 
changed every second to third day. After 12 days of incubation, cells 
were fixed with 4% formaldehyde solution and stained with 0.05% 
crystal violet, and colonies were counted.
To our knowledge our experiments identify the first chro-
matin remodeler contributing to PAX3-FOXO1 transcriptional 
regulation. Since CHD4 contains ATPase activity, it might be 
an amenable target to inhibit PAX3-FOXO1 activity indirect-
ly. However, the ATPase domain is highly conserved within the 
SNF2 family of helicase-like ATPases and therefore might be dif-
ficult to target specifically (65). Alternatively, CHD4 contains 2 
plant homeodomain (PHD) fingers and tandem chromodomains 
required for ATP-dependent chromatin remodeling, which could 
provide targets for drug design similar to the striking success in 
targeting BET bromodomains (66–70). Given the recognized role 
of the NuRD complex in other sarcomas, such as Ewing sarcoma, 
inhibition of CHD4 might be of therapeutic benefit for a broader 
range of tumors as well.
Methods
Cell lines. The aRMS cell lines RH4 (provided by Peter Houghton, Gree-
hey Children’s Cancer Research Institute, San Antonio, Texas, USA), 
RMS13 (provided by Roland Kappler, Ludwig–Maximilian University, 
Munich, Germany), and RMS (provided by Janet Shipley, The Institute 
of Cancer Research, London, United Kingdom), and MRC5 normal lung 
fibroblast cells, the eRMS cell line RD, and the HEK293T cell line for 
the production of lentiviral particles (all 3 purchased from the ATCC, 
LGC Promochem, Molsheim, France), were routinely maintained in 
DMEM (Sigma-Aldrich) supplemented with 10% FBS (Thermo Fisher 
Scientific, LuBioScience), 2 mM l-glutamine, and 100 U/ml penicillin/
streptomycin. The human myoblast cell line KM155C25Dist (provided 
by Vincent Mouly, Institut de Myologie, Paris, France) was maintained 
in Skeletal Muscle Cell Growth Medium Supplement Mix (PromoCell), 
15% FBS, 2 mM l-glutamine, and 100 U/ml penicillin/streptomycin. All 
cells were cultured in 5% CO2 at 37°C. All RMS and the MRC5 cell line 
were authenticated by short tandem repeat analysis (STR) profiling in 
2014/2015 and positively matched (71). As the human myoblast cell line 
has not yet been characterized by STR profiling, negative matching with 
all available cell lines in the database was used for verification.
Purification of FLAG-PAX3-FOXO1. RH4 and RMS13 cells were 
transfected with pCMV-N/C-FLAG-PAX3-FOXO1 or pBABE puro 
N-FLAG-PAX3-FOXO1 in 15-cm plates and lysed 48 hours after 
transfection with a mild lysis buffer containing 50 mM Tris-Cl (pH 
7.5), 125 mM NaCl, 10% glycerol, 0.3% NP-40, 1.5 mM MgCl2, 25 
mM NaF, 10 mM sodium β-glycerolphosphate, 5 mM sodium pyro-
phosphate, and 2 mM sodium orthovanadate and supplemented 
with Complete Mini Protease Inhibitor cocktail (Roche Diagnos-
tics). FLAG-PAX3-FOXO1 was immunoprecipitated using 100 μl 
Dynabeads Protein G (10004D, 30 mg/ml; Thermo Fisher Scien-
tific, LuBioScience) per plate coupled to 8 μg monoclonal ANTI-
FLAG M2 antibody (F1804, Sigma-Aldrich). After incubation for 10 
minutes at 4°C, beads were washed 3 times with lysis buffer, and 
bound FLAG-PAX3-FOXO1 was eluted with 40 μl elution buffer 
containing 200 μg/ml 3X FLAG peptide (F4799, Sigma-Aldrich), 
50 mM Tris-Cl (pH 7.4), and 150 mM NaCl. For each MS experi-
ment the eluates of 12 plates (RMS13) or 24 plates (RH4) were 
combined and concentrated using the Uppa-Protein Concentrate 
kit (786-120, GBiosciences, VWR International AG), according 
to the manufacturer’s instructions. After addition of 4X NuPAGE 
LDS buffer (Thermo Fisher Scientific, LuBioScience), proteins 
were separated by gel electrophoresis and stained with colloidal 
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Mayers HTX (catalog 01820, Histolab; 10 minutes) and Eosin aque-
ous (catalog 2C-140, Waldeck; 0.5%, 5 minutes). After staining, slides 
were dehydrated and mounted with Pertex. Immunohistochemistry 
was performed on Leica BondMax instruments using Refine HRP Kits 
(Leica DS9800) including all buffer solutions from Leica Microsys-
tems, processed according to the manufacturer’s guidelines. Antigen 
retrieval for Cleaved Caspase-3 (9661, Cell Signaling Technology; 
dilution 1:500) was performed with Epitope Retrieval buffer (Lei-
ca AR9640) at 100°C for 60 minutes. Slides for CHD4 ChIP Grade 
(ab70469, Abcam Ltd.; dilution 1:500) were pretreated with Epitope 
Retrieval buffer (Leica AR9961) at 100°C for 30 minutes.
Statistics. All statistical analysis (with the exception of microarray 
and GSEA analysis) was performed with GraphPad Prism software 
version 6. One-way ANOVA tests with Dunnett’s method for multi-
ple comparisons with a 95% CI were used to analyze data involving 
2 or more test groups and a control group. All statistical analysis of 
quantitative real-time PCR data was performed on the level of the 
ΔΔCt values. One-way ANOVA tests with uncorrected Fisher’s LSD 
method with a 95% CI were used for pairwise comparisons of several 
test groups. P values less than 0.05 were considered statistically sig-
nificant. Data are presented as the geometric mean with 95% CI or as 
mean ± SD unless otherwise noted.
Study approval. All animal experiments were approved by the 
Swiss veterinary authorities and were performed according to the ani-
mal license 208/2012.
Information regarding plasmids, transfection methods, lentiviral 
transduction, immunohistochemistry, tissue array, antibodies, quan-
titative real-time PCR, MS, and database searching including protein 
identification can be found in Supplemental Methods.
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Cell death and caspase-3/7 activity assays. Cells were seeded in 
white 384-well plates with clear bottom (Greiner Bio-One). Caspase 
activity was determined by Caspase-Glo 3/7 Assay (Promega) at 
indicated time points according to the manufacturer’s instruc-
tions. Luminescence was measured using the multidetection 
microplate reader Synergy HT (Bio-Tek Instruments). For analysis 
of caspase-3/7 activity in individual cells, they were stained with 
NucView 405 Caspase-3 Substrate (Biotium, Chemie Brunschwig 
AG) and analyzed by flow cytometry. For quantification of dead cells, 
NucView 405 Caspase-3 Substrate was combined with 7-AAD stain-
ing solution (BD Biosciences).
Microarray analysis. For gene expression profiling, RNA of RH4 cells 
was isolated from untreated cells, and 24, 48, and 72 hours after induction 
of CHD4 silencing (shCHD4#1) using RNeasy Kit (Qiagen), with DNase 
digestion step, according to the manufacturer’s instructions. Affymetrix 
GeneChip expression analysis was performed using HGU133plus2 arrays 
(Affymetrix Inc.). cRNA target synthesis and experimental procedures 
for GeneChip hybridization and scanning were carried out according to 
the “GeneChip eukaryotic small sample target labeling technical note” 
(Affymetrix, ATLAS Biolabs). Expression data were combined with pre-
vious published PAX3-FOXO1 gene expression data (19). The data sets 
are available for unrestricted download from Gene Expression Omnibus 
under the accession numbers GSE73480 and GSE73483. Batch normal-
ization and unsupervised hierarchical clustering were performed using 
dChip software. Gene set enrichment analysis (GSEA) was performed 
using GSEA version 2 software (Broad Institute) (72).
ChIP. ChIP has been recently described (73). For each ChIP assay, 
30 μg of cross-linked and sonicated chromatin was incubated with 
4 μg of antibody. Purified ChIP DNA was measured for enrichment 
of PAX3-FOXO1 binding sites by quantitative real-time PCR using 
TaqMan assays. Primer set and TaqMan probes are described in Sup-
plemental Table 5.
Xenograft studies. For the generation of xenograft, 5 × 106 RH4 
cells, containing stably integrated tetracycline-inducible shCHD4#1 or 
shscr expression construct, were transplanted s.c. into 8- to 12-week-
old female NOD/SCID mice (Charles River). After first detection of 
palpable tumors, mice were treated i.p. with either sterile PBS or doxy-
cycline solution at 53.3 mg/kg on 2 consecutive days. Doxycycline was 
diluted in PBS at a concentration of 8 mg/ml. Additionally, starting 
from the first day of treatment, mice were fed with doxycycline-supple-
mented food (625 mg doxycycline/kg) or control food. Tumor size was 
determined every day by measurement of 2 diameters (d1, d2) in right 
angles using a digital caliper. Total tumor volumes were calculated by 
the formula V = (4/3)πr3; r = (d1 + d2)/4. Control mice were euthanized 
when reaching a tumor volume of 1,700 mm3.
Immunohistochemistry. Tumor tissue was cut into slices of 4–5 
mm and fixed in 4% vol/vol neutralized formalin for 24 hours at room 
temperature, processed in a Pathos Delta (Milestone) overnight with 
ethanol and isopropanol for dehydration and paraffin embedding. 
Samples were molded in paraffin blocks and sectioned on a Leica 
rotary microtome into 3-μm-thick slices. After drying at 64°C for 30 
minutes, slides were stained with H&E in a Leica Autostainer using 
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 ABSTRAcT  Alveolar rhabdomyosarcoma is a life-threatening myogenic cancer of children and ado-
lescent young adults, driven primarily by the chimeric transcription factor PAX3–FOXO1. 
The mechanisms by which PAX3–FOXO1 dysregulates chromatin are unknown. We fi nd PAX3–FOXO1 repro-
grams the  cis -regulatory landscape by inducing  de novo super enhancers. PAX3–FOXO1 uses super  enhancers 
to set up autoregulatory loops in collaboration with the master transcription factors MYOG, MYOD, and 
MYCN. This myogenic super enhancer circuitry is consistent across cell lines and primary tumors. Cells 
harboring the fusion gene are selectively sensitive to small-molecule inhibition of protein targets induced 
by, or bound to, PAX3–FOXO1-occupied super enhancers. Furthermore, PAX3–FOXO1 recruits and requires 
the BET bromodomain protein BRD4 to function at super enhancers, resulting in a complete dependence on 
BRD4 and a signifi cant susceptibility to BRD inhibition. These results yield insights into the epigenetic func-
tions of PAX3–FOXO1 and reveal a specifi c vulnerability that can be exploited for precision therapy. 
 SIGNIFICANCE: PAX3–FOXO1 drives pediatric fusion-positive rhabdomyosarcoma, and its chromatin-
level functions are critical to understanding its oncogenic activity. We fi nd that PAX3–FOXO1 estab-
lishes a myoblastic super enhancer landscape and creates a profound subtype-unique dependence on 
BET bromodomains, the inhibition of which ablates PAX3–FOXO1 function, providing a mechanistic 
rationale for exploring BET inhibitors for patients bearing PAX-fusion rhabdomyosarcoma.  Cancer 
Discov; 7(8); 884–99. ©2017 AACR. 
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 inTRoDUcTion 
 Transcription factors (TF) recognize specifi c noncoding 
sequences across the genome, recruiting epigenetic machin-
ery to regulate key cell identity genes, and are sequentially 
exchanged during development and differentiation ( 1 ). Onco-
genic fusion genes involving TFs are predicted to profoundly 
alter normal developmental progression and cell identity in 
many malignancies ( 2 ). 
 Rhabdomyosarcoma (RMS) is a cancer of childhood and 
adolescence characterized by its inability to exit the pro-
liferative myoblast-like state. Genomic and transcriptomic 
characterization implicates either chromosomal transloca-
tion resulting in the oncogenic fusion transcription factor 
PAX3/7–FOXO1 (fusion-positive alveolar subtype, FP-RMS) 
or mutations in receptor tyrosine kinase/RAS pathways 
(fusion-negative embryonal subtype, FN-RMS; refs.  3, 4 ). 
FP-RMS is characterized by a strikingly low somatic muta-
tional burden indicating that the fusion gene is the primary 
oncogenic driver. Many other transcription/chromatin factor 
fusion gene–driven sarcomas have similar low mutational 
burdens ( 5–7 ). Importantly, patients with RMS who harbor a 
PAX3 fusion are more likely to be metastatic at presentation, 
relapse despite aggressive therapy, and have very poor survival 
( 8 ), underscoring the critical need to develop therapeutic 
strategies for this subset of patients. 
 Early (PAX family TFs) and late (MYOG) regulators of 
normal myogenesis are temporally mutually exclusive in nor-
mal muscle development, yet FP-RMS tumors concurrently 
express high levels of PAX3–FOXO1 and the myogenic MYOD, 
MYOG, as well as MYCN ( 9, 10 ). Although the transcriptional 
perturbation caused by the PAX fusions has been previously 
reported ( 11, 12 ), the chromatin mechanisms by which PAX 
fusions dysregulate the myogenic program are unknown. In 
this work, we interrogated the underlying epigenetics that 
enforce the myogenic and oncogenic transcriptional program 
of cell lines and clinical tumor samples with PAX3 fusions. In 
charting the genome-wide landscape of histone modifi cations, 
we discovered that PAX3–FOXO1 drives expression of its target 
oncogenes by creating large deposits of active histone marks 
exclusively at enhancers, collaboratively with myogenic TFs, 
and by recruiting chromatin reader bromodomain-containing 
protein 4 (BRD4), which function at looped enhancer–pro-
moter pairs within topological domain boundaries. Integrat-
ing epigenetic and mechanistic drug screening data exposed 
multiple biological nodes of chemical vulnerability, including 
BET bromodomains. The BRD4 inhibitor JQ1 has recently 
shown effi cacy in RMS ( 13 ), but no mechanistic connection 
has been shown between BRD4 and PAX3–FOXO1. Here, we 
report that BRD4 inhibition disrupts a hitherto undiscovered 
PAX3–FOXO1 interaction with BRD4, causes a rapid degrada-
tion of the fusion gene, and ablates its transcriptional output, 
thus revealing a subtype-selective therapeutic vulnerability to 
BRD4 inhibition. 
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RESULTS
PAX3–FOXO1 Establishes Active Chromatin at 
Distal Enhancers
The hallmark reciprocal translocation of chromosomes 
2 and 13 (14) has coding potential for two fusion pro-
teins (Supplementary Fig. S1A), but the only expressed 
allele has the 5′ end of PAX3 (DNA binding domain) 
and the 3′ transactivation domain of FOXO1 (Supple-
mentary Fig. S1B). To gain insight into the epigenetic 
consequences of PAX3–FOXO1, we mapped the landscape 
of active and repressive histone marks by sequencing DNA 
enriched by chromatin immunoprecipitation (ChIP-seq) 
from a patient-derived fusion-positive FP-RMS cell line, 
RH4. Genome-wide, PAX3–FOXO1 resided predominantly 
(99%) in sites more than 2.5 kb distal from the nearest 
transcriptional start site (15), all of which harbored active 
Figure 1.  Chromatin state mapping pinpoints PAX3–FOXO1 (P3F) in active enhancers. A, PAX3–FOXO1 peak distribution and heat maps of PAX3–
FOXO1, H3K27ac, H3K4me1, and H3K4me2 at distal regulatory elements in PAX3–FOXO1-bearing cell line (RH4). The scatter plot is accompanied by a 
histogram showing the amounts of PAX3–FOXO1 in intronic, exonic, intergenic, or promoter-proximal sites. TSS, transcription start site. Rows are cen-
tered around PAX3–FOXO1 peaks and extended 4 kb in each direction, sorted by PAX3–FOXO1 signal strength. B, PAX3–FOXO1, H3K27ac, H3K27me3, 
and H3K4me3 signal at PAX3–FOXO1 peaks (left), genes nearest to PAX3–FOXO1 peaks (center), and Polycomb-repressed chromatin (right). Mean dis-
tance of PAX3–FOXO1 to its nearest genes (18 kb) is indicated. C, Chromatin states in FP-RMS cells (left) and abundance of PAX3–FOXO1 peaks per Gb 
of each state (right). States were discovered de novo using ChIP-seq data for all histone marks (plus, CTCF and RAD21) with the hidden Markov modeling 
algorithm chromHMM, which bins the genome into states by recurring patterns. Frequency corresponds to the probability of each mark being present in 
a given state. D, High-confidence PAX3–FOXO1 sites bound to enhancers recurrent (n = 1,107) in FP-RMS cell lines and tumors, some of which are shared 
with FN-RMS (n = 334) and/or myogenic cells and tissue (n = 446).
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enhancer marks (Fig. 1A), including acetylation at histone 
3 lysine 27 (H3K27ac) and H3 lysine 4 mono/dimethylation 
(H3K4me1 and H3K4me2), but not the active promoter-
associated mark H3K4me3 (Fig. 1B). PAX3–FOXO1 sites 
showed no evidence of poised and repressed chromatin, as 
demarcated by Polycomb-deposited trimethylation of H3 
lysine 27 (H3K27me3), and, conversely, regions marked by 
H3K27me3 lacked both PAX3–FOXO1 and H3K27ac (Fig. 
1B). Because histone marks are deposited in a combinato-
rial fashion, we defined reoccurring patterns associated 
with various chromatin functional states (16), providing 
the first epigenomic map upon which to overlay PAX3–
FOXO1 occupancy (Fig. 1C). We found PAX3–FOXO1 
most frequently occupied the strong enhancer chromatin 
state (Fig. 1C), exemplified by known PAX3–FOXO1 target 
FGFR4 (Supplementary Fig. S1C) and oncogenes MYC, ALK, 
and MET (Supplementary Fig. S1D).
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Binding of PAX3–FOXO1 to Enhancers of High 
Disease and Biological Relevance
To identify which of these PAX3–FOXO1 sites are of 
high disease relevance, we first performed ChIP-seq in two 
additional cell FP-RMS lines, RH3 and SCMC, to identify a 
broader set of targets and recurrent sites. There were 1,783 
peaks shared among 2 and 555 peaks for all 3 cell lines, and 
these showed the most statistical significance and largest sig-
nal per peak (Supplementary Fig. S1E–S1F). We next mapped 
a key histone marker of enhancers H3K27ac in a panel of 
FP-RMS cell lines and tumor samples, and found 1,107 high-
confidence PAX3–FOXO1 sites occupying enhancers in one or 
more of the cell lines (Fig. 1D; Supplementary Table S1). We 
then generated a similar map of enhancers in FN-RMS cell 
lines and tumors, which shared 334 enhancer loci. Four hun-
dred forty-six PAX3–FOXO1-bound enhancers were also pre-
sent in myogenic samples. The enhancers unique to FP-RMS 
were enriched, by GREAT ontology (17), in pathways involved 
in early development, whereas shared enhancers were enriched 
for late muscle differentiation (Supplementary Fig. S1G).
PAX3–FOXO1 acting across large one-dimensional sequence 
distances has confounded target gene identification. Previous 
reports to identify these targets were based on either changes 
in gene expression (11, 12, 18) or proximity of a gene to a 
PAX3–FOXO1 peak in a single-cell line with no consideration 
of expression or chromatin context (15). We therefore identi-
fied high-confidence PAX3–FOXO1 target genes by a series of 
criteria (see Supplementary Fig. S2A–S2B and Supplementary 
Methods). In brief, we (i) used only PAX3–FOXO1 bound to 
enhancers that were recurrent in cell lines and tumors (from 
Fig. 1D), (ii) selected for expressed genes, as PAX3–FOXO1 was 
found only in active chromatin states, (iii) excluded nearby 
expressed genes if they were not found within the same topo-
logically associated domain (TAD; predicted by HiC data, ref. 
19) as the PAX3–FOXO1 bound enhancer, and (iv) included the 
maximally expressed gene within each TAD harboring PAX3–
FOXO1. Using this approach, we found 1,010 high-confidence 
targets, 678 of which were novel, and, of note, 439 were signifi-
cantly reduced by short hairpin RNA (shRNA) knockdown of 
PAX3–FOXO1 for 48 hours (Supplementary Fig. S2C–S2G). 
Novel targets included oncogenes (n = 24), TFs (n = 53), and 
several imprinted genes (n = 7; Supplementary Table S2).
Thus, our data support the hypothesis that PAX3–FOXO1 
enables transcription by directing active chromatin marks 
to distal enhancers surrounding oncogenes, imprinted and 
myogenic genes.
FP-RMS Tumors and Cell Lines Possess a Myogenic 
Transcriptional Program
TFs act on enhancers in a stoichiometric manner, and those 
that are expressed at unusually high concentrations and are 
able to bind a majority of enhancers are defined as master 
transcription factors (MTF) and key determinants of cell fate 
(1). Although PAX3–FOXO1 is the primary driver, as an MTF 
it is likely to not work alone. We identified other MTFs that 
were overexpressed compared with normal tissues (P < 10−30), 
had consistently high levels (average FPKM >20), were super 
enhancer regulated, and had significant motif enrichment 
in enhancers (Fig. 2A). To do this, we first compared the 
RNA-sequencing (RNA-seq) profiles of RMS primary tumors 
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Figure 2.  Transcriptional and epigenetic landscapes of RMS cell lines and primary tumors. A, Strategy for identifying MTFs from RNA-seq and ChIP-
seq datasets. B, RNA sequencing of patient RMS tumors reveals a set of candidate MTFs (n = 170) identified by filtering for significant overexpression  
(P < 1E−30) across one or both RMS subtypes, and removal of general TFs (those ubiquitously expressed in all tumors and tissues). Candidates were 
ranked and plotted based on average overall expression in fusion-positive RMS (cell lines and tissues) and myoblasts/myotubes. C, Violin plots of gene 
expression of MYOD1, MYOG, and MYCN across RMS, myoblasts, myotubes, and normal tissues. (continued on next page) 
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(n = 103) and cell lines (n = 37; ref. 3) with normal human 
organ tissues (n = 188). This identified a consistently overex-
pressed core of 170 TFs, suggesting a convergent underlying 
epigenetic state (Fig. 2B; Supplementary Table S3). The TFs, 
of these RMS tumors resembled those of myoblasts and 
myotubes (20), and all have remarkably high levels of the 
lineage-determining TFs MYOD1 and MYOG as compared 
with other normal tissues (Fig. 2B and C). Unlike myoblasts, 
MYF5 is typically missing from RMS, although when present 
it appears to be mutually exclusive with MYOD1 (21). Another 
important divergence from normal myogenesis was high 
expression of the transcriptional amplifier MYCN (Fig. 2C), 
a known target of PAX3–FOXO1 (15). MYCN expression was 
generally higher in FP-RMS tumors whereas MYC expression 
was higher in FN-RMS; however, many tumors had expres-
sion of both, such that the sum was consistently high for all 
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patients with RMS (Supplementary Fig. S3A and S3B). RMS 
cell lines faithfully recapitulated the transcriptional commit-
ment of the primary tumors to these candidate MTFs.
Super Enhancer Analysis in RMS Cell Lines and 
Primary Tumors Implicates MYOD, MYOG, and 
MYCN as Master Regulators
A small fraction of active enhancers acquire a large fraction 
of transcriptional machinery and active chromatin marks (fre-
quently demarcated by H3K27ac), and have been defined as 
super enhancers (22, 23). These regions are cell type–specific 
and control expression of cell identity genes in normal tissues 
and oncogenes in cancer. Although super enhancers may simply 
be clusters of additive enhancers (24), they nevertheless capture 
the most active enhancers associated with the core regulatory 
MTF circuitry (25). In RMS cells bearing PAX3–FOXO1 (RH4), 
we identified 776 super enhancers (ranked as the top 4% of all 
enhancers with 38% of the total H3K27ac signal) that were 
associated with hallmark RMS genes such as IGF2, FGFR4, ALK, 
MYOD1, MYOG, and MYCN (Fig. 2D). To evaluate the clinical 
relevance of our cell lines as models for enhancer architecture, 
we mapped super enhancers by H3K27ac signal in a set of 3 FP-
RMS and 5 FN-RMS primary tumors. We found concordance 
of super enhancers among PAX3–FOXO1-driven cell lines and 
tumors (Fig. 2D). MYCN had the highest ranked super enhancer 
in MYCN-amplified cell lines and tumors. A common epigenetic 
landscape was found in FN-RMS cell lines and tumors (Fig. 2E; 
Supplementary Fig. S3C), which differed from FP-RMS at super 
enhancers such as FOXO1, MYCN, and ALK (Supplementary Fig. 
S3D). MYCN itself possessed a remarkable 5 super enhancers 
within the surrounding TAD structure (HiC data from ref. 19), 
which circularized chromatin conformation capture followed 
by sequencing (4C-seq) revealed all physically interact not only 
with MYCN, but also with each other (Supplementary Fig. 
S3E). Motif analysis at super enhancer sites revealed a highly 
significant enrichment of MYOD, MYOG, PAX3–FOXO1, and 
MYCN recognition sequences (Fig. 2F; Supplementary Table 
S4). Importantly, we observed a consistent reduction in cell 
viability in 2 FP-RMS cell lines when PAX3, MYCN, or MYOD1 
were targeted by siRNAs (Fig. 2G). The suppression was greater 
in FP-RMS than in FN-RMS, further implicating them as essen-
tial master regulators of FP-RMS.
MYOD alone can reprogram cells into myogenesis (26), 
and it is intriguing that FP-RMS tumors remain undif-
ferentiated despite extremely high levels of the myogenic 
TFs MYOD and MYOG. Given this, we hypothesized that 
PAX3–FOXO1 acts as a strong chromatin activator, prevent-
ing decommissioning of distal enhancers that are lost during 
normal muscle differentiation. To study this, we analyzed 
active enhancer mark H3K27ac (27) around PAX3–FOXO1 
peaks, in myoblasts, myotubes, and muscle tissue. We found 
that enhancers controlling MYOD1 decreased during mus-
cle differentiation and were absent in other tissues and 
cell lines, whereas in FP-RMS cells the MYOD1 enhancer 
locus was expanded and contained multiple PAX3–FOXO1 
peaks (Fig. 2H). Genome-wide, myogenic enhancers found at 
PAX3–FOXO1 peaks decreased during the transition from 
myoblasts to myotubes to skeletal muscle (Fig. 2I). Genes 
associated with these decommissioned enhancers included 
TFs (MYCN, MYC, MSC, and MYOD1 itself) and epigenetic 
modulators which have known involvement in regulating 
self-renewal, embryonic development, muscle development, 
and chromatin organization (Supplementary Table S5), and 
imprinted genes involved in mesoderm development (MEST, 
IGF2). These data suggest that PAX3–FOXO1 may induce a 
myoblastic state by maintaining active chromatin at enhanc-
ers controlling these genes. This was further supported by 
the observation that after 48 hours of PAX3–FOXO1 knock-
down these enhancers lost substantial H3K27ac signal as 
measured by ChIP with reference exogenous genome (ChIP-
Rx; ref. 28; Fig. 2J).
PAX3–FOXO1 Collaborates with MYOG, MYOD, 
and MYCN at Super Enhancers
Our results indicated that PAX3–FOXO1 activates the MTFs 
MYOD, MYOG, and MYCN, and together with these, estab-
lishes the epigenome and transcriptome of FP-RMS (Fig. 3A). 
To validate this, we performed ChIP-seq on MYOD, MYOG, 
and MYCN and studied the extent of their collaboration with 
PAX3–FOXO1 to shape the enhancer landscape. We observed 
widespread binding of MYOD, MYOG, and MYCN, each cov-
ering 9 to 15 times as much genomic space as PAX3–FOXO1 
(Supplementary Fig. S4A). When all four MTFs were colo-
calized in the genome they harbored greater signal of active 
histone marks, especially H3K27ac (Supplementary Fig. S4B–
S4C). Enhancers with all 4 MTFs were frequently super enhanc-
ers (Fig. 3B). Almost every super enhancer was occupied by 3 or 
more of these MTFs, unlike typical enhancers (Fig. 3C). Super 
enhancers spanned a median of 23.5 kb (compared with 1.2 
kb for typical enhancers) and exhibited a higher load of MTFs 
only when considering their constituent peaks (Fig. 3C; Sup-
plementary Fig. S4D). PAX3–FOXO1 occupied only a small 
fraction of typical enhancers (5%) but many super enhanc-
ers (47%). MYOG, MYOD, and MYCN are bound to almost 
every super enhancer, and although PAX3–FOXO1 was found 
in only half of all super enhancers, its preference for super 
enhancers over typical enhancers was profound (Fig. 3D and 
E). Super enhancer–associated genes were transcribed at signifi-
cantly higher levels than typical enhancer genes, and enhancers 
occupied by 4 MTFs were found to be most highly transcribed 
compared with enhancers with fewer MTFs (Fig. 3F).
The genome-wide placement of super enhancers was 
strongly determined by the myogenic MTFs recognizing the 
underlying DNA sequence CAGCTG (Fig. 2F), but interest-
ingly there was low enrichment of the canonical MYCN 
motif CACGTG (Supplementary Table S4). More than 80% 
of MYCN peaks were distal (Supplementary Fig. S4E), and 
de novo motif analysis discovered MYCN prefers a myogenic 
E-box sequence (RRCAGCTG) nearly identical to that of 
MYOG and MYOD (Supplementary Fig. S4F). Thus, MYCN 
may behave in a manner akin to MYC acting as a general tran-
scriptional amplifier, following to locations opened by more 
sequence-specific (and lineage determining) TFs (29, 30).
Master (or lineage determining) TFs are predicted to main-
tain cell identity by mutual and self-reinforcement, creating 
autoregulatory feed-forward loops (1, 31). We found this to 
be the case in FP-RMS, where the super enhancers controlling 
PAX3–FOXO1, MYOD, and MYCN contain all four of these MTFs 
(Fig. 3G). The MYOG super enhancer is bound by all except the 
PAX fusion, consistent with the logic and timing of normal 
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Figure 3.  PAX3–FOXO1 (P3F) collaborates with MTFs MYOD, MYOG, and MYCN at super enhancers (SE). A, Characteristics enlisting candidate MTFs 
in FP-RMS: SE-driven, high expression, with motifs enriched across all SEs predicting TF binding. B, The percentage of enhancers (divided into groups by 
the number of MTFs therein) which classify as either typical (TE) or super. Null hypothesis (that the % of super enhancers does not depend on number 
of MTFs present in an enhancer) was evaluated with Fisher exact test; *, P < 0.04; ****, P < 0.0001; ns, not significant. C, Left, read density profiles of 
H3K27ac, H3K4me1, and H3K4me2 at regions of TE and SE architecture. Median enhancer length is indicated. Right, collaborative co-occupancy of MTFs 
in TEs and SEs. Presence of each MTF at enhancer is indicated by the respective colors. D, Top, enhancer occupancy of each MTF at TEs or SEs. Bottom, 
fold enrichment of SEs over TE for each MTFs. E, Average number of MTFs per enhancer type. Error bars show 95% confidence interval. F, Expression 
of genes associated with enhancers of various MTF combinations (left) or SE and TE genes (right), associated by proximity. RNA-seq reported as FPKM, 
fragments per kilobase of transcript per million mapped reads. Error bars, 95% confidence interval. P values calculated by Welch unpaired t test. G, Mutual 
and self-reinforcement of MTFs via SEs for PAX3–FOXO1, MYOD1, MYCN, and MYOG. Tracks show signal in RPM, reads per million mapped reads. TEs 
are indicated by gray bars and SEs by red. To illustrate an example of multiple adjacent motifs presence within SEs, we have zoomed in on the PAX3 and 
MYOD/MYOG motifs present upstream of MYCN.
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myogenesis which successively progresses from dominance of 
PAX3 to MYOD to MYOG (32). To investigate the contribu-
tion of interconnection to gene expression, we used shRNA 
against each factor followed by RNA-seq. PAX3–FOXO1 
depletion disrupted both enhancer acetylation and RNA 
expression at MYOD and MYCN, but an indirect increase at 
MYOG (Supplementary Fig. S4G). MYOG expression was the 
most profoundly reduced by knockdown of either MYOD1 
or MYCN (Supplementary Fig. S4H and S4I). All MTFs were 
sensitive to MYCN depletion, and MYCN expression was 
sensitive to depletion of any one factor (Supplementary Fig. 
S4G and S4H).
BRD4, MED1, and p300 Occupy Key  
PAX3–FOXO1-Established Super Enhancers
Because PAX3–FOXO1 binds between 10Kb and 1Mb away 
from nearby promoters, it may mediate its transcriptional 
impact through chromatin factors looping over long dis-
tances. The transactivation domain of FOXO1 is known to 
recruit the coactivator p300 (33), which enzymatically acety-
lates histones, leading to binding of additional factors, includ-
ing BRD4 and Mediator (34). We therefore hypothesized that 
PAX3–FOXO1 recruits p300 and the other cofactors leading 
to chromatin remodelling. To test this, we performed ChIP-
seq of these components and analyzed their co-occupancy at 
PAX3–FOXO1-bound enhancers. Our results confirmed that 
these proteins co-occupy enhancers with PAX3–FOXO1 and 
were sites of open chromatin as determined by DNase hyper-
sensitivity (Fig. 4A). We observed that p300 followed PAX3–
FOXO1 at virtually every site, and BRD4 was co-occupant 
at the majority of these enhancers (72%), especially those 
with super enhancer architecture (95% of super enhancers; 
Fig. 4B). PAX3–FOXO1 locations lacking BRD4 showed no 
evidence of looping machinery MED1, CTCF, and RAD21, 
Figure 4.  PAX3–FOXO1 (P3F) opens chromatin and recruits BRD4 at looped enhancers. A, Heat maps of PAX3–FOXO1, DNase, p300, H3K27ac, BRD4, 
MED1, CTCF, and RAD21 signal at PAX3–FOXO1 peaks, ranked by distance to closest BRD4 peak in RH4. Rug graph indicates which locations (red lines) 
are within super enhancers (SE). B, PAX3–FOXO1 and BRD4 co-occupancy at enhancers (top, typical; bottom, super). C, Introduction of PAX3–FOXO1 
into a fibroblast causes increased sensitivity to DNase, deposition of H2K27ac and recruitment of BRD4 at PAX3–FOXO1 sites. D, Metagene analysis 
of DNase, H3K27ac, PAX3–FOXO1, and BRD4 upon PAX3–FOXO1 introduction into fibroblasts (left) compared with RH4 cells (end right). E, Opening of 
chromatin at the MYOD1 SE by PAX3–FOXO1 in fibroblasts (7,250) with empty vector (middle) or PAX3-FOXO1 (bottom), compared with RH4 cells (top). 
F, Hi-C profile (top) surrounding MYOD1 locus from NHEK cells (19) with CTCF, RAD21, PAX3–FOXO1, p300, MED1, BRD4, and H3K27ac ChIP-seq data in 
RH4 cells. 4C-seq (bottom) from MYOD1 SE looping to adjacent SE region and MYOD1 promoter, and vice versa, in RH4 cells. Viewpoints are indicated by 
arrows anchored to their genomic locations.
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whereas sites bound by BRD4 did (Supplementary Fig. S5A). 
We predicted that these two PAX3–FOXO1 modes (with and 
without BRD4; Supplementary Fig. S5B–S5C) would have 
divergent functional consequences, and found that sites with 
BRD4 had greatly increased expression from associated genes 
(Supplementary Fig. S5D), and GREAT ontology analysis 
showed only BRD4-containing peaks were enriched for FP-
RMS gene sets (Supplementary Fig. S5E).
It is unknown if PAX3–FOXO1 itself is capable of inducing 
de novo myogenic enhancer formation. We thus stably expressed 
PAX3–FOXO1 in a human fibroblast cell line (7250) and studied 
changes in chromatin and the corresponding changes in gene 
expression. We found that PAX3–FOXO1 opened the chromatin 
landscape, as evidenced by an increase in DNA hypersensitivity 
at enhancers compared with control parental cells (Fig. 4C). Fur-
thermore, PAX3–FOXO1-bound enhancers saw an increase in 
H3K27ac and recruitment of the acetylated lysine reader BRD4 
(Fig. 4C). These sites of opening (n = 836) are active, PAX3–FOXO1 
bound, and BRD4 loaded in FP-RMS cells (Fig. 4D). Many of the 
enhancers, such as the super enhancers upstream of MYOD1 (Fig. 
4E), MYOG, and FGFR4 (Supplementary Fig. S5F), are faithfully 
reconstituted with a size and shape similar to those in RMS. Of 
the 568 high-confidence PAX3–FOXO1 super enhancers, 349 are 
recapitulated in these fibroblasts reprogrammed by exogenous 
PAX3–FOXO1 (Supplementary Fig. S5G).
The proximity of the PAX3–FOXO1-directed super enhanc-
ers near MYOD1 and their coappearance with MYOD1 tran-
scription led us to predict three-dimensional looping to bring 
these super enhancers to the promoter. We confirmed these cis 
interactions in RH4, using 4C-seq from two viewpoints (one at 
the most distal PAX3–FOXO1-bound super enhancer and the 
other at the MYOD1 promoter; Fig. 4F). These loops enable the 
physical interaction of the super enhancer–bound proteins 
MED1, p300, and BRD4 with the promoter of MYOD1 to 
facilitate transcription. The 4C interactions were restrained to 
the TAD predicted by HiC data (19) in other human cells (Fig. 
4F). Thus, PAX3–FOXO1 acts as a pioneering factor, opening 
chromatin, recruiting coactivators, and driving transcription 
through looped myogenic super enhancers.
Molecular Sensitivities of PAX3–FOXO1 Tumor 
Cells Are Associated with Super Enhancers
Our results thus far showed that PAX3–FOXO1 estab-
lishes super enhancers not only at myogenic genes but also 
at multiple druggable oncogenic drivers. Because super 
enhancers are cell-type restricted, we hypothesized that FP-
RMS would be selectively vulnerable to inhibition of these 
super enhancer–driven pathways. Hence, we determined 
the landscape of molecular sensitivities in PAX3–FOXO1- 
positive patient-derived cell lines (RH41, RH5) by dose responses 
at 48 hours for 1,912 compounds. To deprioritize compounds 
with nonselective cytotoxicity, we also treated fibroblast cell 
lines (NIH3T3, 7250, and T9195). Our small-molecule library 
MIPE4 (35) was assembled to have high mechanistic diversity 
with an emphasis on clinically relevant compounds (Supple-
mentary Fig. S6A–S6B; Supplementary Table S6). Area under 
the dose response curve (AUC) was used as the measure of 
potency, as this metric captures both dose dependence and 
maximum response (see Supplemental Methods and Supple-
mentary Fig. S6C–S6E). PAX3–FOXO1-expressing cells were 
selectively sensitive to super enhancer–driven RTKs (FGFR4, 
IGF2/IGF1R, and ALK) and downstream kinases (PI3K, AKT, 
and mTOR). Furthermore, transcriptional cofactors (HDACs, 
BRD4) originally identified as super enhancer–associated pro-
teins (23) were also selective for FP-RMS cells (Fig. 5A–B; 
Supplementary Fig. S6F). Thus, the identification of super 
enhancer–associated genes highlighted multiple candidate tar-
gets for therapy, which may be a useful approach for other can-
cers. Of note, FP-RMS was sensitive to inhibiton of BRD4 (36), 
which has recently shown promising results in RMS tumor 
models (13), although no molecular explanation in connec-
tion with PAX3–FOXO1 has previously been made. Thus, with 
these new data reported herein that BRD4 lies at an important 
node in the PAX3–FOXO1 circuitry (Supplementary Fig. S6G), 
we next sought a mechanistic explanation for the sensitivity.
Cells with PAX3–FOXO1 Are Selectively Sensitive 
to BET Bromodomain Inhibition
Given the sensitivity of FP-RMS cells to chemical BRD 
inhibition, we sought to determine if this was attributable to 
PAX3–FOXO1, or if the FN-RMS subtype was also vulnerable. 
Thus, we tested an expanded panel of RMS cell lines against 
5 structurally diverse BET bromodomain inhibitors (BRDi) 
and 1 pan-bromodomain inhibitor, Bromosporine. Thieno-
diazepine inhibitors, JQ1 and the clinical analogue OTX015, 
were the most potent, with dose response consistently in the 
nanomolar IC50 range for FP-RMS cell lines, whereas most 
often in the micromolar range in fusion-negative (mutant 
RAS) RMS lines (Fig. 5C; Supplementary Fig. S7A–S7C). 
BRD4 inhibition dramatically reduced proliferation over 
time in PAX3–FOXO1-driven cells, whereas mutant RAS-
driven RMS cells were relatively unhindered (Fig. 5D; Supple-
mentary Fig. S7D). JQ1 action was mediated by programmed 
cell death in a dose-dependent manner (Supplementary Fig. 
S7E). Importantly, although MYCN amplification clearly con-
fers special sensitivity to BRD4 inhibition in neuroblastoma 
(37), FP-RMS cells with (RH5 and SCMC) or without (RH3, 
RH4, and RH41) MYCN amplification were all sensitive (Fig. 
5C). PAX3–FOXO1 also conferred 11-fold increased BRDi 
sensitivity to fibroblasts (Fig. 5E). Patient-derived xenografts 
grown in culture further confirmed PAX-fusion vulnerability, 
and FN-RMS resistance, to JQ1 (Supplementary Fig. S7F).
The JQ1 targets BRD2/3/4 (but not BRDT) are expressed 
in RMS, but not overexpressed compared with normal tissues 
(Supplementary Fig. S8A). RNAi screening of bromodomain- 
containing proteins revealed greatest dependence on EP300, 
KAT2A, BRD3, and BRD4 (Supplementary Fig. S8B). Among 
the BET family members, BRD4 was the most sensitive to 
genetic depletion, which incurred apoptotic events (Supple-
mentary Fig. S8C–S8E).
PAX3–FOXO1 Requires BRD4 for Function  
and Stability
The sensitivity of PAX3–FOXO1-driven cell lines to BET 
inhibition and our data showing co-occupancy of BRD4 in all 
PAX3–FOXO1-bound super enhancers led us to the hypoth-
esis that PAX3–FOXO1 is dependent on BRD4 to mediate 
transcription of its target genes. This is consistent with the 
known role of BRD4 in stimulating transcriptional elongation 
(38) and previous reports that BRD4 inhibition causes rapid 
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Figure 5.  Molecular sensitivity landscape of FP-RMS is enriched in super enhancer (SE)–associated targets including BRD4. A, Potency in PAX3–
FOXO1 RMS cell lines versus toxicity in normal cell lines measured by dose response and summarized across 240 mechanistically distinct subcategories. 
The percent area under the dose response curve (%AUC) was averaged for all compounds within a target subcategory. The number of compounds in each 
category is indicated by the size of the bubble, and the difference in AUC (normal – RMS) is indicated by color scale. B, Differential sensitivities against 
molecules targeting proteins associated with SEs, compared to non-SE targets and SE-signal transduction. Size of the bubble indicates number of 
molecules against each target. C, IC50 heat map of 5 BET bromodomain inhibitors and 1 pan-bromodomain inhibitor across 5 PAX-fusion and 4 fusion-neg-
ative RMS cell lines. D, Growth curves of FP-RMS cells (RH5) and FN-RMS cells (CTR) exposed to increasing concentrations of JQ1 or DMSO. Confluence 
measured by phase-contrast images every 4 hours over multiple days of treatment. Inset, images of RH5 cells with DMSO or 120 nmol/L JQ1. E, PAX3–
FOXO1 increases sensitivity of fibroblasts to JQ1.
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decommissioning of super enhancers and selective inhibition 
of super enhancer–driven genes (39). To test this, we compared 
the fold change in super enhancer–associated versus typical 
enhancer–associated genes before and after treatment with JQ1 
for 6 hours by RNA-seq. Indeed, we found that super enhancer–
associated genes in FP-RMS cells were especially sensitive to 
JQ1, and that this selectivity was also seen upon genetic deple-
tion of PAX3–FOXO1 itself (Fig. 6A; Supplementary Table S7). 
Gene set enrichment analysis (GSEA) revealed that JQ1 was 
able to selectively downregulate PAX3–FOXO1 target genes, 
with enrichment mirroring knockdown of PAX3–FOXO1 (Fig. 
6B; Supplementary Fig. S9A–S9B). Many key super enhancer–
driven TFs and PAX3–FOXO1 targets were suppressed whereas 
cell-cycle arrest and apoptosis genes were upregulated by JQ1 
(Fig. 6C). The known sensitivity of MYC family proteins to 
BRD inhibition was seen at both the transcript and protein 
levels (Fig. 6C; Supplementary Fig. S9C). Coordinately, master 
regulators MYOD and MYOG were also reduced at the pro-
tein level upon JQ1 treatment in a dose- and time-dependent 
fashion (Fig. 6D; Supplementary Fig. S9D). These effects were 
not a consequence of reducing PAX3–FOXO1 transcription, as 
evidenced by exon-level expression in RNA-seq data (Fig. 6E).
Although ChIP-seq evidenced that BRD4 and PAX3–FOXO1 
are co-occupant spatially, it was unclear whether they bind 
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Figure 6.  JQ1 selectively ablates PAX3–FOXO1-driven transcription and BRD4 interaction. A, Selective disruption of super enhancer (SE) genes upon 
BET bromodomain inhibition (top) or inducible shRNA depletion of PAX3–FOXO1 (P3F; bottom) in RMS cells (RH4). Fold change in gene expression calcu-
lated by comparison with log2 of FPKM in controls (DMSO, scramble shRNA). Error bars show the 95% confidence interval. P values calculated by Welch’s 
unpaired t test. B, GSEA revealed the inhibition of PAX3–FOXO1 fusion gene targets, both by JQ1 and PAX3–FOXO1 knock down. NES, normalized enrich-
ment score; FDR, false discovery rate. Genes used were high-confidence PAX3–FOXO1 targets with recurrent enhancers in 83–100% of FP-RMS samples, 
as reported in Supplementary Table S2. C, mRNA expression alterations of SE (red bar) and PAX3–FOXO1 (red peak) targets after 6 hours of 500 nmol/L 
JQ1 treatment in RH41 and RH4 cells. Heat map indicates the log2 fold change in FPKM. D, Protein levels of MYOD and MYOG by immunoblotting of RH4 
cell lysates after treatment with JQ1(1 μmol/L) over time. E, Exon level expression and fold change in RH4 cells upon JQ1 treatment (6 hours, 500 nmol/L), 
for PAX3–FOXO1, MYOD1, MYOG, MYC, and MYCN. PAX3–FOXO1 expression remains intact upon JQ1 treatment, unlike the other key TFs. F, BRD4 and 
PAX3–FOXO1 localization shown via ChIP-seq (top) and re-ChIP-qPCR in the presence and absence of JQ1 (bottom) at the MYOD upstream SE, MYOG 
downstream SE and PIPOX intronic SE. RH4 cells were treated for 6 hours with DMSO or 1 μmol/L JQ1. G, Coimmunoprecipitation of PAX3–FOXO1 and 
BRD4 from RH4 cells treated with DMSO or 1 μmol/L JQ1 for 24 hours. H, PAX3–FOXO1 immunoblot after 6-hour treatment of DMSO or JQ1 with increas-
ing concentrations. Bar chart (top) quantization of PAX3–FOXO1 normalized to loading controls (β-actin). I–J, Stability of PAX3–FOXO1 protein measured 
by immunoblotting after halting translation with cycloheximide (CHX) in RH4 cells treated with DMSO or JQ1 (1 μmol/L).
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chromatin cotemporally. To study this, we performed tandem 
chromatin immunoprecipitations (re-ChIP) for PAX3–FOXO1 
followed by BRD4, and vice versa, in RH4 cells treated with 
either DMSO or JQ1 for 6 hours. Quantitative PCR of re-ChIP 
DNA at enhancer sites bound by both PAX3–FOXO1 and 
BRD4 (MYOD1, PIPOX) revealed strong enrichment regardless 
of ChIP order (Fig. 6F), which was almost completely ablated in 
JQ1-treated cells. This was not observed at BRD4-only enhanc-
ers near MYOG. To corroborate this, we performed coimmuno-
precipitation with BRD4 and PAX3–FOXO1 in the presence of 
DMSO or JQ1 (Fig. 6G), and found that JQ1 indeed ablated 
this endogenous interaction. The PAX3–FOXO1 and BRD4 
interaction was seen in both directions using exogenous, 
tagged versions of these proteins (Supplementary Fig. S9E). 
Given no alteration in PAX3–FOXO1 mRNA levels, and only 
modest reduction in protein levels (Fig. 6H), we suspected JQ1 
caused destabilization of the PAX3–FOXO1 protein. Remark-
ably, the half-life of PAX3–FOXO1 was reduced from >8 hours 
to 28 minutes with JQ1 compared to DMSO (Fig. 6I–J; Supple-
mentary Fig. S9F) in the presence of cycloheximide to inhibit 
protein translation. This appears to be an on-target effect, as 
shRNA against BRD4 also caused PAX3–FOXO1 to decrease 
at the protein level, but not the transcript level (Supplemen-
tary Fig. S9G). Thus, PAX3–FOXO1 interacts with BRD4 at 
enhancers, and treatment with JQ1 leads to loss of this interac-
tion with rapid degradation of PAX3–FOXO1 protein.
JQ1 Selectively Disrupts PAX3–FOXO1-Driven 
Transcription to Suppress Tumor Growth In Vivo
The in vitro sensitivity of FP-RMS to BRD4 inhibition by the 
rapid and the specific inhibition of PAX3–FOXO1 function 
indicated this may be an effective therapeutic strategy. To test 
this, we developed an imagable readout to monitor in vivo activ-
ity of PAX3–FOXO1 super enhancer affected by drugs admin-
istered to mice. We engineered RMS cells to express luciferase 
(and GFP), controlled either by a constitutively active cytomeg-
alovirus (CMV) promoter or a PAX3–FOXO1-dependent super 
enhancer (cloned from the intronic ALK super enhancer; Sup-
plementary Fig. S10A). This ALK super enhancer was consist-
ent in FP-RMS cell lines and tumors, while completely absent 
in FN-RMS (Supplementary Fig. S3D). No activity was seen 
from the ALK super enhancer construct in FN-RMS cells lack-
ing PAX3–FOXO1 (Supplementary Fig. S10B). The ALK super 
enhancer was suppressed by knockdown of PAX3–FOXO1 
or by point mutation of the PAX3–FOXO1 binding motif 
(Supplementary Fig. S10C–S10E). BRD inhibition with JQ1 
suppressed only the ALK super enhancer– but not the CMV-
driven reporter in a dose-dependent manner in vitro (Fig. 7A), 
whereas the general transcription CDK7 inhibitor THZ1 sup-
pressed both. Use of these reporter lines in vivo demonstrated a 
selective inhibition of PAX3–FOXO1 activity with subsequent 
significant suppression of tumor growth (Fig. 7B and C; Sup-
plementary Fig. S10F). The tumor-suppressive activity of JQ1 
was confirmed in a second FP-RMS cell line xenograft, SCMC 
(Supplementary Fig. S10G–S10H).
DiScUSSion
Pediatric sarcomas that harbor fusion oncogenes are reported 
with relatively few genomic alterations despite their clinically 
Figure 7.  PAX3–FOXO1-dependent super enhancer disruption by BET 
inhibition in vivo. A, JQ1 selectively abolishes PAX3–FOXO1-dependent 
enhancer activity, as measured in PAX3–FOXO1 containing cells (RH4) 
stably transduced with a lentiviral pGreenFire reporter construct under 
the control of the PAX3–FOXO1-driven ALK super enhancer (SE), while 
not reducing the CMV-driven expression. CDK7 inhibitor THZ1 inhibits 
activity of both constructs. PAX3–FOXO1-driven luciferase (red line) is 
graphed on the left y-axis (linear), and CMV-driven luciferase (blue-
green line) is graphed to the right y-axis (log 10 scale). Error bars show 
standard deviation of duplicate wells, and results are representative of 
2 independent experiments. B, CMV (left flank) and ALK SE (right flank) 
reporter contructs in RH4 xenografts. JQ1 or vehicle treatment began on 
day 0 after the first image was taken. C, Left, RMS (RH4) tumor growth 
with vehicle- or JQ1-treated mice. Measurements were taken with caliper 
and include both CMV and PAX3–FOXO1-SE legs. Right, tumor volume at 
day 27. P value calculated by Welch unpaired t test.
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aggressive behavior (7). Here, we report that the PAX3–FOXO1 
fusion gene directs a profound epigenetic chromatin remod-
eling in cooperation with the master regulators MYOD, MYOG, 
and MYCN by the establishment of super enhancers.
By comprehensively charting the first epigenetic landscape 
of RMS in cell lines and primary tumors, we identified a core 
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commitment to super enhancer regulation of MYOD, MYOG, 
and MYCN, which in turn drive virtually all densely acetylated 
enhancer clusters that specify RMS cell identity. Although 
the concept of a “super” enhancer remains controversial, and 
may simply be a cluster of additive enhancers (24), we found 
the classification useful in that the most uniquely and highly 
expressed candidate MTFs were all driven by super enhancers, 
often more than one. Our results indicate that PAX3–FOXO1 
directly establishes super enhancers to drive itself, MYOD1, and 
MYCN, and indirectly establishes a super enhancer (through 
MYOD and MYCN) to drive MYOG. Downstream, these fac-
tors are acting in concert, whereas in normal development 
they act sequentially (32). Virtually all of the discovered super 
enhancers were bound by 3 or 4 of these MTFs, and associ-
ated with the highest levels of gene expression. Remarkably, 
the presence of MYCN at these hyperactive regions resembles 
the function of MYC as a general transcriptional amplifier 
(29) and may underlie transcriptional addiction in FP-RMS 
(40). Together, these four MTFs cause a profound epigenetic 
reprogramming, freezing the cells in a myoblastic state with 
PAX3–FOXO1 as the conductor.
Cell type–specific distribution of BRD4 is accomplished 
by TF recruitment to their enhancers (41). Our study 
showed that PAX3–FOXO1 can direct de novo recruitment 
of BRD4 to specific chromatin sites when introduced into 
human fibroblasts, accompanied by opening of chroma-
tin and acetylation of H3K27 at enhancers proximal to 
key RMS genes. This purely activating function of PAX3–
FOXO1 in pediatric RMS is in sharp contrast to the dual 
functionality of EWS–FLI1 in pediatric Ewing sarcoma (5), 
which has both activating and repressive functions depend-
ing on genomic context.
The extent to which epigenetic profiling can aid prediction 
and interpretation of chemical sensitivities remains unclear. 
Using mechanistically informed drug screening, we observed 
that molecules targeted to super enhancer–bound coactivators 
(BRD4 and HDAC; ref. 22) and super enhancer targets (such 
as the receptor tyrosine kinases FGFR4 and ALK) are the most 
selectively potent in these FP-RMS cells. These data reinforce 
previous strategies that showed FP-RMS sensitivity to FGFR 
and IGF1R inhibition (42, 43) and HDAC inhibitors (4, 44, 45), 
and add previously unknown mechanistic insights to recently 
discovered BRD4 vulnerability (13). The observation that super 
enhancer–associated targets represent key vulnerabilities may be 
broadly applicable to cancers driven by epigenetic reprograming 
through super enhancer networks and may be critical to prior-
itizing combination strategies as well.
The same translocation which causes FP-RMS also creates an 
Achilles’ heel by addicting cells to BRD4. Our data add to the 
pleiotropic utility of BRD4 inhibitors, with a recent wave of stud-
ies in a diverse group of cancers (37, 46–50). The transcriptional 
impact of BRD4 inhibition appears to be context dependent, 
where its antitumor effect is linked to dampening one or more 
master regulators, often including MYC in hematologic malig-
nancies (51, 52), MYCN in neuroblastoma (37), POU2AF1 and 
PAX5 in DLBCL (47), or FOSL1 in adenocarcinoma (53), among 
others. JQ1 was shown recently to be effective in reducing RMS 
tumor growth by antiangiogenic properties, but the underly-
ing chromatin-based mechanisms or FP-RMS subtype selectiv-
ity were not explored (13). Here, we find BRDi caused selective 
downregulation of MYC, MYCN, MYOD1, MYOG, and many other 
downstream PAX3–FOXO1- and super enhancer–driven genes. 
Surprisingly, JQ1 did not decrease expression of PAX3–FOXO1 
mRNA at 6 hours, yet it rapidly decreased PAX3–FOXO1 pro-
tein stability. This may result from the disruption of interaction 
between BRD4 and PAX3–FOXO1, discovered by both coimmu-
noprecipitation and re-ChIP experiments, which JQ1 abrogated 
within hours of drug exposure. Thus, BRD inhibition by JQ1 
leads to significant tumor suppression in vitro and in vivo, ablating 
the transcription-driving function of the fusion gene. Indeed, this 
mechanism may partially explain the antitumor effects seen with 
BI-2536 in FP-RMS mouse models (54), as this PLK1 inhibitor 
was recently found to possess a nanomolar inhibition of BET 
bromodomains (55). Excitingly, this provides a means of selec-
tively drugging PAX3–FOXO1, a long-standing goal of FP-RMS 
research (56), and provides a new precision therapeutic for treat-
ment of the aggressive PAX fusion–bearing RMS.
METHoDS
Cell Lines and Primary Tumors
All cell lines were routinely tested for Mycoplasma within one or 
two passages of each experiment herein, and cell line identities have 
been ensured by RNA-seq and genotyping. RH4, RH3, RH5, and 
RH41 were kind gifts from Dr. Peter Houghton (obtained between 
2008 and 2010), SCMC from Dr. Janet Shipley (obtained between 
2013 and 2015), and RD, CTR, and Birch from Dr. Lee Helman 
(obtained between 2008 and 2010). CRL7250 and NIH3T3 were 
obtained from the ATCC (obtained between 2008 and 2010). Valida-
tion was performed by DNA fingerprinting AmpFlSTR Identifiler 
PCR Amplification Kit (Catalog Number 4322288) by Life Technolo-
gies. Cell lines were grown in DMEM, 10% FBS, and supplemented 
with penicillin/streptomycin. Primary RMS cultures established 
from patient-derived tumor xenografts were collected at the St. Jude 
Children’s Research Hospital (57). Cells were maintained in Neu-
robasal-A medium (ThermoFisher Scientific) supplemented with 2xB-
27 supplement (ThermoFisher Scientific), 20 ng/mL bFGF, and 20 
ng/mL EGF (both from PeproTech), and cultured on gelatin-coated 
plates in 5% CO2 at 37°C. Primary tumors were acquired via the 
NCI-coordinated ClinOmics protocol as previously described (58).
ChIP-seq and RNA-seq
ChIP-seq (59) and RNA-seq (3) were performed as previously 
described. Raw sequencing data and processed files have been made 
available through Gene Expression Omnibus (GEO) SuperSeries 
accession number GSE83728, which is comprised of SubSeries acces-
sion numbers GSE83724, GSE83725, GSE83726, and GSE83727. 
Details, including Illumina sequencing and bioinformatic methods, 
are available in Supplementary Methods.
DNase-seq with 10,000 Cells
Sites of DNase-sensitive chromatin were captured from 10,000 
cells as recently described (60) with slight modifications. Briefly, 
freshly trypsinized cells were resuspended in DMEM, counted in 
duplicate (Nexcelom Automated Cell Counter), pelleted and resus-
pended in lysis buffer to achieve 120 μL of 60K cells, which was then 
divided into 6 replicates (10K cells per tube). DNaseI (Roche 04-716-
728-001) was added to the cells (0.25–0.5 units) and incubated for 5 
minutes at 37°C. The digestion was halted with 50 μL of stop buffer 
(9.5 mL H2O + 100 μL 1M TrisHCl pH 7.4 + 20 μL 5 mol/L NaCl + 
200 μL 0.5 mol/L EDTA, with 150 μL 10% SDS and 125 μL protein-
ase K added just before use). Proteinase K activation at 55°C for 1 
hour was followed by DNA purification by column (MiniElute PCR 
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purification kit, Qiagen). Library preparation was performed as with 
ChIP-seq samples, except that paired-end was used rather than single-
end sequencing on the NextSeq 500 (Illumina).
Small-Molecule Compounds
All molecules were dissolved in DMSO to a final concentration of 
10 mmol/L and diluted to a final DMSO concentration of <0.03% 
by volume in DMEM for cell culture experiments. JQ1 was a gift 
from Jay Bradner (Novartis) and Jun Qi (Dana-Farber Cancer Insti-
tute). Bromosporine was provided by Peter Brown of the Structural 
Genomics Consortium. THZ1 was supplied by Nat Gray (Dana-
Farber Cancer Institute). Other bromodomain inhibitors (OTX015, 
I-Bet-151, I-Bet-762, and I-Bet-726) were generously supplied by the 
Developmental Therapeutics Program (NCI, NIH).
Time Course of Dose-Response Cell Growth Assay
Dose responses were performed by quantifying percent cell con-
fluence from phase contrast images taken every 4 hours using 
the IncuCyte ZOOM in 384-well plate format. Dose response was 
achieved using a range of 12 concentrations from 30 μmol/L to 
0.17 nmol/L (dilutions divided by 3) and were performed in trip-
licate. Cells were plated to achieve 15% confluence at time of drug 
dosing, and monitored until control (DMSO) wells reached >95% 
confluence. IC50 values were calculated for each time point using the 
R statistical package drc (https://cran.r-project.org/web/packages/
drc/drc.pdf).
Luciferase-Expressing Cells
pGreenFire vector from Systems Biosciences was modified by 
insertion of a cis-regulatory element surrounding the PAX3–FOXO1 
binding site within the super enhancer found within the intronic 
region of the ALK gene (chr2:29880537–29880842). Cloning was 
performed using pCR2.1–TOPO system from PCR amplification 
product from genomic DNA of RH4 FP-RMS cells, and shuttled into 
the pGF1 vector at the EcoRI restriction site upstream of a minimal 
CMV promoter, which was completely inactive on its own in RMS 
cell lines. Viral particles were produced in HEK293T cells, harvested, 
filtered, and pelleted. pGF1 cloning vectors developed at SBI are self-
inactivating as a result of a deletion in the U3 region of 3′-LTR. Upon 
integration into the genome, the 5′ LTR promoter is inactivated, 
which prevents formation of replication-competent viral particles. 
Pooled cells were selected using puromycin.
Animal Studies
Animal studies were approved by the National Cancer Institute’s 
Animal Care and Use Committee, and all animal care was in accord-
ance with institutional guidelines. Complete details are reported in 
Supplementary Methods.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Authors’ Contributions
Conception and design: B.E. Gryder, M.E. Yohe, H.-C. Chou, 
J.S. Wei, C.J. Thomas, J. Khan
Development of methodology: B.E. Gryder, H.-C. Chou, Y. Song, 
R. Rota, X. Wen, S. Sindiri, M. Ferrer, J.F. Shern, C.J. Thomas, J. Khan
Acquisition of data (provided animals, acquired and managed 
patients, provided facilities, etc.): B.E. Gryder, M.E. Yohe, X. Zhang, 
J. Marques, M. Wachtel, N. Sen, Y. Song, R. Rota, X. Wen, J.S. Wei, 
F.G. Barr, S. Das, T. Andresson, M. Lal-Nag, M. Ferrer, C.J. Thomas, J. Khan
Analysis and interpretation of data (e.g., statistical analysis, 
biostatistics, computational analysis): B.E. Gryder, H.-C. Chou, 
J. Marques, M. Wachtel, B. Schaefer, N. Sen, A. Cleveland, X. Wen, 
S. Sindiri, J.S. Wei, F.G. Barr, R. Guha, M. Lal-Nag, M. Ferrer, J.F. Shern, 
K. Zhao, C.J. Thomas, J. Khan
Writing, review, and/or revision of the manuscript: B.E. Gryder, 
M.E. Yohe, H.-C. Chou, B. Schaefer, N. Sen, R. Rota, J.S. Wei, 
F.G. Barr, R. Guha, M. Ferrer, J.F. Shern, K. Zhao, C.J. Thomas, J. Khan
Administrative, technical, or material support (i.e., reporting or 
organizing data, constructing databases): B.E. Gryder, H.-C. Chou, 
X. Wen, J. Khan
Study supervision: R. Rota, C.J. Thomas, J. Khan
Other (writing original manuscript): B.E. Gryder
Other (wet-lab investigation, providing materials): A. Gualtieri, 
S. Pomella
Acknowledgments
The authors are very grateful to C. Thiele, B. Stanton, J. Waterfall, 
L. Cao, T. Misteli, and C. Vakoc for helpful discussions and review 
of the manuscript. We are thankful to J. Qi, J. Bradner, N. Gray, P. 
Brown, the Structural Genomics Consortium, and the Developmen-
tal Therapeutics Program (NCI, NIH) for providing small molecules. 
We also appreciate the help of S. Li, N. Shivaprasad, S. Michael, and 
M. Skarzynski in providing reagents, cell lines, and antibodies. We 
thank C. Lin and R. Patidar for sharing scripts and bioinformatic 
advice.
Grant Support
This project has been funded with federal funds from the National 
Cancer Institute, NIH, contract no. HHSN261200800001E. A. Gual-
tieri is a recipient of a Fondazione Veronesi fellowship. R. Rota has 
been supported by Associazione Italiana Ricerca sul Cancro (AIRC) 
and PE-2013-02355271.
The content of this publication does not necessarily reflect the views 
or policies of the Department of Health and Human Services, nor does 
mention of trade names, commercial products, or organizations imply 
endorsement by the U.S. government. Frederick National Laboratory 
is accredited by AAALAC International and follows the Public Health 
Service Policy for the Care and Use of Laboratory Animals. Animal care 
was provided in accordance with the procedures outlined in the “Guide 
for Care and Use of Laboratory Animals” (National Research Council, 
2011; National Academies Press, Washington, DC).
Received November 19, 2016; revised March 20, 2017; accepted 
April 21, 2017; published OnlineFirst April 26, 2017.
REFERENCES
 1. Lee Tong I, Young Richard A. Transcriptional regulation and its mis-
regulation in disease. Cell 2013;152:1237–51.
 2. Rabbitts T. Chromosomal translocations in human cancer. Nature 
1994;372:143–9.
 3. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. 
Comprehensive genomic analysis of rhabdomyosarcoma reveals a 
landscape of alterations affecting a common genetic axis in fusion-
positive and fusion-negative tumors. Cancer Discov 2014;4:216–31.
 4. Chen X, Stewart E, Shelat Anang A, Qu C, Bahrami A, Hatley M, 
et al. Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma. 
Cancer Cell 2013;24:710–24.
 5. Riggi N, Knoechel B, Gillespie Shawn M, Rheinbay E, Boulay G, Suvà 
Mario L, et  al. EWS-FLI1 utilizes divergent chromatin remodeling 
mechanisms to directly activate or repress enhancer elements in 
ewing sarcoma. Cancer Cell 2014;26:668–81.
 6. Kadoch C, Crabtree Gerald R. Reversible Disruption of mSWI/SNF 
(BAF) Complexes by the SS18-SSX oncogenic fusion in synovial sar-
coma. Cell 2013;153:71–85.
 7. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 
Philadelphia: Lippincott Williams & Wilkins;  2015.
16-CD-16-1297_p884-899.indd   897 7/20/17   2:21 PM
Cancer Research. 
on August 23, 2018. © 2017 American Association forcancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst April 26, 2017; DOI: 10.1158/2159-8290.CD-16-1297 
Gryder et al.RESEARCH ARTICLE
898 | CANCER DISCOVERY August  2017 www.aacrjournals.org
 8. Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, 
Petel F, et al. PAX3/FOXO1 fusion gene status is the key prognostic 
molecular marker in rhabdomyosarcoma and significantly improves 
current risk stratification. J Clin Oncol 2012;30:1670–7.
 9. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, et  al. 
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA 
microarrays. Cancer Res 1998;58:5009–13.
 10. Davis RJ, Barr FG. Fusion genes resulting from alternative chromo-
somal translocations are overexpressed by gene-specific mechanisms 
in alveolar rhabdomyosarcoma. Proc Nat Acad Sci 1997;94:8047–51.
 11. Davicioni E, Graf Finckenstein F, Shahbazian V, Buckley JD, Triche 
TJ, Anderson MJ. Identification of a PAX-FKHR gene expression sig-
nature that defines molecular classes and determines the prognosis of 
alveolar rhabdomyosarcomas. Cancer Res 2006;66:6936–46.
 12. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, 
et al. cDNA microarrays detect activation of a myogenic transcription 
program by the PAX3–FKHR fusion oncogene. Proc Natl Acad Sci 
U S A 1999;96:13264–9.
 13. Bid HK, Phelps DA, Xiao L, Guttridge DC, Lin J, London C, et al. 
The bromodomain BET inhibitor JQ1 suppresses tumor angiogen-
esis in models of childhood sarcoma. Mol Cancer Ther 2016;15: 
1018–28.
 14. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rear-
rangement of the PAX3 paired box gene in the paediatric solid 
tumour alveolar rhabdomyosarcoma. Nat Genet 1993;3:113–7.
 15. Cao LA, Yu YK, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, 
et  al. Genome-Wide Identification of PAX3–FKHR binding sites in 
rhabdomyosarcoma reveals candidate target genes important for 
development and cancer. Cancer Res 2010;70:6497–508.
 16. Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky 
M, Yen A, et  al. Integrative analysis of 111 reference human epig-
enomes. Nature 2015;518:317–30.
 17. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. 
GREAT improves functional interpretation of cis-regulatory regions. 
Nat Biotechnol 2010;28:495–501.
 18. Begum S, Emani N, Cheung A, Wilkins O, Der S, Hamel PA. Cell-type-
specific regulation of distinct sets of gene targets by Pax3 and Pax3//
FKHR 2005;24:1860–72.
 19. Rao Suhas SP, Huntley Miriam H, Durand Neva C, Stamenova Elena 
K, Bochkov Ivan D, Robinson James T, et al. A 3D map of the human 
genome at kilobase resolution reveals principles of chromatin loop-
ing. Cell 2014;159:1665–80.
 20. Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, et al. 
The dynamics and regulators of cell fate decisions are revealed by 
pseudotemporal ordering of single cells. Nat Biotech 2014;32:381–6.
 21. Tenente IM, Hayes MN, Ignatius MS, McCarthy K, Yohe M, Sindiri 
S, et al. Myogenic regulatory transcription factors regulate growth in 
rhabdomyosarcoma. eLife 2017;6:e19214.
 22. Hnisz D, Abraham Brian J, Lee Tong I, Lau A, Saint-André V, Sigova 
Alla A, et al. Super-enhancers in the control of cell identity and dis-
ease. Cell 2013;155:934–47.
 23. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, 
et  al. Master transcription factors and mediator establish super-
enhancers at key cell identity genes. Cell 2013;153:307–19.
 24. Dukler N, Gulko B, Huang Y-F, Siepel A. Is a super-enhancer greater 
than the sum of its parts? Nat Genet 2017;49:2–3.
 25. Lin CY, Erkek S, Tong Y, Yin L, Federation AJ, Zapatka M, et al. Active 
medulloblastoma enhancers reveal subgroup-specific cellular origins. 
Nature 2016;530:57–62.
 26. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected 
cDNA converts fibroblasts to myoblasts. Cell 1987;51:987–1000.
 27. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein 
CB, et al. Mapping and analysis of chromatin state dynamics in nine 
human cell types. Nature 2011;473:43–9.
 28. Orlando David A, Chen Mei W, Brown Victoria E, Solanki S, 
Choi Yoon J, Olson Eric R, et  al. Quantitative ChIP-Seq normali-
zation reveals global modulation of the epigenome. Cell Reports 
2014;9:1163–70.
 29. Lin Charles Y, Lovén J, Rahl Peter B, Paranal Ronald M, Burge Chris-
topher B, Bradner James E, et  al. Transcriptional amplification in 
tumor cells with elevated c-myc. Cell 2012;151:56–67.
 30. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et  al. c-Myc is a 
universal amplifier of expressed genes in lymphocytes and embryonic 
stem cells. Cell 2012;151:68–79.
 31. Saint-André V, Federation AJ, Lin CY, Abraham BJ, Reddy J, Lee TI, 
et  al. Models of human core transcriptional regulatory circuitries. 
Genome Res 2016;26:385–96.
 32. Hettmer S, Wagers AJ. Muscling in: Uncovering the origins of rhabdo-
myosarcoma. Nat Med 2010;16:171–3.
 33. Kitamura T, Feng Y, Kitamura YI, Chua SC, Xu AW, Barsh GS, et al. 
Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin 
on food intake. Nature medicine 2006;12:534–40.
 34. Shi J, Vakoc Christopher R. The mechanisms behind the Therapeu-
tic Activity of BET Bromodomain Inhibition. Mol Cell 2014;54: 
728–36.
 35. Jones LH, Bunnage ME. Applications of chemogenomic library 
screening in drug discovery. Nat Rev Drug Discov 2017;16:285–96.
 36. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, 
et  al. Selective inhibition of BET bromodomains. Nature 2010;468: 
1067–73.
 37. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, et al. 
Targeting MYCN in neuroblastoma by BET bromodomain inhibi-
tion. Cancer Discovy 2013;3:308–23.
 38. Jang MK, Mochizuki K, Zhou M, Jeong H-S, Brady JN, Ozato K. The 
bromodomain protein Brd4 Is a positive regulatory component of 
P-TEFb and stimulates RNA polymerase II-dependent transcription. 
Mol Cell 2005;19:523–34.
 39. Lovén J, Hoke Heather A, Lin Charles Y, Lau A, Orlando David A, 
Vakoc Christopher R, et al. Selective inhibition of tumor oncogenes 
by disruption of super-enhancers. Cell 2013;153:320–34.
 40. Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. 
Cell 2017;168:629–43.
 41. Roe J-S, Mercan F, Rivera K, Pappin Darryl J, Vakoc Christopher R. 
BET bromodomain inhibition suppresses the function of hemat-
opoietic transcription factors in acute myeloid leukemia. Mol Cell 
2015;58:1028–39.
 42. Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, 
et  al. FGFR4 blockade exerts distinct antitumorigenic effects in 
human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer 
Res 2012;18:3780–90.
 43. Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pedi-
atric malignancies. Oncologist 2009;14:83–91.
 44. Abraham J, Nuñez-Álvarez Y, Hettmer S, Carrió E, Chen H-IH, Nishijo 
K, et al. Lineage of origin in rhabdomyosarcoma informs pharmaco-
logical response. Genes Deve 2014;28:1578–91.
 45. Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, 
et al. Histone deacetylase inhibitors induce growth suppression and 
cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 
2003;9:5749–55.
 46. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, et al. 
Therapeutic targeting of BET bromodomain proteins in castration-
resistant prostate cancer. Nature 2014;510:278–82.
 47. Chapuy B, McKeown Michael R, Lin Charles Y, Monti S, Roemer 
Margaretha GM, Qi J, et al. Discovery and characterization of super-
enhancer-associated dependencies in diffuse large B cell lymphoma. 
Cancer cell 2013;24:777–90.
 48. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff 
M, Chan WI, et  al. Inhibition of BET recruitment to chromatin as 
an effective treatment for MLL-fusion leukaemia. Nature 2011;478: 
529–33.
 49. De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, et al. 
PRC2 loss amplifies Ras-driven transcription and confers sensitivity 
to BRD4-based therapies. Nature 2014;514:247–51.
 50. Zuber J, Shi JW, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. 
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid 
leukaemia. Nature 2011;478:524–U124.
16-CD-16-1297_p884-899.indd   898 7/20/17   2:21 PM
Cancer Research. 
on August 23, 2018. © 2017 American Association forcancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst April 26, 2017; DOI: 10.1158/2159-8290.CD-16-1297 
PAX3–FOXO1 Establishes Super Enhancers and BRD4 Dependency RESEARCH ARTICLE
 August  2017 CANCER DISCOVERY | 899 
 51. Delmore Jake E, Issa Ghayas C, Lemieux Madeleine E, Rahl Peter B, 
Shi J, Jacobs Hannah M, et  al. BET bromodomain inhibition as a 
therapeutic strategy to target c-Myc. Cell 2011;146:904–17.
 52. Rathert P, Roth M, Neumann T, Muerdter F, Roe J-S, Muhar M, et al. 
Transcriptional plasticity promotes primary and acquired resistance 
to BET inhibition. Nature 2015;525:543–7.
 53. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of 
human lung adenocarcinoma cell lines to targeted inhibition of BET 
epigenetic signaling proteins. Proc Nat Acad Sci 2012;109:19408–13.
 54. Thalhammer V, Lopez-Garcia LA, Herrero-Martin D, Hecker R, Laub-
scher D, Gierisch ME, et al. PLK1 Phosphorylates PAX3–FOXO1, the 
inhibition of which triggers regression of alveolar rhabdomyosar-
coma. Cancer Res 2015;75:98–110.
 55. Ciceri P, Müller S, O’Mahony A, Fedorov O, Filippakopoulos P, Hunt 
JP, et al. Dual kinase-bromodomain inhibitors for rationally designed 
polypharmacology. Nat Chem Biol 2014;10:305–12.
 56. Linardic CM.PAX3–FOXO1 fusion gene in rhabdomyosarcoma. 
Cancer Lett 2008;270:10–8.
 57. Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, 
et  al. The childhood solid tumor network: a new resource for the 
developmental biology and oncology research communities. Devel 
Biol 2016;411:287–93.
 58. Chang W, Brohl A, Patidar R, Sindiri S, Shern JF, Wei JS, et al. Multi-
dimensional clinomics for precision therapy of children and adoles-
cent young adults with relapsed and refractory cancer: a report from 
the Center for Cancer Research. Clin Cancer Res 2016;22:3810–20.
 59. Barski A, Cuddapah S, Cui K, Roh T-Y, Schones DE, Wang Z, et al. 
High-resolution profiling of histone methylations in the human 
genome. Cell 2007;129:823–37.
 60. Jin W, Tang Q, Wan M, Cui K, Zhang Y, Ren G, et al. Genome-wide 
detection of DNase I hypersensitive sites in single cells and FFPE tis-
sue samples. Nature 2015;528:142–6.
16-CD-16-1297_p884-899.indd   899 7/20/17   2:21 PM
Cancer Research. 
on August 23, 2018. © 2017 American Association forcancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst April 26, 2017; DOI: 10.1158/2159-8290.CD-16-1297 
 122 
 
 
 
 
 
 
Chapter Three: 
Discussion 
Discussion
 ________________________________________________________________________________________________________ 
 
123 
 
Enhancers, the harbor of oncogenic transcription 
factors and their cofactors 
Transcription is commonly deregulated in cancer to support cell proliferation and 
transformation. Numerous oncogenes encode for transcription factors (TFs) and are 
recurrently mutated or overexpressed in cancer. For example, chromosomal translocations 
frequently result in chimeric TFs230,231 which bind to gene regulatory elements and disrupt 
gene expression programs. 
Gene regulatory elements fall into three basic categories (Fig. 23): promoters, enhancers, 
and insulators. Promoters lie within 100 to 1000 bp from the TSS (transcription start site) 
and allow the assembly of basal transcription machinery. Enhancers are distal elements that 
control promoter activity by recruiting TFs and cofactors. Insulators do not directly 
influence gene expression, but they delimitate the regions of influence of enhancers232.  
The two pediatric cancers studied above are the result of the activity of two aberrant fusion 
TFs. Fusion-positive rhabdomyosarcoma (FP-RMS) is driven by PAX3-FOXO1 and Ewing 
sarcoma (ES) by EWS-FLI1. To further understand how these TFs control gene expression, 
we need to investigate their genome localization and identify their transcription cofactors. 
  
Promoter 
Enhancer 
Insulator 
Fig. 23 Gene regulatory elements. Adapted from232. 
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1. Characterizing the epigenetic landscape of pediatric sarcomas 
Post-translational modifications (PTMs) of histones demarcate the functional elements of 
the genome (Fig.24). By performing chromatin-immunoprecipitation assays followed by 
DNA sequencing (ChIP-seq), we can assess the location of the different histone marks and 
subdivide the chromatin into its different regulatory elements163. Then, we can localize TFs 
and cofactors within the regulatory elements by overlaying their ChIP-seq signal. 
Our ChIP-seq assays, performed with a monoclonal antibody against PAX3-FOXO1 
breakpoint in FP-RMS cell lines, confirmed the previously described localization of PAX3-
FOXO1 to distal enhancers233. In addition, we observed that most of the super-enhancers 
(SEs) present in FP-RMS are occupied by the fusion protein.  
SEs (Fig.25) are defined as clusters of enhancers that span through large regions of DNA. 
They are densely decorated by the activation marks H3K27ac and H3K4me1, the mediator 
complex, the bromodomain-containing protein BRD4, and cell-type-specific TFs. Although 
the role of SEs as a new element of transcription regulation is still debatable234, they are 
usually associated with the control of gene expression related with cell identity, while 
regular/typical enhancers are associated with the control of genes common to a variety of 
cell types235,236. In agreement with this definition, we found that in FP-RMS SEs are highly 
occupied by the master transcription factors of myogenesis, MYOD1 and MYOG, as well as 
by BRD4, p300 and the mediator complex. In addition, most of the SEs found in FP-RMS cells 
were also co-occupied by the NuRD members HDAC2, RBBP4, and CHD4.  
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Fig. 24 The differential distribution of histone marks and proteins in the genome and their association with the 
gene regulatory domains. Adapted from163. 
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The presence of NuRD in enhancers and super-enhancers has been already described in 
many cells, such as breast cancer or embryonic stem cells237–241. Hence, it has been proposed 
that rather than being recruited by TFs, NuRD has a general affinity to open chromatin. 
In parallel, similar studies performed by others in Ewing sarcoma have identified that the 
fusion protein EWS-FLI1 binds also to enhancers together with p300 and BRD4. In addition, 
this fusion protein recruits the chromatin remodeler complex BAF and the component of 
the MLL complex WDR5 to active enhancers242–244.  
 
2. Enhancer regulation is essential for tumorigenesis  
It is well-known that oncogenic fusion proteins, like PAX3-FOXO1 and EWS-FLI1, are not 
only unique to their tumor types but also are essential for tumor survival17. Transcriptomic 
studies demonstrate that their relevance in tumorigenesis is caused by the target genes they 
regulate, which control cell proliferation, invasiveness, and survival33,100. Now, a growing 
interest in epigenetic gene expression regulation has provided clues of how these oncogenic 
TFs drive their gene expression signatures. 
Here, we report that PAX3-FOXO1 fusion establishes new enhancers and super-enhancers 
together with the master regulators MYOD1, MYOG, and MYCN. In fact, PAX3-FOXO1 
depletion reduces the abundance of the enhancer and activation mark H3K27ac and deeply 
affects enhancer-driven transcription, specially the one of SEs. Consequently, oncogenes, 
such as ALK and MYCN, are downregulated which leads to tumor cell death. Similarly, in 
Ewing sarcoma, the fusion protein EWS-FLI1 not only binds to enhancers but also is able to 
establish de novo enhancers that drive tumorigenesis242,245. Unlike PAX3-FOXO1, which 
mainly activates gene expression, EWS-FLI1 can both activate or repress transcription 
depending on the underlying DNA sequence. Hence, EWS-FLI1 depletion can both increase 
or decrease the presence of H3K27ac at enhancers. Activated targets, including CCND1, 
NKX2-2, EZH2, and SOX2, become repressed and repressed genes, like the known tumor 
suppressors ERRFI1, CABLES1, IER3, and TGFBI, become activated. These changes in gene 
expression are then the cause of cell death upon fusion protein silencing. 
Housekeeping genes Cell-identity genes 
Fig. 25 The structure of typical enhancer versus super-enhancer. Adapted from232. 
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3. Enhancer targeting as a therapeutic strategy 
The dependence of these and other tumors on the expression signatures of their driver 
oncogenic TFs opens new possibilities for targeted therapy. In fact, targeting transcription 
regulators, although they are broadly expressed in healthy cells, affects oncogenic 
expression and cancer cells more than healthy cells143. For example, inhibition of cyclin-
dependent kinase 7 (CDK7) by THZ1 particularly disrupts MYCN-driven transcription in 
neuroblastoma cells, and, consequently, inhibits tumor growth246. Small cell lung cancer is 
also sensitive to THZ1 treatment which deeply impairs the expression of the oncogenic TF 
MYC and other TFs like SOX2, SOX4 and OTX2247.  
SE-associated genes are especially sensitive to perturbations of the transcriptional 
regulators that populate them. A CRISPR screen in murine embryonic stem cells showed 
that SEs are dependent on basically all the epigenetic regulators that bind to them to drive 
gene expression248. The loss of the mediator complex in embryonic stem cells  preferentially 
affects genes regulated by SEs and not housekeeping genes, which are controlled by typical 
enhancers236. Pharmacological inhibition of BRD4 also drastically impacts the expression of 
oncogenes associated with SE and impairs tumor progression in different cancers249–251. In 
multiple myeloma, BRD4 inhibition leads to its displacement from SEs, impaired SE-driven 
oncogene expression, including MYC, and consequent decrease of cell proliferation252. In 
acute myeloid leukemia (AML), BRD4 depletion removes the mediator complex from 
enhancers and suppresses the transcription of MYB target genes250. Large B-cell lymphoma 
is also susceptible to BRD4 inhibition which, by diminishing SE-driven transcription, 
impairs the transcriptional programs of MYC and E2F251.  
Here, we showed that BRD4 depletion caused a preferential decrease of SE-driven gene 
expression in FP-RMS, as described for other tumors. Moreover, treatment of FP-RMS cell 
lines with the BRD4 inhibitor JQ1 drastically affected PAX3-FOXO1 target gene signature 
and impaired tumor growth. Similar findings were observed for CHD4 depletion. Silencing 
of this chromatin remodeler deeply impaired the SE-driven expression of PAX3-FOXO1 
targets. This consequently led to tumor cell death in vitro and tumor regression in vivo. To 
our knowledge, this is the first report that associates CHD4 with the disruption of SE-
associated gene expression in cancer. These findings make both CHD4 and BRD4 possible 
targets for FP-RMS therapy.  
Ewing sarcoma is also dependent on CHD4 and BRD4. Recent data showed that both genetic 
depletion or pharmacological inhibition of BRD4 impaired enhancer-driven expression of 
EWS-FLI1 target genes, decreased cell viability and delayed tumor growth244,253–255. As 
observed in FP-RMS, JQ1 treatment removed BRD4 from the chromatin. These results 
suggest a very similar effect of BRD4 inhibition in FP-RMS and ES.  
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Since CHD4 was shown to co-regulate the expression of repressed targets of EWS-FLI1112, 
we hypothesize that, similarly to FP-RMS, CHD4 is required for EWS-FLI1 gene expression 
regulation at enhancers. In fact, our results showed that CHD4 depletion causes a drastic 
decrease in ES cell viability and reduces tumor growth, which makes CHD4 not only a 
possible therapeutic target in FP-RMS but also in Ewing sarcoma. Currently, we are 
collecting data to support the function of CHD4 as an EWS-FLI1 coregulator of enhancer 
driven gene expression. We will perform ChIP-seq assays to identify the genome localization 
of CHD4. Then, we will correlate EWS-FLI1 location with the one of CHD4 and perform RNA-
seq assays to evaluate the effect of this chromatin remodeler in EWS-FLI1 target genes. 
Since, EWS-FLI1 regulates both gene activation and repression, it will be interesting to know 
if CHD4 participates in one of these processes or both. Nevertheless, data gathered by us 
and others support CHD4 and BRD4 as possible therapeutic targets in these two childhood 
malignancies. 
 
4. CHD4 a regulator of enhancer accessibility  
Previously published work has already localized CHD4 to enhancers240, but the role it plays 
in those locations has not been clarified yet. Cooperation between CHD4 and transcription 
factors in gene expression regulation has also been described, although the exact 
mechanism by which CHD4 contributes to gene expression has not been elucidated. During 
differentiation of T helper 2 cells, Chd4 forms complexes with the TF Gata3 which are able 
to either activate or repress gene expression208. In glioblastoma, CHD4 interacts with the TF 
ZFHX4 and regulates gene expression related with stem cell-like functions and 
tumorigenicity256. Here, we reported that CHD4 is able to physically interact with the fusion 
PAX3-FOXO1 in FP-RMS, while others have described an interaction between CHD4 and 
EWS-FLI1 in ES112. 
CHD4 is a member of the SNF2 family and has ATP-dependent nucleosome disruption 
activity similar to the one of the BAF complex175, meaning that it is able to control 
nucleosome-spacing170. Due to its remodeling function, we wondered if CHD4 functioned by 
keeping the chromatin open and permissive to the binding of TFs and cofactors to 
enhancers. DNase hypersensitivity assays demonstrated that CHD4 silencing deeply affects 
the DNA accessibility at SE which results in a decrease of the ChIP signal of PAX3-FOXO1 
and of its cofactor BRD4 at those locations. These results suggest that CHD4 is necessary to 
keep the chromatin available to the binding of the transcription machinery (Fig.26). 
Similarly, in mouse embryonic stem cells, CHD4 was also found to regulate the positioning 
of the TF Sall4238. There, the dissolution of the NuRD complex, and consequent loss of CHD4 
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remodeling activity, also conditioned the access of transcription factors to regulatory 
sequences241.  
Additionally, we found that CHD4 interacts with BRD4. These results suggest that these 
proteins might collaborate in the regulation of SE-driven transcription. Interestingly, a 
direct physical interaction between CHD4 and the extra-terminal (ET) domain of BRD3 has 
already been reported257. Due to the high conservation of the ET domain, a similar binding 
interaction might occur between CHD4 and BRD4.  
Since BRD4 exerts partially its function in transcription activation by controlling RNA Pol 2 
pause release258, and since CHD4 interacts with it, we will further investigate if CHD4 plays 
a role in Pol2 pause release as well. In fact, silencing of Chd4 in mouse embryonic stem cells 
was shown to decrease Pol2 levels from active promoters259. To evaluate the effect of 
chromatin remodeling in Pol2 positioning in FP-RMS genome, we will track Pol2 location by 
performing ChIP-seq assays in the presence and absence of CHD4. 
In Ewing sarcoma, we observed that CHD4 interacts also with BRD4 in ES cell lines (data 
not shown). Moreover, BRD4 in ES exists in a large protein complex together with EWS-
FLI1, RNA Pol2 and Mediator244. These results suggest a similar mechanism of gene 
regulation between ES and FP-RMS, where CHD4 and BRD4 collaborate to regulate the 
fusion protein activity.   
 
5. Lessons learnt from CHD4 transcriptomics in FP-RMS 
The role of CHD4 in gene expression regulation is so far ambiguous and seems to be 
dependent on the context, meaning on which cofactors interact with CHD4. In T helper 2 
cells, Chd4 activates gene expression together with p300 and represses it together with 
other members of NuRD208. In colon cancer, it collaborates with DNMTs at promoter regions 
to silence tumor suppressor genes through DNA methylation260,261. In mouse embryonic 
stem cells, Chd4 is required for transcription driven from active promoters while it 
represses the one from bivalent promoters259.   
Fig. 26 Proposed mechanism of CHD4 action in PAX3-FOXO1 (P3F) containing 
enhancers 
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In FP-RMS, we found that CHD4 silencing leads to upregulation and downregulation of 
approximately the same number of genes, suggesting a both activating and repressive role. 
A study of CHD4 in 293 cells also revealed that it can equally activate and repress gene 
expression187. The changes described above in chromatin architecture and cofactor binding 
at SE suggest a direct effect of CHD4 on gene activation in FP-RMS. Co-immunoprecipitation 
assays demonstrated that CHD4 also interacts with the PRC2 members EZH2 and SUZ12 in 
FP-RMS (data not shown), which could imply that CHD4 might control transcription 
repression through PRC2. Indeed, during astroglial differentiation Chd4 interacts with Ezh2 
to suppress the expression of the key astrogenic marker Gfap212.  
Gene set enrichment analysis showed that the FP-RMS signature was highly affected by 
CHD4 depletion. Moreover, enhancer-driven gene expression was negatively correlated 
with CHD4 silencing, which supports the described role of CHD4 in SE regulation. 
Genes related with development (e.g. components of the BMP pathway) and myogenesis 
(e.g. Myl1) were also found among the CHD4 signature. This is in agreement with the 
growing evidence that shows that CHD4 plays a key role during muscle differentiation and 
facilitates lineage specification.  During muscle differentiation, this chromatin remodeler, 
through binding to distal regulatory regions, directly regulates the expression of genes 
required for cardiac muscle development211. Embryos without CHD4 can form a normal 
early blastocyst but are unable to successfully complete the first lineage decision and form 
trophectoderm, which prevents implantation and leads to embryo lethality262. In other 
cellular contexts, CHD4 has also been associated with cell-fate. During lymphocyte 
development, the TF Ikaros binds to active regions with CHD4 and to regulates its function. 
In fact, upon silencing of Ikaros, CHD4 genome location changes which produces alterations 
in chromatin architecture and decreases the expression of lymphoid cell-specific gene 
expression which enables the progression of the leukemic state263.  
Surprisingly, CHD4 transcriptomic data revealed that this chromatin remodeler controls the 
expression of known EWS-FLI1 target genes in FP-RMS. This result allowed us to speculate 
that the similarities between both ES and FP-RMS go beyond their pediatric presentation. 
In fact, despite the many efforts to identify the oncogenic signature of these sarcomas, it is 
still not known which PAX3-FOXO1 or EWS-FLI1 target genes are responsible for cell 
transformation. The discovery of a common gene signature among these tumors could help 
to elucidate this question.  
The function of the NuRD complex in FP-RMS 
The NuRD complex is uniquely characterized by two enzymatic functions: ATP-dependent 
chromatin remodeling, carried out by CHD3 or CHD4, and histone deacetylase activity, 
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performed by HDAC1/2. More recently, it has been shown that the lysine-specific histone 
demethylase 1 (LSD1) is also be associated with the this complex in certain cell types264. 
Other non-enzymatic subunits include methyl-CpG-binding domains (MBD2/3), metastasis-
associated proteins (MTA1/2/3), retinoblastoma-binding proteins (RBBP4/7), and 
GATAD2A/B201. Multiple functions have been attributed to NuRD and it is so far thought that 
combinatorial assembly of the non-enzymatic subunits confers functional specificity.  
 
1. CHD4 dependency on NuRD 
Although CHD4 is many times described as a core member of the complex, a recent 
publication has defined it as a peripheral subunit. In that report, the authors demonstrate 
the existence of a NuDe complex to which CHD4 can bind to reconstitute the NuRD265. In 
addition, it was already shown that CHD4 can function as an ATPase by itself195,196.  
Our results show that CHD4 co-localizes with PAX3-FOXO1 to enhancers together with the 
NuRD members HDAC2 and RBBP4. Moreover, BRD4 not only interacts with CHD4 but also 
with the NuRD members HDAC1/2 and MTA2. Since CHD4 depletion deeply affects FP-RMS 
cell viability, we hypothesized that if its activity was dependent on NuRD, the dissolution of 
the complex would also lead to cell death. To test this, we performed a NuRD-centered 
CRISPR screen and found that knockout of RBBP4, HDAC1, and GATAD2A/B decreased FP-
RMS cell proliferation. RBBP4 and HDAC1 are found in other remodeling complexes besides 
NuRD178. Hence, the results from our NuRD screen might reflect the effect of other 
complexes. Furthermore, unlike CHD4 depletion, silencing of RBBP4 did not affect the 
expression of PAX3-FOXO1 target genes nor did it cause tumor cell death. The effect on cell 
viability upon HDAC1 knockout is in agreement with the antiproliferative effect of HDAC 
inhibitors in FP-RMS described in the literature266–268. Nonetheless, these inhibitors seem to 
act in a ROS-dependent manner and independently of a direct effect on the chromatin266.  
These results support a different function of HDAC1 and RBBP4, in comparison with CHD4, 
in FP-RMS cell proliferation. 
Interestingly, in mouse embryonic stem cells, in the absence of nuclear Mbd3 Chd4 remains 
only associated with Gatad2b in the nucleus241. Moreover, re-establishing nuclear Mbd3 did 
not affect the chromatin localization of CHD4241. These findings support a NuRD-
independent function of CHD4 and could explain why we observe an effect upon 
GATAD2A/B knockout but not with other NuRD members. Moreover, GATAD2A/B, like 
CHD4, have been described as peripheral members of the NuRD269.  
The NuRD complex is formed by an assembly of binary complexes, one containing the MTA, 
HDAC, and RBBP subunits and the other with MBD and GATAD2186. The MBDs are mutually 
exclusive in NuRD and commonly referred as the core members of the complex179,269. Thus, 
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the absence of any effect upon knockout of the MTA or MBD proteins suggests that the cell 
death phenotype observed upon CHD4 silencing in FP-RMS is independent of the assembly 
of the NuRD complex.  
 
2. A CHD4-free NuRD complex localizes to promoters in FP -RMS 
In FP-RMS, the localization of the NuRD components HDAC2 and RBBP4 highly correlates 
with histone activating marks H3K27ac, H3K4me1, and H3K4me3. This correlation was also 
observed in mouse embryonic stem cells (ESCs)241. We observed that the ChIP peaks of 
CHD4 and HDAC2+RBBP4 did not overlap completely. This pattern was also observed by 
others241 and is consistent with the already described NuRD-independent function of CHD4. 
Curiously, the CHD4-free HDAC2+RBBP4 regions were highly enriched in the promoter 
mark H3K4me3 (Fig.27). The absence of CHD4 from promoters is in line with the fact that 
methylation of H3K4 inhibits the binding of the PHD domains of CHD4 to histones193,194. 
Nevertheless, it is contradictory to other studies where, in other cellular contexts, NuRD-
containing CHD4 was shown to localize to promoters as well as enhancers 209,214,241,263,270–
272. 
Since CHD4 and CHD3 are mutually exclusive subunits of the complex, the promoter regions 
enriched in HDAC2 and RBBP4 might represent CHD3-containing NuRD locations. In fact, 
studies have shown that CHD3 and CHD4 have distinct nuclear localization and also carry 
different remodeling activities187.  
The NuRD occupied promoters regulated the expression of genes related to housekeeping 
functions such as RNA splicing and ribosome biogenesis. Housekeeping and developmental 
gene expression are known to be differently regulated273,274. Our data suggests that 
enhancers related with development and muscle differentiation are occupied by CHD4, 
while promoters involved in cell homeostasis contain CHD4-free NuRD, which can explain 
the lack of effect in cell proliferation upon NuRD disruption.  
 
Fig. 27 Scheme of CHD4-free NuRD presence in promoters. 
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3. NuRD, a repressor and activator 
NuRD is classically defined as a repressor, and many published papers corroborate this. At 
poised genes, NuRD deacetylates H3K27 enabling the recruitment of PRC2 and subsequent 
gene repression by methylation of H3K27209. In human oral squamous cell carcinomas, 
NuRD opposes the SWI/SNF complex and again deacetylases H3K27 which leads to the 
binding of PRC2 and KDM1A, followed by H3K27 methylation and H3K4 demethylation272. 
Nevertheless, a gene expression activation capacity has also been attributed to this complex. 
NuRD collaborates with the TF GATA1 for activation and repression of its target genes207. 
More recently, a role in fine-tuning gene expression has also been described for NuRD. In 
ESCs, NuRD is found in promoters of actively transcribed genes and is required there to 
restrict the expression of pluripotency-associated genes, rather than to repress it 
completely214. Hence, NuRD can attenuate the expression of such genes and keeps them 
responsive to differentiation signals. Another study in mouse ESCs claims that NuRD 
presence in active enhancers and promoters is essential to fine-tune gene expression 
response to outside signals and allows proper lineage commitment. Indeed, loss of Mbd3, 
and consequent dissolution of NuRD, results in only moderate changes in gene 
expression241. Similarly, another study showed that NuRD binds to promoters of rRNA 
(ribosomal RNA) and keeps them poised but permissive to transcription activation. In that 
study, knockdown of CHD4 impaired the association of Pol I with rDNA and inhibited rRNA 
synthesis275.  
In FP-RMS, we found NuRD components in active promoters of housekeeping genes, but it 
was not clear if the presence of CHD4-free NuRD in those regions acts to restrict 
transcription, as suggested in previous studies. NuRD components were also present in 
active enhancers. There, our results show that silencing of RBBP4 did not affect the 
expression of genes related to those enhancers, suggesting that NuRD does not play an 
active role there. Nonetheless, we cannot exclude that RBBP4 depletion is perhaps not 
enough to dissolve the NuRD complex. Thus, studies on other NuRD members are necessary 
to validate this conclusion. 
 
4. NuRD in Ewing sarcoma 
The transcriptional repressive activity of EWS-FLI1 seems to be dependent on NuRD112. The 
fusion protein interacts with the NuRD members HDAC1, CHD4, and MTA2, and HDAC 
inhibition reduces c-MYC and EWS-FLI1 levels and leads to re-expression of neuronal 
differentiation markers276. In addition, pharmacological inhibition of HDACs reduces ES cell 
proliferation, impairs colony formation, and induces apotosis276,277. In addition, a high-
throughput small molecule screen demonstrated that HDAC inhibitors diminish 
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accessibility at EWS-FLI1 target sites and disrupt the fusion protein-mediated 
transcription278. These results led to the advance of these inhibitors into clinical trials. In 
fact, phase I trials have already shown that Pracinostat is reasonably well tolerated in 
children with refractory Ewing sarcoma279. Besides direct effect on gene expression, HDAC 
inhibitors may also work by regulating p53 function. In fact, HDAC1 interacts with p53 and 
keeps it deacetylated and inactive280. 
Another member of NuRD that affects Ewing sarcoma is LSD1. Pharmacological inhibition 
of LSD1 affects both activated and repressed EWS-FLI1 target genes281.  This effect seems to 
be EWS-FLI1-dependent since LSD1 inhibition in HEK cells had no effect in selected EWS-
FLI1 target genes112. In addition, LSD1 inhibition decreases ES cell proliferation, induces 
apoptosis, and reduces tumor growth in a xenograft mouse model281. 
As previously stated, we demonstrated that silencing of CHD4 in Ewing sarcoma leads to 
cell death and tumor regression, but we do not know if this phenotype is related to NuRD. 
To investigate this, we are currently performing ChIP-seq assays not only for CHD4 but also 
for HDAC2 and RBBP4 to identify the location of NuRD in Ewing sarcoma. Moreover, we are 
performing a similar NuRD-centered CRISPR screen in ES cell lines to analyze the 
vulnerability of this tumor to the NuRD subunits. Then, we will associate the phenotypical 
effects observed upon CHD4/NuRD knockout to their genome location and their 
relationship with the fusion protein EWS-FLI1. At last, we will identify genes coregulated by 
CHD4 and the fusion by RNA-seq and correlate them to alterations in chromatin 
accessibility obtained by DNase hypersensitivity assays. These experiments will allow us to 
understand if the role played by CHD4 in Ewing sarcoma is similar to the one that we 
described for this remodeler in FP-RMS. 
Targeting CHD4 
We have shown that CHD4 causes tumor cell death in FP-RMS and Ewing sarcoma. In 
addition, we showed that CHD4 depletion had no effect on cell proliferation of healthy 
human myoblasts and fibroblasts. These results were exciting and revealed a tumor specific 
susceptibility to this chromatin remodeler, which was confirmed by other authors. A RNAi 
screen identified CHD4 as an essential gene in breast cancer with no effect on cell 
proliferation of non-transformed mammary epithelial cells (MCF10A)282. Another study has 
shown that CHD4 is required for the maintenance of childhood acute myeloid leukemia but 
not for the proliferation and survival of normal primary hematopoietic cells283. These 
studies demonstrate the potential of CHD4 as a drug target. 
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1. Structure-based drug design 
CHD4 is composed of a C-terminal ATPase, 2 plant homeodomains (PHD1/2), 2 
chromodomains and 2 C-terminal domains of unknown function (DUF)190.  The 
chromodomains bind directly to DNA, while the PHD domains interact with histones191. 
High resolution structure information, mainly NMR based, is available for both 
chromodomains and PHD domains193,284 but not for the ATPase, most likely due to its high 
complexity and molecular weight which makes protein purification and NMR studies more 
difficult. All proteins from the SNF2-like family166,169,171, which carry a diversity of essential 
physiological roles, have similar ATPase domains. This would make the design of specific 
inhibitors targeting the ATPase domain of CHD4 possibly unfeasible.  
The ATPase activity of CHD4 is dependent on the simultaneous binding of the PHD domains 
to histones195,196 and of the chromodomains to DNA, which suggests that targeting either the 
PHDs or chromodomains might impair CHD4’s remodeling activity. Since protein-DNA 
interactions are difficult to inhibit with small molecules and inhibitors of  histone reader 
domains have already been successfully developed, as exemplified by the case of the BRD4 
bromodomain inhibitor JQ1226, we decided to target the reader domains of CHD4, more 
specifically its second PHD domain as it has higher affinity to the histone tail than PHD1285. 
Plant homeodomains (PHDs) are small (circa 65 residues) zinc-finger reader domains that 
can recognize and bind to different histone marks286. The PHD domains of CHD4 recognize 
the N-tail of histone 3, with increased affinity when Lys9 is methylated or acetylated192–194. 
This domain fold is quite loose, with a short two-stranded antiparallel β-sheet, a short C-
terminal α-helix, and three unstructured loops287. This minimal fold is maintained by the 
Zinc ions and conserved hydrophobic residues that form a small hydrophobic core288. The 
histone-binding surface of the PHD finger is shallow and polar. Therefore, while still deemed 
feasible targets for structure-based drug design efforts, PHD fingers are very difficult 
targets289. Indeed, only a few reports of successful efforts in identifying inhibitors of H3K4-
binding PHD fingers are available290,291.  
Our in silico efforts gathered a library of 105 candidate PHD2-CHD4 ligands which were 
validated by NMR binding assays, based on protein and ligand observation. One compound, 
DSP_C42_003, showed weak binding capability towards the PHD2 domain. Although this 
ligand should undergo optimization cycles in order to improve its binding affinity, this is the 
first small molecule binder of a H3K9-binding PHD domain and also the first CHD4 
candidate inhibitor identified. We believe that this study represents a first attempt on 
targeting CHD4 and that it suggests the feasibility of structure-based drug design as a means 
to develop inhibitors against difficult targets such as PHD domains. 
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Chromatin remodelers in cancer therapy 
Cancer is a very heterogenous disease with a high degree of variability within tumor types, 
which makes it difficult to find common drug targets. Nevertheless, many studies have been 
carried out to identify essential genes to which the tumor cell might be vulnerable292.  
BET-bromodomains inhibitors cause drastic decreases in cell proliferation in many cancer 
types, which has brought attention to epigenetics as a promising field for cancer therapy. 
Since its development, the BRD4 inhibitor JQ1 has been shown, in vitro and in vivo, to affect 
many hematological malignancies and a variety of solid tumors such as glioblastoma, 
medulloblastoma, hepatocellular carcinoma, colon cancer, pancreatic cancer, prostate 
cancer, lung cancer, and breast cancer293. Two phase I clinical trials were performed to test 
the BET-bromodomain inhibitor OTX015, which targets BRD2, BRD3, and BRD4, in patients 
with myeloma, lymphoma and acute myeloid leukemia. These trials showed an acceptable 
toxicity and a good therapeutic response for some patients, although no predictor markers 
were found294,295. These studies show that, despite the broad expression of these 
bromodomains, we are still able to find therapeutic windows for treatment with epigenetic 
inhibitors. 
Despite the growing evidence that chromatin remodelers play important roles in cancer, 
they have been so far overlooked as drug targets. Here, we describe in detail the mechanism 
by which the chromatin remodeler CHD4 influences FP-RMS and provide concrete evidence 
of its potential as a drug target for both FP-RMS and ES. Other tumors, like synovial sarcoma, 
also have their tumorigenesis process dependent on chromatin remodeling. Synovial 
sarcoma is a pediatric malignancy driven by the aberrant fusion protein SS18-SSX296. Unlike 
PAX3-FOXO1 and EWS-FLI1, SS18-SSX does not have a DNA binding sequence. 
Nevertheless, it is able to reshape gene expression by interacting with the chromatin 
remodeler BAF complex and reverse Polycomb-mediated gene repression297,298. Hence, we 
decided to take a closer look at chromatin remodelers as potential drug targets. 
 
1. CHD4 as a broad cancer susceptibility  
We took advantage of two publicly available databases of tumor susceptibilities, Achilles 
and DRIVE, to identify cancer sensitivities to chromatin remodelers. Achilles database is a 
project of the BROAD Institute aimed at identifying essential cancer genes by using genome-
scale CRISPR/Cas9 technology to knockout thousands of individual genes in 391 cancer cell 
lines. Since the Achilles project is still ongoing, the number of guide RNAs used per target 
varies. The DRIVE is a project of Novartis which shares the same goal as the Achilles, but 
uses 20 shRNAs per target, instead of CRISPR, in 387 cancer cell lines299.  
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The analysis of all SNF2-like ATPases present in chromatin remodelers in those two 
platforms clearly identified CHD4 as a new tumor susceptibility189. We observed that CHD4 
depletion, like the one of BRD4, impaired tumor cell viability in virtually all cancer cells 
analyzed in both projects (in the DRIVE database 323 out of 387 and in the Achilles database 
386 out of 391 cancer cell lines). This astonishing result is in line with published data where 
CHD4 silencing was shown to affect breast cancer282, glioblastoma300, acute myeloid 
leukemia283, liver cancer301, lung cancer302, and colorectal cancer260,261. Furthermore, CHD4 
is rarely found mutated in cancer216, which is an indicator of tumor dependency. 
Nevertheless, a missense single nucleotide variation (SNV) found in the N-terminal of CHD4 
was associated with lung cancer, malignant lymphoma, rectum cancer, and to interact with 
smoking in order to confer it a higher risk. Of note, this SNV did not affect neither the ATPase 
nor the PHD domains of CHD4, and its implications in CHD4 function are yet to be 
described303. In addition, in colorectal cancer and hepatocellular carcinoma, CHD4 levels are 
correlated with a poorer prognosis260,301. In glioma, amplification of the CHD4 gene, which 
results in CHD4 overexpression, is also associated with an increase in the recurrence rate304. 
A correlation with prognosis was not detected by our studies in FP-RMS.  
The mechanism of dependence to CHD4 may vary in the different tumors. Colorectal cancer 
depends on CHD4 since it mediates the silencing of tumor suppressor genes by recruitment 
of DNMTs and EZH2260. In glioblastoma, CHD4 permits the transcription driven by the 
tumor-associated TF ZFHX4256. In acute myeloid leukemia, CHD4 depletion induces 
transcription alterations that impair colony formation305. Here, we have revealed a 
transcriptional addiction of FP-RMS to CHD4. Besides the implications of CHD4 in 
transcription, other functions might be also related to its vast tumor susceptibility. For 
example, CHD4 has been highly associated with DNA-damage repair. In fact, CHD4 depletion 
leads to the accumulation of spontaneous DNA damage, increased ionizing radiation 
sensitivity, and impaired homologous recombination repair198,199.  
CHD4 inhibition could also be used in combination therapy. In hepatocellular carcinoma, 
CHD4 knockdown increases chemosensitivity to epirubicin301 and, in acute myeloid 
leukemia, it leads to a global relaxation of chromatin which renders the cell more 
susceptible to double-strand breaks and to the genotoxic action of agents such as 
daunorubicin and cytarabine305. 
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In conclusion (Fig.28), we have identified a new general tumor dependency to the 
chromatin remodeler CHD4. Importantly, we and others have shown that healthy cells are 
not susceptible to CHD4 inhibition, which makes it a promising target for therapy. In 
addition, our studies in FP-RMS revealed a new function of CHD4 in the regulation of SE-
driven oncogene expression which might explain the vulnerability of transcriptionally 
addicted cancers to CHD4. At last, we initiated the development of the first CHD4 inhibitor 
by studying the feasibility of targeting one of its PHD reader domains. This work puts CHD4 
side-by-side with BRD4 as a prominent tumor target and hopefully will motivate the drug 
discovery field to look at CHD4 as promising new cancer target.  
Fig. 28 Tumor susceptibility to CHD4. Many tumor types overexpress CHD4 in comparison to 
healthy cells. CHD4 depletion seems to not affect the proliferation of the healthy cells but to 
cause tumor cell death, possibly by apoptosis. 
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List of abbreviations 
ALL – acute lymphoblastic leukemia 
AML – acute myeloid leukemia 
aRMS – alveolar rhabdomyosarcoma 
BET – bromodomain and extra-terminal 
bp – base pairs 
BRD4 – bromodomain-containing protein 4 
CHD4 – chromodomain-helicase-DNA binding protein 4 
ChIP-seq – chromatin immunoprecipitation and sequencing 
CML – chronic myeloid leukemia 
CT – computed tomography 
DDR – DNA-damage repair 
DMEM – Dulbecco's modified Eagle's medium  
DNA – deoxyribonucleic acid 
DNase-HS – DNase hypersensitivity 
DNMT – DNA-methyl transferase 
DSS – 4,4-dimethyl-4-silapentane-1-sulfonic acid 
EMT – epithelial-mesenchymal transition 
eRMS – embryonal rhabdomyosarcoma 
ES – Ewing sarcoma 
ESC – embryonic stem cell 
ET – extra-terminal 
FACS – fluorescence-activated cell sorting 
FISH – fluorescence in situ hybridization 
FN-RMS – fusion-negative rhabdomyosarcoma 
FP-RMS – fusion-positive rhabdomyosarcoma 
GSEA – gene set enrichment analysis 
H3 – histone 3 
HDAC – histone deacetylase 
HE – hematoxylin and eosin  
HMT – histone methyltransferase 
HSQC – heteronuclear single quantum coherence 
IHC – immunohistochemistry  
IPTG – isopropyl-thiogalactopyranoside  
LOH – loss of heterozygosity 
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LOI – loss of imprinting 
LSD1 – lysine-specific histone demethylase 1A 
MBT – malignant brain tumor  
MRI – magnetic resonance imaging 
MSC – mesenchymal stem cell 
MTF – master transcription factor 
NPC – neural progenitor cell 
NuRD – nucleosome remodeling and deacetylase complex 
P3F – PAX3-FOXO1 
PET – positron emission tomography 
PFA – paraformaldehyde  
PHD – plant homeodomain 
PRC2 – Polycomb protein complex 
P-TEFb – positive elongation factor complex b 
PTM – post-translational modification 
qPCR – Quantitative polymerase chain reaction 
RMS – rhabdomyosarcoma 
RNA – ribonucleic acid  
RPMI – Roswell Park Memorial Institute 
rRNA – ribosomal RNA  
RT-PCR – real-time polymerase chain reaction 
SE – super-enhancer 
SEC – size exclusion chromatography  
shRNA – short hairpin RNA 
sgRNA – Guide RNA 
TEV – tobacco etch virus 
TF – transcription factor 
TSS – transcription start site 
WHO – world health organization
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